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Abstract 
 
 Tau is the main axonal microtubule-associated protein in the mammalian central 
nervous system (CNS) and functions primarily in microtubule assembly and axonal 
transport. However, tau also has diverse other functions ranging from postsynaptic 
receptor scaffolding to chromatin protection and organization. Tauopathies are a family 
of over 20 neurodegenerative diseases characterized by tau pathology in the brain, 
which is an indication of tau dysfunction and dysregulation. Importantly, tauopathies 
include Alzheimer’s disease and frontotemporal dementia, which are among the leading 
causes of early-onset dementia and are growing in prevalence due to an increasingly 
older population. To date, no disease-modifying therapies exist for tauopathies in part 
because the complex and multifunctional nature of tau biology makes it difficult to 
understand its role in disease pathogenesis. 
 Mouse modeling is an invaluable research tool frequently employed to test 
hypotheses about the role of tau in tauopathies, but has unfortunately yielded 
inconsistent results and extreme phenotypic variability. ‘Conventional’ techniques have 
historically been used to generate such mouse models, involving random insertion of 
synthetic mini-gene constructs into the mouse genome. In the current work, we have 
employed new ‘targeted’ genome engineering techniques to precisely insert a human tau 
(hTau) transgene into a predetermined, non-disruptive locus. We hypothesized that a 
targeted model harboring the pathogenic P301L hTau mutation would develop a 
disease-like phenotype and thus could be used as a positive control in comparison to 
genetically matched mice with different hTau modifications.  
Unlike the widely used conventionally-made tauopathy model rTg4510, which 
harbors a P301L hTau transgene, our targeted equivalent (rT2/T2) did not quickly 
develop a robust tauopathy-like phenotype. We found this discrepancy could be 
explained by a large transgene insertion-deletion (TgINDEL) mutation that disrupts and 
dysregulates Fgf14, a gene important for neuronal function. A tet-transactivator (tTA) 
transgene, required to activate hTau expression, also caused a TgINDEL that disrupts 
another five genes in this mouse line, four of which have prominent forebrain expression. 
Comparing this model to rT2/T2 mice revealed that the two TgINDELs allow for 
acceleration of the rTg4510 phenotype, including neurodegeneration and tau 
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histopathology. In addition, we found that extreme overexpression of hTau, or 
‘hyperexpression,’ is necessary to drive the severe phenotype.  
We also generated a targeted transgenic mouse overexpressing non-mutant 
(NM) hTau, with the intention of using it as a genetically-matched negative control in 
comparison to the P301L line. Surprisingly, NM hTau was associated with a 
developmental phenotype, characterized by reduced clearance and 
hyperphosphorylation of hTau. We found that disrupted mitochondrial dynamics and 
elevated oxidative stress were involved in NM hTau pathogenicity, underlying abnormal 
brain development and cognitive deficits. Interestingly, these phenotypes were lost with 
the P301L mutation, suggesting it conferred a beneficial loss of function during 
development. We speculate the molecular and behavioral differences between the NM 
and P301L hTau lines are driven by hTau-microtubule binding, which was found to be 
reduced in the P301L line. 
Together, this work identifies and characterizes confounding variables in mouse 
models of tauopathy including genomic disruption, transgene hyperexpression, and 
overexpression of transgenes during early postnatal development. We take initial steps 
to improve mouse transgenesis approaches and find genetic matching to be 
advantageous for probing molecular phenotypes of different forms of tau. We assert that 
it is important to eliminate confounding variables and use proper controls where possible 
to ensure phenotypes are relevant to the disease of interest. These findings are an 
example of a broader problem affecting neurodegenerative disease research, which can 
be avoided in future studies with more rigorous genomic characterization of mouse 
models as well as careful consideration of the timing and level of transgene expression 
as appropriate for the hypothesis in question. 
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I. Outline and rationale for current work 
Mouse modeling is an invaluable research tool commonly used to test 
hypotheses about neurodegenerative diseases. Because mice do not naturally develop 
these aging-dependent diseases, artificial human transgenes are introduced in the 
hopes of mimicking human disease phenotypes. Tauopathies are a large family of 
neurodegenerative diseases, such as Alzheimer’s disease and frontotemporal dementia, 
characterized by dysfunction and dysregulation of tau. Perhaps due to the complex 
biology underlying these diseases, it has been difficult to determine the role of tau in the 
pathogenesis of tauopathies. Unfortunately, no disease-modifying treatments yet exist 
for tauopathies in part due to a problem of translatability from mouse models to human 
clinical trials. It seems as the impetus for developing therapies becomes more urgent as 
the aging population increases, new discoveries about the biological functions of tau are 
made, making its role in neurodegeneration increasingly complex. 
When this work began, my goal was to use novel transgenic mice expressing 
human tau (hTau) to answer one of the major questions in the tauopathy field: which 
post-translational modifications create toxic species of tau, and are there pathways that 
can be targeted to reverse or slow that toxicity? To accomplish this, the Ashe and Koob 
labs formed a collaboration to generate genetically matched ‘Targeted’ transgenic lines 
harboring different hTau modifications, termed the T-series. As a positive control, the 
P301L mutation was introduced into one of these lines (rT2) to replicate the strong 
tauopathy-like phenotype of a widely accepted yet genetically uncharacterized mouse 
model called rTg4510, generated by the Ashe lab in the early 2000s. My early pilot 
studies revealed that rT2 mice did not develop robust tau histopathology like rTg4510, 
but we hypothesized this was due to the lower level of hTau expression. Making the 
mice homozygous for the transgene (rT2/T2) greatly increased hTau expression to a 
level even higher than that of rTg4510, but surprisingly the histopathology and 
neurodegenerative phenotypes were still not as robust as expected.  
Therefore, it quickly became a priority to determine why the rTg4510 phenotype 
could not be replicated in a targeted model. While the post-translational modification 
question remains of vital importance, it will become clear in the following chapters that 
this work evolved into an investigation of confounding variables that contribute to 
phenotypes of mouse models of tauopathy, in both the ‘conventional’ rTg4510 model as 
well as our new T-series models. My findings provide a few examples of a much broader 
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problem affecting neurodegenerative research, and suggest that the design of mouse 
models needs to be improved in order to truly understand tau pathogenicity in the 
mammalian brain. I have found that not only is detailed genetic characterization of 
transgenic mice of utmost importance to understanding phenotypes, but also the level of 
transgene expression as well as the stage in life during which such transgenes are 
activated. My work highlights confounding aspects of these artificial systems, and takes 
initial steps toward eliminating them. The implications of this work extend to all cases in 
which mouse modeling is used, and do not apply to tauopathy models alone.  
In the following sections, I will show that tau’s biological function is diverse and 
therefore its role in disease is complex and incompletely understood. There are many 
layers of complexity to tau’s function that have been uncovered over the years that 
partially explain why it has been so difficult to develop disease-modifying therapies. On 
the other hand, the failure of therapies found to be successful in mouse models to 
translate to humans suggests there are problems with the mouse models themselves. In 
Chapters Two and Three I will discuss the two projects I conducted that revealed major 
confounding variables in transgenic mouse models of tauopathy that may contribute to 
this problem of translatability.  
 
II. Tauopathies and Alzheimer’s Disease 
A. Historical perspective  
Alois Alzheimer first described the disease that now bears his name in 1907. His 
patient, Auguste Deter, was 51 years old and suffered from paranoia, disorientation, 
memory problems, and language impairments (1). What was striking about this case 
was the young age at which the patient was exhibiting symptoms of senility. Upon 
examining her brain after death, Alzheimer observed not only general cortical atrophy, 
but also argyrophilic “neurofibrils” first described in senile dementia two years prior (2) 
and also by his contemporary Oskar Fischer (3). Today this pathological hallmark is 
known as neurofibrillary tangles (NFTs). Around the same time, Arnold Pick was 
beginning his investigations of a distinct disease clinically similar to Alzheimer’s, but with 
atrophy localized specifically to frontal and temporal lobes (4,5). In what became known 
as Pick’s disease, spherical argyrophilic intraneuronal inclusions found in neuronal 
cytoplasms (now ‘Pick bodies’) were histopathologically distinct from the tangles of 
Alzheimer’s disease (6).  
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Many years later, research unrelated to neurodegenerative disease led to the 
identification and isolation of the protein tau (tubulin-associated unit, or 𝜏), which was 
discovered to be the exchangeable factor responsible for the assembly of microtubules 
(7). Further investigations into its properties revealed that tau could become 
phosphorylated (8), and that this phosphorylation reduced microtubule assembly (9). It 
was not until anti-tau antibodies were generated, and were found to produce a pattern of 
immunohistochemical staining identical to the inclusions of Alzheimer’s and Pick’s 
disease, that a connection was finally made between tau and the pathology of these 
diseases (10,11). Advancements in electron microscopy enabled the observation that 
the NFTs of Alzheimer’s disease were composed of filaments (12). Biochemical analysis 
revealed that tau indeed formed the core of the filaments (13). Confirming the identity of 
the core element of neurofibrillary tangles launched decades of research on the complex 
protein, tau. 
 
B. Classification of tauopathies 
Since the discovery of tau inclusions in Alzheimer’s disease and Pick’s disease, 
tau pathology of various shapes and sizes has been observed in a number of other 
neurodegenerative disorders. This collection of over 20 disorders associated with tau 
pathology is known as tauopathies. The classification of tauopathies has evolved over 
time as our understanding of disease etiology has improved. Broadly, tauopathies are 
divided into primary and secondary tauopathies. In primary tauopathies tau pathology is 
the only or the predominant neuropathology, but in secondary tauopathies, comorbidities 
are found such as amyloid-β (Aβ) plaques, α-synuclein Lewy bodies, and transactive 
response DNA-binding protein 43 (TDP-43) inclusions.  
Secondary tauopathies include Alzheimer’s disease, Down’s syndrome, Lewy 
body disorders, prion disease, and chronic traumatic encephalopathy, among ten other 
disorders (14). Other well-known neurodegenerative diseases such as Parkinson’s (15) 
and Huntington’s (16) disease have also been proposed to be identified as secondary 
tauopathies based on accumulating evidence of tau pathology in the brains of these 
patients. Comparisons between the progression of primary and secondary tauopathies 
suggests that the presence of comorbid pathologies exacerbates the severity of disease 
due to synergistic effects (17), but more research in this area is warranted.  
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 Primary tauopathies are grouped into a class of diseases called frontotemporal 
lobar degeneration with tau-immunopositive inclusions (FTLD-Tau), and are named 
according to the affected brain regions. Frontotemporal lobar degeneration (FTLD) is a 
pathological description of what presents clinically as frontotemporal dementia, and 
FTLD-Tau makes up 40% of these diseases (18). The other 60% are characterized by 
inclusions of TDP-43, fused in sarcoma (FUS), Ewing’s sarcoma (EWS), TATA-binding 
protein-associated factor 15 (TAF15), and ubiquitin proteasome system markers (18). 
Frontotemporal dementia is one of the most common causes of early-onset dementia, 
behind Alzheimer’s disease and vascular dementia (19), and thus it is critical that we 
continue to better our understanding of disease mechanisms to develop new therapeutic 
strategies.  
The molecular subtypes of primary tauopathies are differentiated post mortem 
based on the morphology of the tau inclusions. Primary tauopathies include Pick’s 
disease, progressive supranuclear palsy, corticobasal degeneration, globular glial 
tauopathy, argyrophilic grain disease, multiple system tauopathy with dementia, and 
neurofibrillary tangle dementia. These subtypes differ in the predominant tau isoforms 
comprising the inclusions, the cell types containing inclusions, the degree of tau 
phosphorylation, and morphology of the inclusions themselves (18). For instance, Pick 
bodies are composed primarily of tau isoforms containing 3 instead of 4 microtubule-
binding domains (see discussion of isoforms in part III), and tau inclusions of a glob-like 
morphology are found primarily in oligodendrocytes and astrocytes in globular glial 
tauopathy (18). As our understanding of pathogenic mechanisms of tauopathies 
becomes more complete, this classification system will undoubtedly continue to evolve.  
The clinical presentation of primary tauopathies is quite heterogeneous and can 
range from pure cognitive to pure motor syndromes. While secondary tauopathies like 
Alzheimer’s are distinct clinicopathological entities and have validated criteria for 
diagnosis, diagnosis of primary tauopathies presents a clinical challenge because they 
are so diverse. Furthermore, only 40% of clinical frontotemporal dementia has 
underlying tauopathy, so clinical assessment alone is insufficient to diagnose these 
diseases. However, increasingly finely-tuned cognitive testing and imaging of brain 
structural changes (20) may allow for more conclusive diagnosis of FLTD-Tau subtypes. 
In addition, tau positron emission tomography (PET) tracers have recently been 
developed but have yet to be used in the clinic (21). The involvement of tau in such a 
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large number of diverse neurodegenerative diseases underlines the importance of 
‘untangling’ its pathogenic properties. 
 
C. Treatments and outlook for public health 
The prevalence of tauopathies has been increasing as the population ages, and 
Alzheimer’s alone contributes to 5.7 million Americans, costing the nation $277 billion 
just in 2018 (22). It is projected that by 2050, the number of people with Alzheimer’s will 
increase to almost 14 million, costing the nation as much as $1.1 trillion (22). Soon, the 
United States will not be able to afford to care for these patients, causing some to call 
this a public health crisis. No disease-modifying treatments, or those that slow or halt the 
progression of disease, yet exist for any tauopathies. Symptomatic treatments for 
Alzheimer’s focus on clinical features of the disease and include acetylcholinesterase 
inhibitors, N-methyl-D-aspartate (NMDA) antagonists (memantine), antidepressants, and 
atypical antipsychotics (23). Disease-modifying therapies have been largely focused on 
amyloid-β, but none have been FDA-approved.  
More recently, the field is shifting its focus to tau-directed therapies. As of 
January 2018, there were ten tau-directed therapies in clinical trials, one in phase III and 
nine in phase II, split between inhibitors of aggregation and immunotherapies (24). While 
these studies are showing promising results, it is still hotly debated whether tau 
aggregates are toxic or a protective response, so it may be premature to assume 
prevention of tau aggregation will be beneficial. Regarding immunotherapies, because 
tau is primarily intracellular, the size and charge of antibodies should be carefully 
considered to increase neuronal uptake, and species-specificity presents further 
constraints when moving from preclinical rodent studies to humans (25). Other tau 
therapeutic avenues being investigated include altering post-translational modifications, 
stabilization of microtubules, and gene therapy to reduce tau levels (26). The pipeline for 
Alzheimer’s treatments consisted of 112 agents as of January 2018 (24). The number of 
participants and amount of funding needed to conduct well-designed studies are 
prohibitively large. With pharmaceutical industries terminating Alzheimer’s research due 
to repetitive failures, academic researchers may need to take initiative in drug 
development to overcome this enormous hurdle. 
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III. The tau gene and mutations in tauopathies 
 The tau gene, Microtubule-Associated Protein Tau (MAPT), is located on the 
long arm of chromosome 17 (region 17q21.31) and has eight currently known splice 
variants expressed from a total of sixteen exons (Figure 1). Two of these splice forms, 
referred to as “big tau”, are expressed in the peripheral nervous system and limited 
areas of the central nervous system (CNS) (27,28), whereas the rest are expressed only 
in the CNS (29). Usage of an alternative polyadenylation site encodes an additional 
ubiquitous form of tau that localizes to neuronal nuclei (30). The splice variants specific 
to the CNS differ in inclusion of two N-terminal exons and exon 10, which encodes a 
fourth microtubule-binding repeat domain of the protein (Figure 1).  
An important function of tau is the stabilization and assembly of microtubules, 
and therefore exon 10 splicing is of great interest in the tauopathy field. Splice variants 
lacking exon 10 are referred to as three-repeat, 3R, isoforms whereas inclusion of exon 
10 results in 4-repeat, 4R, isoforms. The CNS MAPT variants undergo precise regulation 
in the developing and adult brain. In both humans and mice, 3R isoforms predominate in 
the developing brain (31,32) but adult mice express exclusively 4R tau (33) whereas 
adult humans express equal amounts of 3R and 4R tau (34). This developmental switch 
is thought to play an important role in dynamic developmental processes such as 
neuronal maturation due to differences in microtubule binding capacity. The functions of 
MAPT protein isoforms will be discussed in more detail in subsequent sections. 
MAPT displays a pattern of linkage disequilibrium resulting in two haplotypes, H1 
and H2. These haplotypes diverged nearly 3 million years ago due to a 900 kilobase-pair 
inversion of several genes including the entire MAPT sequence (35). The H1 haplotype 
(non-inverted) recombines and is more common worldwide, but less so in those of 
European descent, whereas the H2 haplotype (inverted) has shown limited diversity 
(35). In general, H1 is considered to be a risk factor for neurodegenerative diseases 
because it is over-represented in individuals with progressive supranuclear palsy and 
corticobasal degeneration (36), as well as in those with sporadic Parkinson’s disease 
(37). The proposed pathogenic mechanisms of H1 include increased inclusion of exon  
10 (38) perhaps due to an additional 238 base pairs in intron 9 (39), and enhanced 
promoter activity driving higher tau expression levels (37).  
In contrast, H2 is thought to be protective for neurodegenerative diseases by 
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Figure 1. The eight known human MAPT transcript splice variants. Alternatively spliced 
exons in the periphery include exons 4a, 6, and 8, and alternatively spliced exons in the central 
nervous system (CNS) include exons 2, 3, and 10. Short-hand names of the splice variants are 
based on inclusion of 1 or 2 ‘N’-terminal exons and the presence of 3 or 4 microtubule-binding 
‘r’epeat domains in the protein isoforms, and are indicated to the left of each. Length in base 
pairs, or ‘bp’, is indicated at the top, and the National Center for Biotechnology Information (NCBI) 
RefSeq accession numbers for each variant are indicated to the right of each. Two additional 
exons encoding the 5’ and 3’ untranslated regions are not shown.  
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increasing inclusion of exon 3 (40). The inversion polymorphism does affect expression 
of other genes in the region (41), but it is assumed that the linkage to neurodegenerative 
disease depends on MAPT specifically due to its high expression level in the brain. The 
situation is further complicated by the existence of multiple sub-haplotypes due to single-
nucleotide polymorphisms (42), some of which cause H1 to be protective and H2 to be a 
risk factor. Interestingly, the H2 haplotype may predispose individuals to a microdeletion 
syndrome characterized by mental retardation (43). Overall, the complexity of the MAPT 
genomic region can drive differences in tau expression levels and ratios of splice 
variants, which modify susceptibility to disease. 
While MAPT haplotypes can serve as risk factors, there are particular autosomal 
dominant genetic mutations within the MAPT gene that are known to cause 
neurodegenerative disease. Diseases caused by mutations are familial, or heritable, and 
are typically rare and associated with an earlier age of onset (44). In contrast, sporadic 
forms of disease have unknown causes and are much more common. Alzheimer’s and 
FTLD can occur in either a familial or sporadic form, and it is currently unknown whether 
these forms share common mechanisms. Mutations in MAPT account for 5-20% of 
FTLD-Tau cases depending on geographic distribution, making them the second or third 
most common cause of familial FTLD behind C9ORF72 and possibly progranulin (GRN) 
mutations (45). A recent study of a large cohort found that 9% of FTLD-Tau patients had 
MAPT mutations whereas 62% had sporadic disease, and the other 25% had some 
family history (46). Although MAPT mutations are rare, they provide a convenient tool to 
study tau pathogenicity, and may ultimately give insights into mechanisms of both 
familial and sporadic disease. 
A tauopathy called frontotemporal degeneration and parkinsonism linked to 
chromosome 17 (FTDP-17) has typically been considered separate from the rest of 
FTLD-Tau because it can also be caused by mutations in GRN also on chromosome 17, 
resulting in FTLD associated with TDP-43-immunopositive inclusions (FTLD-TDP) 
(47,48). However, because FTDP-17 is associated with similar neuropathological 
phenotypes to sporadic FTLD-Tau, some argue that it should be classified together with 
FTLD-Tau or that the term FTDP-17 should be done away with altogether (44). 
Regardless, FTDP-17 is an autosomal dominant neurodegenerative disease recognized 
to have a genetic cause by a series of important studies that progressively narrowed 
down the genomic locus to MAPT (49-52). It was this realization that established tau 
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itself as a disease-causing agent, and sparked renewed interest into the complex 
protein.  
MAPT mutations not only cause FTDP-17, but can also be associated with Pick’s 
disease, progressive supranuclear palsy, corticobasal degeneration, and globular glial 
tauopathy. There is generally poor correlation between mutations and disease 
phenotype (53), and there can even be diverse symptoms between family members with 
the same mutation (54). Because of this phenotypic diversity frontotemporal dementia 
disorders are typically referred to as a spectrum (55), but they can broadly be divided 
into dementia-dominant and parkinsonism-dominant. Anecdotal evidence suggests that 
mutations affecting exon 10 splicing are more often of the parkinsonism-type whereas 
mutations with other pathogenic effects cause the dementia-type (56). Because, 
particular mutations are not associated with specific phenotypes, other genetic or 
perhaps epigenetic mechanisms may be responsible for clinical manifestation. In 
addition, MAPT mutation carriers may have a broad range of age-of-onset from the 
second to the eighth decade (57), however, disease onset is before 50 years of age in 
about 50% of cases (58). Interestingly, this is on average earlier than for mutations in 
other genes underlying FTLD, including GRN and C9ORF72, suggesting that tau 
pathogenicity may be particularly potent.  
A recent study found that of the 87 MAPT mutations that have been identified, 22 
of these have confirmed pathogenicity based on strict criteria including segregation of 
the mutation with the phenotype within families, existence of multiple independent cases, 
existence of other mutations at the same residue, and supportive functional studies (14). 
Complementary to this study as well as the alzforum.org database, I have made an 
updated table summarizing the characteristics of the known MAPT mutations in FTDP-
17, which now total to 96 (Table 1). Using next generation sequencing technology, a 
recent report suggests that more mutations may need to be added to this list (59). 
Importantly, mutations in 21 genes besides MAPT can be associated with tau pathology, 
suggesting that tau may be a pathogenic agent in some diseases, but tangles can 
develop in other diseases in the absence of mutation-driven tau toxicity per se (60). 
To add to the complexity of the MAPT gene, pathogenic mutations do not have 
consistent effects on tau biology. Generally, they can affect microtubule (MT) assembly, 
propensity of tau aggregation, and the 4R to 3R isoform ratio (Table 1). Amino acid 
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Table 1. Known MAPT mutations in FTDP-17 and postulated pathogenic effects. Confirmed 
pathogenic mutations are in bolded font. Note that amino acid numbering is based on the 2N4R 
isoform except for mutations in exons 4a, 6, 8. This list was updated in March 2019. 
Type of 
mutation 
Mutation Location 
Pathogenic 
effects 
References 
Missense 
(71) 
P4T Exon 1 Unknown (61) 
R5L Exon 1 
↑ MT assembly 
↑ soluble tau 
↑ aggregation 
(62,63) 
R5H Exon 1 
↑ aggregation 
↓ MT assembly 
(64) 
R5C Exon 1 Unknown  (65) 
A41T Exon 1 Unknown (65) 
L48V Exon 2 Unknown (66) 
G55R Exon 2 ↑ MT assembly (67) 
V75A Exon 3 Unknown (68) 
A90V Exon 3 Unknown (61) 
Q124E Exon 4 Unknown (69) 
D177V Exon 4a Unknown (70,71) 
G213R Exon 4a Unknown (72,73) 
V224G Exon 4a Unknown (61,72) 
Q230R Exon 4a Unknown (72) 
A297V Exon 4a Unknown (72) 
S318L Exon 4a Unknown (72) 
L410F Exon 6 Unknown (74) 
A152T Exon 7 
↑ aggregation 
↑ proteolysis 
↓ MT assembly 
(72,75) 
A178T Exon 7 Unknown (76,77) 
S427F Exon 8 Unknown (65,78) 
P512H Exon 8 Unknown (74) 
P513A Exon 8 Unknown (71) 
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G201S Exon 9 Unknown (78) 
R221Q Exon 9 Unknown (79) 
A239T Exon 9 Unknown (78,80,81) 
K257T Exon 9 
↑ aggregation 
↑ proteolysis 
↓ MT assembly 
(80,82) 
I260V Exon 9 
↑ aggregation 
↓ MT assembly 
(83) 
T263P Exon 9 Unknown (84) 
L266V Exon 9 
↑ aggregation 
↑ 4R:3R 
↓ MT assembly 
(85,86) 
G272V Exon 9 ↑ aggregation (87) 
G273R Exon 9 Unknown (88) 
N279K Exon 10 ↑ 4R:3R (89,90) 
L284R Exon 10 Unknown (91) 
S285R Exon 10 ↑ 4R:3R (92) 
V287I Exon 10 Unknown (72) 
C291R Exon 10 ↑ 4R:3R (93) 
N296D Exon 10 Unknown (94) 
N296H Exon 10 
↑ aggregation 
↑ 4R:3R 
↓ MT assembly 
(95-97) 
K298E Exon 10 
↓ MT assembly 
↑ 4R:3R 
(98) 
H299Y Exon 10 Unknown (99) 
P301T Exon 10 ↑ aggregation (100,101) 
P301S Exon 10 
↑ aggregation 
↓ MT assembly 
↓ axonal 
transport 
↓ synapses 
(102-104) 
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P301L Exon 10 
↑ aggregation 
↓ MT assembly 
(63,105,106) 
G303V Exon 10 ↑ 4R:3R (107) 
G304S Exon 10 Unknown (108) 
S305N Exon 10 ↑ 4R:3R (54,109,110) 
S305I Exon 10 ↑ 4R:3R (111) 
L315R Exon 11 ↓ MT assembly (112) 
K317M Exon 11 Unknown (113) 
K317N Exon 11 
↑ aggregation for 
4R 
↓ aggregation for 
3R 
↑ 4R:3R 
(114) 
S320F Exon 11 ↓ MT assembly (115) 
P332S Exon 11 ↓ MT assembly (116) 
G335S Exon 12 ↓ MT assembly (117) 
G335V Exon 12 
↑ aggregation 
↓ MT assembly 
(118) 
Q336R Exon 12 
↑ aggregation 
↑ MT assembly 
(119,120) 
Q336H Exon 12 
↑ aggregation 
↑ MT assembly 
(120) 
V337M Exon 12 
↑ aggregation 
↓ MT assembly 
(50,121) 
E342V Exon 12 ↑ 4R:3R (122) 
S352L Exon 12 
↑ aggregation 
↓ MT assembly 
(123,124) 
S356T Exon 12 Unknown (125) 
I360V Exon 12 Unknown (65) 
V363I Exon 12 ↑ MT assembly (126,127) 
P364S Exon 12 ↓ MT assembly (128,129) 
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↑ chromosome 
instability 
G366R Exon 12 
↓ MT assembly 
↑ chromosome 
instability 
(128,129) 
K369I Exon 12 ↓ MT assembly (130) 
E372G Exon 13 
↑ aggregation 
↓ MT assembly 
(131) 
G389R Exon 13 
↓ MT assembly 
↑ proteolysis 
(132-136) 
R406W Exon 13 ↓ MT assembly (34,105,137) 
N410H Exon 13 
↓ MT assembly 
↑ aggregation 
↑ 4R:3R 
(138) 
D418N Exon 13 
↑ chromosome 
instability 
(129) 
T427M Exon 13 Unknown (139) 
Silent 
(22) 
T39T Exon 1 Unknown (76) 
P176P Exon 7 Unknown (106) 
g(+33)a Intron 9 Unknown (106) 
t(-15)c Intron 9 
↓ 4R:3R 
 
(140) 
g(-10)t Intron 9 ↑ 4R:3R (141) 
L284L Exon 10 ↑ 4R:3R (142,143) 
N286N Exon 10 Unknown (144) 
N296N Exon 10 ↑ 4R:3R (96,145) 
P301P Exon 10 Unknown (146) 
S305S Exon 10 ↑ 4R:3R (147-149) 
g(+3)a Intron 10 ↑ 4R:3R (51,150,151) 
a(+4)c Intron 10 ↓ 4R:3R (140) 
t(+11)c Intron 10 ↑ 4R:3R (152) 
c(+12)t Intron 10 ↑ 4R:3R (153) 
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a(+13)g Intron 10 ↑ 4R:3R (80) 
c(+14)t Intron 10 ↑ 4R:3R (105,154-156) 
a(+15)c Intron 10 ↑ 4R:3R (157) 
c(+16)t Intron 10 ↑ 4R:3R (105,158) 
c(+19)g Intron 10 ↓ 4R:3R (144,159) 
c(+25)t Intron 10 Unknown (160) 
g(+29)a Intron 10 ↓ 4R:3R (142,159,160) 
a(+34)g Intron 11 Unknown (161) 
Deletion 
(43) 
K280 Exon 10 
↑ aggregation 
↓ 4R:3R 
↓ MT assembly 
(106,162-164) 
N296 Exon 10 
↑ aggregation 
↓ MT assembly 
(96,165) 
Nonsense (1) R448* Exon 8 Unknown (65) 
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substitutions caused by missense mutations in the MT-binding domains may cause 
conformational changes or changes in electrical charge that influence the ability of tau to 
bind and assemble MTs (34). This can lead to abnormalities in neuronal cytoskeletal 
structure as well as disruption of axonal transport (166), which each have the potential to 
affect a broad range of cellular functions. Other missense mutations can change the 
propensity for domains on tau to form β-structures that enhance fibrillization into 
pathological aggregates. Finally, silent mutations in splicing enhancer or silencer sites, 
or those in the stem-loop structure in the 5’ region of intron 10 of tau RNA have the 
ability to influence inclusion of exon 10 in the mature messenger RNA (mRNA) (167). 
Other silent mutations in exons may be pathogenic via changes in tRNA utilization (168). 
While the majority of mutations with known effects seem to reduce MT assembly (e.g. 
A152T, L266V, P301L, V337M), others can increase MT polymerization (e.g. R5L, 
Q336H). Similarly, most mutations increase tau aggregation (e.g. G272V, P301L, 
G335V) and the 4R to 3R ratio (e.g. N279K, G303V, Intron 10 g(+3)a), but others have 
the opposite effect (e.g. K317N for aggregation; K280 for 4R:3R) (Table 1). 
Frustratingly, this prevents generalization of any of these pathogenic effects as being 
causative of disease. These paradoxes indicate that either the effects of MAPT 
mutations need to be studied beyond these parameters, or simply that tau dysregulation 
in general is pathogenic.  
The most common MAPT mutation is the P301L mutation, identified in 32 
families worldwide (AD & FTD mutation database)(169). This mutation is confirmed to be 
pathogenic and, as it is located in exon 10 which encodes one of the MT-binding 
domains, it has been shown to reduce MT binding (34) and consequently the ability of 
tau to facilitate MT assembly (106). The P301L mutation is also known to make tau a 
more favorable substrate for phosphorylation by kinases (170) and to enhance tau 
aggregation (63,171,172). Finally, P301L tau has a unique ability to infiltrate dendritic 
spines, where it may interfere with synaptic transmission through dislocation of 
glutamatergic receptors from the cell membrane (173). The prevalence of the P301L 
MAPT mutation has caused it to become the most well-studied of all the tau mutations, 
and has motivated the generation of eight different animal models harboring the 
mutation to elucidate its effects in the mammalian brain (Alzforum research model 
database). Despite these efforts and although much has been learned about mutant tau 
from this work, the mechanisms of P301L-induced toxicity remain unclear.  
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IV. The tau protein and its diverse functions 
A. Typical functions  
As the main microtubule-associated protein in neuronal axons, the ‘typical’ or 
canonical functions of tau are directly related to its ability to bind microtubules (MTs) in 
this cellular region. In the healthy adult brain, the main function of tau is to facilitate MT 
polymerization in axons (7) in a way that reduces dynamic instability (174). Tau 
decorates the MT bundles that extend throughout neuronal axons, and is therefore 
important for providing support to this elongated structure. The tau protein itself has little 
secondary structure, and is divided into four sub-regions: the N-terminal projection 
domain, proline-rich region, MT-binding repeat domain, and C-terminal domain. The MT-
binding repeat domain facilitates tau-MT interactions and MT assembly (175) while the 
C-terminal domain negatively regulates MT polymerization (176). The proline-rich 
domain can also bind MTs (177) but is also involved in cell signaling through a variety of 
binding partners (14). The negatively-charged projection domain is repelled away from 
MTs (178) and therefore determines spacing between MTs (179) – splicing of exons 2 
and 3 at the N-terminus lengthens that distance. Various imaging techniques suggest 
that tau binds laterally to the inner surface of protofilament sheets while the proline-rich 
region curves around the side (180), or that the entire tau molecule binds longitudinally 
to protofilaments (181). At any given time, up to 98% of tau in cells is MT-bound (182), 
however, the dwell time on microtubules lasts only 40ms (183), freeing tau up to interact 
with other proteins and perform other functions. 
Transient binding of tau to MTs through this “kiss and hop” mechanism (183) is 
sufficient for tau to facilitate axonal transport of cargo such as mitochondria and 
neurotransmitter-containing vesicles along MTs through interactions with molecular 
motors kinesin and dynein (184). Within the axon tau levels exhibit a gradient, with the 
highest concentration at the axon terminal (185). This gradient of tau, combined with its 
ability to cause detachment of kinesin from MTs (184) facilitates release of cargo at the 
axon terminal. Tau’s inhibition of kinesin depends on both the tau isoform and the 
nucleotide-binding state of the microtubules (186), making this interaction and 
consequently tau’s role in axonal transport inherently complex. Nonetheless, by aiding 
the delivery of newly synthesized neurotransmitter to the axon terminal, tau has a role in 
synaptic transmission at the presynaptic side.  
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In the adult brain, tau is primarily localized to neuronal axons perhaps due to 
selective stabilization of tau protein in this region or to selective degradation of tau in 
other subcellular compartments (187). In addition, tau mRNA contains an axon 
localization signal in its 3’ untranslated region (3’UTR) (188). RNA-binding proteins such 
as interleukin enhancer binding factor 3 (Ilf3) can bind this signal and act as chaperones 
to escort tau mRNA (189) to the axon where it can be locally translated (188). Tau is 
prevented from leaving axons through several mechanisms. Interactions with membrane 
proteins such as Annexin A2 keep tau in this region (190). In addition, it has been 
suggested that a molecular barrier exists at the axon initial segment (AIS) that prevents 
tau from leaving the axon (191).  
 In the developing brain, before neurons have axons or dendrites, tau is involved 
in neuronal morphogenesis and differentiation, as well as neurite outgrowth and 
elongation through its interactions with MTs (192). In support of this, loss of tau prevents 
proper neuronal maturation in vitro (193). While neurites form normally, neurite polarity, 
or differentiation of dendrites vs. axon, fails to be established and these tau-deficient 
neurons fail to form an axon (194). Initial observations that tau is concentrated at the 
growth cone of maturing neurites (185) suggested it had functions other than 
stabilization of MTs per se. More recent work has revealed that tau directly interacts with 
and regulates localization of the core MT plus-end tracking proteins required for neurite 
elongation during differentiation (195).  
As stated previously, 3R tau isoforms are more prominently expressed in the 
brain than 4R isoforms during development and at young ages (31). The nature of tau 
interactions with MTs depends on the number of repeat domains, and this has important 
functional implications. 4R tau has a three-fold higher MT-binding capacity than 3R tau 
(196), and therefore is better at facilitating MT polymerization (197). 4R tau is also a 
more potent inhibitor of MT dynamics (198,199), suggesting that the more transient 
binding of 3R tau to MTs is necessary for dynamic developmental processes to occur. 
Indeed, the period of 3R tau predominance coincides with the ages at which 
neurogenesis peaks and axon and dendrite densities are on the rise (200). The favored 
view is that 3R tau enables MTs to be in a dynamic state, whereas 4R tau maintains MT 
stability needed in adult neurons (201). This is supported by the fact that 3R tau 
expression in the adult brain is restricted to the subgranular zone of the dentate gyrus, 
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where adult neurogenesis takes place (33). Overall, canonical functions of tau differ at 
different times in the lifespan, mediated by changes splicing.  
 
B. Atypical functions 
A smaller pool of tau exists in the brain that performs functions unrelated to its 
ability to bind axonal MTs. These ‘atypical’ functions occur in neuronal somata, nuclei, 
and dendrites, and also outside of neurons altogether. Despite the mechanisms 
designed to compartmentalize tau to neuronal axons, specific isoforms are found at 
lower levels in other regions of the cell. In a transgenic mouse with the full human MAPT 
sequence, 3R tau was found to be more prominent in the cell body during development 
whereas 4R staining was “synaptic-like” in adult brains suggesting its presence in 
dendrites (33). In addition to exon 10, N-terminal exons 2 and 3 are alternatively spliced 
resulting in 0N, 1N, and 2N isoforms. 0N isoforms are prominent in both neuronal 
somata and axons, 1N isoforms are overrepresented in nuclei, and 2N isoforms are 
prominent in neuronal somata and dendrites (202). Some isoforms such as 2N4R tau 
more readily leak past the AIS barrier (discussed in the previous section) into the 
somatodendritic compartment (203), providing a mechanistic explanation for isoform-
dependent sorting of tau. These isoforms perform specific atypical functions within each 
of those subcellular compartments. 
Tau isoforms present in dendrites, likely 2N isoforms (202), participate in 
synaptic plasticity, which consists of both structural and electrophysiological changes. In 
terms of structure, tau is postulated to play a role in growth and retraction of synapses 
through its interactions with filamentous actin (F-actin) in dendritic spines (204,205). 
Plasticity also occurs on an electrophysiological level in the form of long-term 
potentiation (LTP) and long-term depression (LTD). Following neuronal activation, tau 
has been observed to move from dendritic shafts into spines (206). Not only could this 
translocation of tau be important for plasticity, but also local translation of tau in 
dendrites, which has also been observed to be driven by neuronal activity (207).  
Within dendritic spines, tau interacts with post-synaptic proteins such as PSD-95 
(208) and Src-family tyrosine kinases such as Fyn (209) to facilitate the scaffolding of 
excitatory NMDA receptors (210,211). Site-specific phosphorylation of tau following 
NMDA receptor activation weakens its relationship with Fyn and PSD-95, thus reducing 
receptor anchoring and preventing overexcitation (208). Site-specific phosphorylation of 
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tau also facilitates LTD through internalization of excitatory α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid (AMPA) receptors (212). In support of tau’s functions in 
dendrites, studies done in vivo have shown that loss of tau can result in deficits in LTP 
underlying cognitive impairments (213), as well as deficits in adult neurogenesis 
following environmental enrichment (214).  
Tau isoforms enriched in neuronal nuclei, likely 1N isoforms (202), have an 
established role in DNA protection. A recent study confirmed nuclear localization of tau 
using several methods, including biochemical isolation of nuclei from mouse brain tissue 
(215). Tau can bind to both single- and double- stranded DNA, through part of its 
proline-rich domain and the second microtubule-binding repeat domain (216). Studies 
have shown that tau-DNA binding increases during oxidative stress (217-219), 
suggesting that this interaction is a protective response. This is a reversible process that 
depends on the availability of tau, suggesting tau protection of DNA occurs on demand, 
and stops once the brain is no longer under stress (220). Tau binds DNA even in the 
absence of stress to maintain chromosome stability and prevent chromosomal 
aberrations such as breakages or translocations (221,222). A recent genomics study 
indicated that tau likely plays a role in genome spatial organization, and may also 
influence transcription of genes involved in neurological processes (218). 
Although tau is expressed primarily in neurons, it is expressed at lower levels in 
glial cells including astrocytes (223) and oligodendrocytes (224,225). Little is known 
about tau functions in healthy astrocytes, but the accumulation of hyperphosphorylated 
tau in astrocytes of diseased brains has been well-characterized (226). In contrast, tau 
has a defined biological role in oligodendrocytes, particularly in myelination. Through its 
interactions with MTs, tau sorts into oligodendrocyte processes to control myelin 
formation and thickness, possibly by aiding in the transport of myelin basic protein (225). 
Indeed, downregulation of tau or the mislocalization of tau to the soma results in a 
thinner myelin sheath and can cause movement disorders (227,228). Interestingly, tau 
isoform regulation is different in neurons and oligodendrocytes, indicating cell-type 
specific mechanisms controlling tau splicing over the course of development. While in 
neurons there is a developmental switch from 3R to 4R tau isoforms (31,33,34), both 3R 
and 4R tau are expressed in developing and adult oligodendrocytes (229,230). It is 
thought that the persistence of 3R tau expression in adult oligodendrocytes helps 
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maintain a “young” and plastic physiological state, capable of active adaptation to ever-
changing myelination needs (231).  
 More limited evidence suggests that tau may have a number of other functions, 
which warrant further research. Although tau’s function in neurite outgrowth is believed 
to be dependent on its interactions with MTs, tau can also function as a signaling protein 
to facilitate the downstream effects of nerve growth factor (NGF) stimulation, 
independent of MT binding (232). Tau’s interactions with neuronal plasma membranes 
(233) and cellular organelles such as the endoplasmic reticulum (234), Golgi apparatus 
(235), vacuoles, and mitochondria (236), suggest it may have other diverse functions 
such as in protein production and regulation. 
 
C. Post-translational modifications of tau 
Post-translational modifications modulate tau function. Tau can be 
phosphorylated, acetylated, ubiquitinated, O-GlcNAcylated, sumoylated, oxidated, 
nitrated, and more (237). Such a diversity of post-translational modifications that can be 
applied to the tau protein adds an additional level of complexity to its regulation and 
function in the brain. Phosphorylation is the most well-studied of tau modifications. A 
basal level of phosphorylation is required for endogenous tau function. Serine, threonine, 
and tyrosine residues are targeted by both proline- and non-proline- directed kinases. 
Among the proline-directed kinases, glycogen synthase kinase 3 (GSK-3) and cyclin-
dependent kinase 5 have been shown to be involved in endogenous tau function 
(238,239). Non-proline directed kinases that target tau include cAMP-dependent protein 
kinase (240) and Ca2+/calmodulin-dependent protein kinase 2 (CaMKII) (241).   
Phosphorylation occurs mainly in the proline-rich domain on tau (242) and 
modulates essentially every aspect of tau function in a site-specific manner including MT 
binding (191), neurite elongation (243), tau sorting (191,219), DNA interactions (216), 
interactions with the plasma membrane (244), and plasticity (212). Consistent with tau’s 
role in neurite elongation, a phosphorylation gradient exists in growing axons to allow 
distal MTs to be dynamic (245). Intriguingly, in hibernating animals such as squirrels, tau 
phosphorylation is dramatically upregulated during periods of torpor, or drops in 
metabolic rate (246,247). This effect is reversible and appears to be a mechanism for 
controlled down-regulation of synaptic transmission (248). Tau phosphorylation and 
activation of tau-targeting kinases are also precisely regulated during development. A 
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high level of phosphorylation is maintained early in postnatal development, likely to 
facilitate dynamic interactions with MTs, but phosphorylation declines with age, likely to 
maintain MT stability (249,250).  
It should be noted that many of the studies of tau’s function have been performed 
in rodents, and differential portions of sequence in primate-specific tau may impact its 
function, particularly in relation to its binding partners (251). The involvement of tau in 
such diverse functions essential for neuronal survival raise the possibility that 
tauopathies are caused by tau loss-of-function. However, much research indicates that 
tauopathies can also be caused by toxic gain-of-function. 
 
V. Tau dysfunction in tauopathies 
A. Formation and spread of pathological tau 
Due to the complex and multifunctional role of tau in the brain, tau dysfunction in 
neurodegenerative diseases is also inherently complex and incompletely understood. 
The prevailing hypothesis for tau’s role in disease pathogenesis is that it becomes 
hyperphosphorylated, is unable to bind MTs, missorts to somatodendritic regions of 
neurons, and causes cellular dysfunctions through numerous molecular pathways. 
Although a certain level of phosphorylation is required for normal tau function, this 
becomes exaggerated in disease (252). Rather than a single phosphorylation site driving 
tau pathogenicity, multiple phosphorylation sites work in concert to generate a 
pathological form of tau (253,254). This hyperphosphorylation, perhaps caused by an 
imbalance in kinase and phosphatase activity, can prevent MT binding by modifying 
electrical affinity of tau for MTs (255) and/or inducing conformational changes in tau 
(256). Tau that is dissociated from MTs can take on conformations such as a “paperclip-
like” conformation (257), which may increase the propensity for motifs in the MT-binding 
domain to form β-sheets (258), which are structural components linked to tau toxicity 
(259). Hyperphosphorylated, dissociated tau is then freed up to mislocalize to 
somatodendritic regions of neurons where it aggregates. Consequently, MTs are 
observed to become destabilized (260), leading to impairments in axonal transport (261) 
and other problems. 
The process of tau aggregation is thought to involve a sequential evolution of 
different tau species (262). Once a tau monomer takes on a pathological conformation, 
formation of tau dimers/trimers and oligomers proceeds spontaneously because it is 
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energetically favorable (263). Dimers, trimers, and small soluble oligomers are 
composed of antiparallel tau monomers linked by disulfide bridging (264). From these 
species or from monomers alone, granular oligomers can form, which are densely 
packed aggregates of about 40 tau monomers and are insoluble, meaning they cannot 
be broken up or dissolved (265). Tau filaments can be formed either from oligomers or 
smaller dimers and trimers when motifs in tau’s MT-binding domain change from random 
coil structure to β-sheets (266). Filaments can take on a variety of shapes in tauopathies 
(267), however paired helical filaments are commonly observed and consist of two 
straight filaments wound around each other (268). Finally, filaments cluster together to 
form neurofibrillary tangles (269). 
There is much debate in the field about which of the tau species on the soluble-
insoluble spectrum are to blame for toxicity. On one hand, the presence and regional 
localization of tangles correlate well with disease progression (270,271), and 
cerebrospinal fluid biomarkers for tau pathology including high levels of total tau and 
phospho-tau are associated with rapid progression from mild cognitive impairment to 
Alzheimer’s disease (272). However, tangles can also be found in cognitively healthy 
individuals (273), can form in mouse models without causing neurodegeneration (274), 
and can remain in surviving neurons for long periods (275). Therefore, tangles are 
hypothesized by some to be a protective response to sequester harmful soluble tau 
species.  
Oligomers are increasingly thought to be involved in disease pathogenesis. 
Growing evidence indicates that hyperphosphorylated, soluble oligomers cause synapse 
loss (276) while granular oligomers cause neurons loss (277). This supports the idea 
that tau toxicity can occur regardless of the presence of insoluble tau. Others are 
investigating the hypothesis that truncated forms of tau are the primary toxic entities in 
neurodegenerative diseases. In non-apoptotic pathways, caspases can cleave tau (278), 
and caspase-3 cleavage of tau at aspartate 421 seems to be more strongly associated 
with cognitive impairments in Alzheimer’s disease than tangles themselves (279). In 
addition, caspase-2 generates a tau fragment that causes synaptic and cognitive deficits 
despite resisting fibrillation in a mouse model of tauopathy (280). Soluble forms of tau 
including oligomers and fragments may act in concert to exert toxic effects in neurons, 
while tangles form as a consequence or perhaps a protective response.  
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 The patterns of tau spreading throughout the brain are heterogenous among 
tauopathies (281,282), but the stereotypical spread through interconnected regions in 
Alzheimer’s has led researchers to propose a neuron-to-neuron propagation mechanism 
(283). There are several ways this could occur. Based on findings indicating that 
application of exogenous pathological tau can stimulate tau aggregation in vivo (284), 
and that tau can be found in the extracellular space (285), a “prion-like” mechanism has 
been proposed whereby pathological tau ‘seeds’ are released from an infected neuron 
and taken up by neighboring neurons where they seed the formation of more insoluble 
aggregates (286). Indeed, cells are able to internalize tau aggregates via endocytosis 
mediated by surface heparan sulfate proteoglycans (287). As neuronal activity is 
associated with increased release of tau and exacerbation of tau pathology (288), 
another postulated mechanism for neuron-to-neuron tau spread is via synaptic transfer. 
Tau spreading may also occur through a microglia-dependent membrane-based 
mechanism (289). In this scenario microglia engulf tau-containing dying neurons and/or 
synapses, and release pathological tau via exosomes. Indeed, exosomes isolated from 
Alzheimer’s disease patients contain pathological tau (290).  
 
B. Mechanisms of tau toxicity 
 Once pathological tau forms in a neuron or is internalized, how does it go on to 
disrupt cellular processes? As stated above, the favored hypothesis is that 
hyperphosphorylation of tau triggers a cascade of pathological events associated with 
missorting, or mislocalization, of tau. Phosphorylation (191) and acetylation (291) at 
specific sites, disease-linked mutations (173), as well as truncation (280) of tau allow it 
to cross the barrier at the AIS and infiltrate somatodendritic regions of neurons. Tau that 
mislocalizes to dendritic spines is observed to reduce synaptic transmission via 
internalization of AMPA receptors (AMPARs), underlying cognitive impairments in a 
transgenic mouse model (173,280). This may occur through activation of calcineurin 
(protein phosphatase 2B), which dephosphorylates AMPARs to cause their 
internalization (292). Similarly, acetylated tau in dendritic spines interferes with AMPAR 
recruitment, thus disrupting long-term potentiation and memory (293). Excitotoxicity 
driven by NMDA receptor (NMDAR) overactivation has also been implicated in 
tauopathies, mediated by tau that has been phosphorylated by Fyn (294). Not only could 
imbalance of AMPARs and NMDARs be involved, but also total loss of synapses due to 
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tau mislocalization (295). These studies show that tau mislocalization to the synapse can 
have a variety of toxic effects, from electrophysiological to structural.  
 Tau dysfunction is also tied to oxidative stress and mitochondrial abnormalities. 
Mitochondria are dynamic organelles that undergo constant fission and fusion, and 
produce ATP to meet the high energy demands of neurons. As part of this process, 
mitochondria normally produce low levels of reactive oxygen species (ROS) as a 
byproduct of oxygen metabolism. Oxidative stress refers to an imbalance of ROS and 
the antioxidants that keep them in check. In tauopathies such as Alzheimer’s disease, 
increased ROS production and reduced antioxidants are observed (296,297), even in 
earlier mild cognitive impairment (MCI) stages (298,299). Therefore, oxidative stress 
seems to be an early event in tauopathies, and has been shown to cause tau 
hyperphosphorylation (300) via upregulation of kinases such as GSK-3 (301) and 
downregulation of phosphatases such as protein phosphatase 2A (302).  
Tau hyperphosphorylation resulting from oxidative stress leads to numerous 
problems with mitochondria, creating a vicious cycle. Tau-induced disassembly of MTs is 
associated with impairments in mitochondrial transport along axonal MTs (303) leading 
to mislocalization and perinuclear accumulation of mitochondria (304). 
Hyperphosphorylated tau also disrupts the delicate balance between mitochondrial 
fission and fusion (305), leading to aberrant fragmentation (306) or elongation (307) of 
mitochondria, possibly through interactions with Dynamin-related protein 1 (Drp1) (308). 
Deficits in mitochondrial bioenergetics are also observed in tauopathies including altered 
levels of mitochondrial enzymes (309), which have the potential to impact ATP 
production, electron transport, and respiratory activity. Not only is tau 
hyperphosphorylation implicated in these toxic mechanisms, but also truncation (310) as 
well as disease-linked MAPT mutations like P301L (311-313). Finally, oxidative stress 
and mitochondrial abnormalities are also linked to autophagic dysfunction, leading to 
reduction of tau clearance (314). Overall, vicious cycles on multiple levels of the 
relationship between pathological tau, mitochondrial dynamics, and oxidative stress may 
contribute to progressive worsening of cell health and eventual cognitive decline in 
tauopathies. 
Tau’s nuclear function can also go awry in disease, leading to problems like 
chromosome instability, aneuploidy, and cell cycle reentry. Several studies suggest that 
pathological tau causes chromatin instability and disorganization (129,315). In tauopathy 
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models and in human neurodegenerative disease, tau dysfunction is associated with 
loss of heterochromatin, tightly packed DNA that is unavailable for transcription (316). 
This ‘relaxation’ of heterochromatin causes aberrant expression of genes normally 
silenced (316). Tau-induced mislocalization of nuclear transcription factors to the 
cytoplasm is another way tau can affect global gene transcription (317). Mature neurons 
are non-dividing because they have exited the cell cycle. However, cell cycle proteins 
have been observed to become aberrantly activated in a fly model (318), mouse model 
(319), and in human tauopathy (320), leading to incomplete ‘de-differentiation’ and cell 
death (321). Tau’s association with the mitotic spindle has been shown to be necessary 
for normal chromosome segregation, and its dysfunction is implicated in aneuploidy, or 
abnormal chromosome number (222). While aneuploidy increases with normal aging 
(322), this is exaggerated in Alzheimer’s disease and is linked to cell death (323,324). 
Nuclear abnormalities in tauopathies provide an example of how tau as a multifunctional 
protein can cause diverse dysfunctions in disease. 
Neuroinflammatory markers have persistently been found to be upregulated in 
tauopathies (325) and have been considered a downstream response to other 
pathological mechanisms. However, recent studies support the idea that 
neuroinflammation, involving both microglia and astrocytes, is a driver of 
neurodegeneration or at least plays an active role in worsening tau pathology. A favored 
hypothesis is that microglia become activated in response to pathological tau (such as 
oligomers) released from affected neurons (326). The microglia release inflammatory 
chemokines and cytokines that activate astrocytes (327), which in turn release more 
proinflammatory molecules. These secreted factors have direct impacts on neurons to 
further exacerbate tau pathology (328-330). This activates a chronic inflammatory 
process composed of a vicious cycle between tau pathology and microglia/astrocyte 
activation that contributes to synaptic and neuronal dysfunction (329,331). Several 
differences between Alzheimer’s and primary tauopathies suggest that different 
inflammatory mechanisms are involved. For example, genetic risk factors like variants of 
immune proteins Triggering receptor expressed on myeloid cells 2 (TREM2) and 
apolipoprotein E (APOE), as well as Aβ may contribute to Alzheimer’s pathogenesis but 
not primary tauopathies (332,333). Many other important questions remain regarding the 
role of neuroinflammation in tauopathies, warranting further investigation. 
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There are several other cellular dysfunctions in tauopathies in which the role of 
tau is gaining increasing attention. The idea that divergence from protein homeostasis 
has negative impacts on cellular functions is not novel. Either increases or decreases in 
tau beyond normal levels can result in abnormalities (37,334). However, mechanisms 
controlling tau homeostasis are currently being investigated, and have so far revealed 
that tau acetylation competes for ubiquitination of lysines to slow tau clearance, resulting 
in increases in tau levels (335). Slowing tau turnover was associated with promotion of 
tau accumulation, exacerbation of neurodegeneration, and behavioral deficits in a 
tauopathy mouse model (335). Recently, somatodendritic mislocalization of tau was 
found to promote a natural stress response in neurons – the formation of complexes 
composed of RNA-binding proteins and mRNA termed ‘stress granules,’ which ensure 
proper translation of proteins involved in the stress response. This area of research 
suggests that in tauopathies, stress granules become overactive and large, and that tau 
and RNA-binding proteins act synergistically to promote pathological tau aggregation, 
exacerbating cellular dysfunction (336-338). This is supported by the idea that tau 
harboring disease-linked MAPT mutations also promotes pathological stress granule 
formation (90).  
A burgeoning body of literature also suggests that the formation of pathological 
tau aggregates has a negative impact on metabolic and neuroendocrine processes. 
Specifically, tau is involved in the dysregulation of glucose metabolism in the brain and 
hypothalamic control of food intake via insulin signaling (339). Insulin resistance has 
been frequently observed in Alzheimer’s disease (340), and has been shown to 
contribute to imbalance of tau kinases and phosphatases to cause tau 
hyperphosphorylation. Conversely, pathological tau can also influence insulin signaling 
via neuroinflammatory pathways or intraneuronal sequestration of insulin (341), resulting 
in a vicious cycle. Finally, roles for tau in suppression of adult neurogenesis (342,343) 
and in blood vessel abnormalities (344) have also been described.  
 
C. Remaining questions and final comments 
 Aside from the research described above for which the pathogenic mechanisms 
of tau remain unclear, a number of general questions remain concerning the role of tau 
in neurodegenerative diseases. For instance, are the mechanisms of tau pathogenicity 
the same between sporadic and familial diseases? Phrased differently, do mutant tau 
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and non-mutant tau disrupt cellular functions in the same way in the aging brain? While 
there are obvious differences in the clinical and neuropathological manifestation of 
sporadic and familial diseases, it is possible that tau mechanisms are similar but more 
severe and earlier onset in familial diseases due to the presence of MAPT mutations. 
Mutations, while they do not have consistent effects on tau biology, exhibit general 
trends in that the majority of mutations increase 4R:3R tau isoform ratios, increase 
aggregation, and reduce MT assembly (Table 1). These phenotypes can be observed in 
sporadic disease as well.  
In sporadic disease, the presence of other pathologies such as Aβ in 
Alzheimer’s, α-synuclein in Lewy body disorders, and TDP-43 in FTLD, amyotrophic 
lateral sclerosis (ALS), and other diseases may have synergistic effects with tau that 
result in a range of different phenotypes. Deciphering the role of tau in Alzheimer’s 
disease is of particular importance because of growing prevalence of this disease 
coupled to lack of disease-modifying therapies. This is a controversial topic because the 
amyloid-cascade hypothesis is at odds with repeated failures of amyloid-targeting drugs 
in clinical trials, leading researchers to favor tau-targeting therapeutic strategies more 
recently (345). However, hypotheses favoring Aβ vs. tau are not necessarily mutually 
exclusive. Multiple lines of evidence suggest that Alzheimer’s disease is an Aβ-assisted 
tauopathy (346), meaning Aβ pathology is permissive for tau toxicity, which ultimately 
drives progression of disease.  
The information covered in this chapter reveals many layers of complexity that 
contribute to tau function and dysfunction in the brain: 1) MAPT mutations have 
contrasting effects, 2) there are many possible toxic species of tau on the soluble-
insoluble spectrum, 3) post-translational modifications modulate virtually all aspects of 
tau biology, 4) tau’s function depends on isoform, cell type, and subcellular 
compartment, and 5) tau’s function changes over the lifespan. The subsequent work in 
this thesis identifies and characterizes confounding variables in transgenic mouse 
models of tauopathy, which, together with the inherent complexity of tau’s role in 
neurodegeneration, have contributed to the failure of therapies to translate from pre-
clinical studies to human clinical trials. The studies presented in the following chapters 
advocate for improvement in the design and use of mouse models in order to enhance 
our understanding of tau pathogenicity and ultimately develop disease-modifying 
therapies for tauopathies. 
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I. Introduction 
The widely used rTg4510 mouse model of tauopathy recapitulates key features 
of these human diseases, including progressive age-related neurofibrillary tangles 
(NFTs), memory impairment and a dramatic loss of neurons in young mice (274,347). 
The rapid onset and severity of neuron loss in this model was particularly surprising 
when first reported given that earlier mouse models incorporating similar human 
Microtubule-Associated Protein Tau (MAPT) transgenes with the pathogenic P301L 
mutation do not develop overt atrophy (348,349). Unlike these other tauP301L 
overexpression models, however, rTg4510 uses a responder-driver system to activate 
transgene expression specifically in forebrain neurons. Responder Tg4510 mice are 
crossed to a driver line (350) that harbors a tetracycline transactivator (tTA) transgene to 
generate bi-transgenic rTg4510 (“r” refers to regulatable) progeny. The particularly high 
level of tauP301L overexpression specifically in the forebrain of these mice has generally 
been accepted as the direct cause of the premature gross forebrain atrophy and other 
tauopathy-like phenotypes in this line, a hypothesis supported by the fact that 
suppression of tauP301L expression by doxycycline (DOX) halted neuronal loss and 
improved memory function (274). Mice from a control line in which wild-type (WT) human 
tau is expressed at levels roughly equivalent to tauP301L in rTg4510 mice do not develop 
either progressive memory deficits or overt atrophy, supporting the idea that the tauP301L 
mutant form of tau in particular was the direct cause of these phenotypes in rTg4510 
(173). 
Our overall goal when we began the project described here was to determine the 
precise molecular features of the tauP301L protein that cause the rapid neurodegeneration 
phenotype characteristic of rTg4510, but we realized that this line was an inadequate 
starting point for this work. Although the transgene construct used to generate Tg4510 
could be systematically altered and used to make new lines by pronuclear injection, the 
random integration process through which Tg4510 was established could never be 
precisely repeated, and any transgenic lines generated from these modified constructs 
would not adequately match the original Tg4510 line. We therefore first sought to 
establish a targeted-insertion equivalent to Tg4510 to which subsequent targeted-
insertion lines expressing specific human tau variants could be precisely matched (an 
overview of the mouse lines generated and used is shown in Figure 20).   
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Preliminary observations of tauP301L histopathology and brain mass in this 
targeted-insertion line (designated rT2/T2) suggested its phenotype was not as early or 
as robust as rTg4510, despite overexpressing even more tauP301L protein than rTg4510. 
To determine if genetic differences contribute to the rTg4510 phenotype, we used whole-
genome sequence analyses, which revealed a transgene insertion/deletion (TgINDEL) 
mutation in rTg4510 consisting of a multimer array of approximately 70 copies of the tau 
transgene, which inserted in a ~250 kilobase deletion of the first exons and promoter 
regions of Fibroblast growth factor 14 (Fgf14). Furthermore, we found that a tTA Tg-
INDEL allele, which drives tauP301L expression in both lines and is known to be sufficient 
to cause a more limited but progressive neuron loss, consists of an approximately 7-
copy tTA-transgene insertion in a ~500kb deletion that disrupts another five annotated 
genes (Vipr2 - Ptprn2). Finally, we found that, in the absence of the Fgf14 tau-TgINDEL, 
matching the high level of transgene overexpression in rTg4510 appears to be 
necessary to cause premature (<7 months) tau histopathology, late-stage (>12 months) 
overt atrophy, and behavior abnormalities. In the following sections, we present our 
genomic findings before phenotypic characterization in order to discuss differences 
between rT2/T2 and rTg4510 in the context of both Tg-INDELs.  
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II. Materials and Methods 
Animals 
We generated ES cells with a Col1A1 “Flp-in” integration cassette by 
electroporating 25ug of purified Col1a-frt-hygro-pA Plasmid (Addgene) into V6.5 Mouse 
Embryonic stem cells (C57BL/6 X 129/sv) (Novus Biologicals NBP1-41162 passage 22). 
After G418 selection, Clone 15 was found to have integrated properly and had a perfect 
karyotype. All further FRT mediated targeting is to this ES modified cell line 
(V6.5Col1a#15). A construct was generated that was essentially identical to the 
construct used to generate Tg4510, but incorporated a Flp-In promoter cassette (PGK 
promoter-ATG-FRT), and 6ug this construct and 0.5ug pCAGGS-FlpE (Gene Bridges 
cat# A201) was transfected into the V6.5Col1a#15 ES cell line. Hygromycin selection at 
140ug/mL was added day 2 through day 6, and Hygro resistant ES clones were picked 
on day 7. DNA was analyzed for 5’ (5ArmCol1A assay primer + TRE start Rev) and 3’ 
(AMP R Reverse + Hygro Connection) junctions, internal Tau (TAU assay F and R), and 
multiple integration assay (AMP R Reverse + TRE start R) by PCR. Southern blot was 
done for multiple integration confirmation using EcoRI digested genomic DNA and a 
470bp probe generated from the AmpR gene (Amp F + Amp R). Clone 6 was positive for 
all assays and the P301L mutation was verified by the Tau Assay below, and this clone 
was expanded and karyotyped, and mice were generated by injection into blastocysts. 
These mice were back-crossed five times to FVB prior to generating the T2/T2 lines. 
 
ES Cell Assay Primer sequences: 
5ArmCol1A pcr assay  5’-CAGGTGCACAGCATTGCGGACATG-3’ 
TRE Start Rev  5’-ATTGCTCCAGGCGATCTGAC-3’ 
Amp R Reverse  5’-GGAATAAGGGCGACACGGAA-3’ 
Hygro Connecton  5’-ATCCACGCCCTCCTACATCGAA-3’ 
Tau Assay F   5’-GTTCGAAGTGATGGAAGATCACG-3’ 
Tau Assay R   5’-TTGGGTGGAGTACGGACCA-3’ 
 
PCR Probe Primers: 
Amp F    5’-CCTCCATCCAGTCTATTAATT-3’ 
Amp R    5’-TCCTTGAGAGTTTTCGCCCCG-3’ 
 
  33 
Generation of rTg4510 mice, which utilizes an activator and responder system for 
transgene expression, has previously been described (274). Briefly, a pTRE-prnp-tau 
plasmid was used to generate Tg4510 responders, which harbor a 0N4R human tau 
cDNA transgene regulated by a tetracycline response element (TRE). Tau expression is 
activated in bigenic rTg4510 progeny of an activator-responder cross. Activator mice 
harbor a tetracycline transactivator (tTA) transgene under the control of the CaMKIIα 
promoter (CKTTA transgene) to drive expression specifically in forebrain excitatory 
neurons (350). To generate tau-homozygous rT2/T2 mice from tau-hemizygous T2 mice, 
transgene-activated hemizygous males (CKTTA+/-Tau+/-) were bred to non-activated 
hemizygous females (CKTTA-/-Tau+/-), resulting in tau homozygous progeny (Tau+/+). To 
maintain the rT2/T2 line, transgene-activated homozygous males (CKTTA+/-Tau+/+) were 
bred to non-activated homozygous females (CKTTA-/-Tau+/+). For the rTg4510 line, 
responder Tg4510 were maintained on a FVB/N background while activator mice were 
maintained on a 129S6 background. To match the genetic background to that of rT2/T2 
mice, we increased the amount of FVB/N and used these mice to compare expression 
levels in rTg4510 and rT2/T2 mice. To generate these mice, responder Tg4510 mice 
were maintained on a FVB/N background while activator mice were maintained on a 
mixed 129S6 and FVB/N background. Non-tau-expressing transgenic littermates were 
used as controls. Both male and female mice were used, and were combined in 
statistical analyses after demonstrating the absence of significant gender effects (P > 
0.05). All experiments with animals described in this study were approved by and 
conducted in full accordance with the American Association for the Accreditation of 
Laboratory Animal Care and the Institutional Animal Care and Use Committee at the 
University of Minnesota. 
 
qRT-PCR 
mRNA expression levels of each Fgf14 variant were quantified relative to a 
reference gene, hypoxanthine-guanine phosphoribosyltransferase (Hprt). All Fgf14 
primers (Table 5) were designed to span at least partially unique regions of each variant. 
Total cellular RNA was extracted from homogenized forebrain tissue using RNeasy Lipid 
Tissue Kit (Qiagen) according to the manufacturer’s instructions.  RNA samples were 
treated with DNaseI (New England Biolabs) to digest contaminating DNA, and subjected 
to cDNA synthesis using the iScript cDNA synthesis kit (Invitrogen) according to the 
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manufacturer’s instructions. PCR reactions were set up in a 20-µl volume in 96-well 
plates, with 2 to 3 replicates per sample. Roche SYBR Green PCR master mix was used 
and reactions were run in the Roche LightCycler® 480 instrument. A final melting curve 
confirmed that single amplicons were present for each variant and reference reactions, 
and a basic relative quantification was performed using the ∆∆CT-Method (LightCycler® 
480 Software release 1.5.0 SP3). All data were normalized to a positive calibrator 
sample used in each experiment.  
 
Protein extraction and phosphatase treatment 
Total protein was extracted from mouse forebrain hemisphere tissue in RIPA 
buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 0.5% Triton X-100, 1% sodium 
deoxycholate, 0.3% SDS, 0.1 mM phenylmethyl sulfonyl fluoride, 0.2 mM 1,10-
Phenoanthroline Monohydrate, Phosphatase Inhibitor Cocktail A (Sigma), Protease 
Inhibitor Cocktail (Sigma), Phosphatase Inhibitor Cocktail 2 (Sigma)). Homogenates 
were nutated and centrifuged at 15,700 xg for 90 minutes at 4°C and the supernatant 
was collected.  
To obtain RIPA-insoluble, sarkosyl-insoluble fractions, a modified version of a 
previously published method was used (351). RIPA-insoluble pellets were homogenized 
in 1% sarkosyl and incubated at room temperature for 30 minutes with constant shaking. 
Samples were centrifuged for 1 hour at 100,000 xg at 20°C, and the supernatant and 
pellet were separated and diluted in O+ buffer (62.5 mM Tris-HCl, pH 6.8; 10% glycerol; 
5% 2-mercaptoethanol; 2.3% SDS; 1 mM EGTA; 1 mM EDTA; 1 mM PMSF; 1 mM 
Na3VO4; 1 mM NaF; 10 μl/ml of protease inhibitor cocktail P8340; Sigma-Aldrich). 
Samples were boiled for 3 minutes and stored at -20°C.  
For treatment with calf intestinal alkaline phosphatase (CIP, New England 
Biolabs), samples were resuspended in 10 µl CIP buffer (100 mM NaCl, 50 mM Tris-HCl, 
10 mM MgCl2, 1 mM dithiothreitol, EDTA-free protease inhibitor cocktail, pH 7.9) per 1 
µg protein. One unit CIP per µg protein was added to the samples prior to incubation at 
37°C for 30 minutes. Samples were then concentrated using Amicon Ultra centrifugal 
filters (Millipore).  
 
Western blot and analysis 
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For sarkosyl-insoluble fractions, total protein concentration was normalized 
according to pellet weights. Total protein concentrations for all other samples were 
determined by Pierce™ Bicinchoninic Acid protein assay (Thermo Scientific). Equal 
amounts of protein for each sample were loaded and separated using SDS-PAGE on 
10%, 10.5-14%, or 10-20% Tris-HCl gels (Bio Rad). Protein was transferred to 
nitrocellulose membranes (Bio Rad), which were blocked with 5% Bovine Serum 
Albumin (Sigma) in 1X TBST buffer (10 mM Tris-Base (Sigma), 0.2 M NaCl (Macron 
Chemicals), 0.1% Tween-20 (Sigma) pH 7.4). Protein was immunoblotted with Tau46 
(Cell Signaling Technology #4019, dilution 1:10,000), Tau13 (BioLegend #MMS-520R, 
dilution 1:60,000), GAPDH (14C10) (Cell Signaling Technology #2118, dilution 1:4,000), 
GAPDH (GA1R) (Thermo Scientific #MA5-15738, dilution 1:5,000), AT8 (Thermo 
Scientific #MN1020, dilution 1:1,000), anti- human tau (Abcam # ab74391, dilution 
1:10,000), and βIII-tubulin (ProSci #79-720, dilution 1:10,000) antibodies. Additional 
antibodies from Peter Davies for phospho-epitopes on tau included MC1 (dilution 1:800), 
CP13 (dilution 1:1,000), and PHF1 (dilution 1:1,500). To visualize antibody 
immunoreactivity using a LiCor imaging system and Image Studio software, IRDye-
linked goat anti-mouse 800CW and goat anti-rabbit 680LT secondary antibodies were 
used (LI-COR Biosciences, dilution 1:100,000). Following LiCor image acquisition using 
Image Studio software (Odyssey), Amido black staining solution (Sigma-Aldrich) was 
used for total protein quantification according to manufacturer’s instructions. 
Immunoreactivity and Amido black staining were quantified by densitometry using 
OptiQuant version 3 software, following guidelines for total protein quantification (352).  
 
Total Tau Measurements by Enzyme-linked Sandwich Immunoassay (Simoa) 
Mouse hemi-forebrains of rT2, rT2/T2, and rTg4510 mice were dissected and 
transferred to 1 mL of ice-cold RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM 
EDTA, 0.5% Triton X-100, 1% sodium deoxycholate, 0.3% SDS, 0.1 mM phenylmethyl 
sulfonyl fluoride, 0.2 mM 1,10-Phenoanthroline Monohydrate, Phosphatase Inhibitor 
Cocktail A (Sigma), Protease Inhibitor Cocktail (Sigma), Phosphatase Inhibitor Cocktail 2 
(Sigma)). Homogenates were nutated and centrifuged at 15,700 xg for 90 minutes at 
4°C and the supernatant was collected. Samples were then diluted 1:100,000 in ice cold 
PBS (0.01 M phosphate buffer, 0.0027 M potassium chloride, 0.137 M sodium chloride 
pH 7.4; Sigma). Samples were analyzed using QuanterixTM ultra-sensitive, single 
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molecule array (Simoa) technology with the HD-1 analyzer (Quanterix, Lexington, MA). 
Total tau (T-tau) was measured using Tau 2.0 kits (QuanterixTM). All measurements were 
performed on the same day in the same run using the same reagents. Background 
signal generated from tTA-only samples was averaged and subtracted from all other 
data.   
 
Immunohistochemistry and analysis 
Mouse brain hemispheres were immersion-fixed in 10% formalin for 48 hours 
before processing. Unstained sagittal TMA sections (4 µm) were de-paraffinized and 
rehydrated using standard methods. Bielschowsky silver staining was performed using 
standard techniques. For antigen retrieval, slides were incubated in 6.0 pH buffer 
(Reveal Decloaking reagent, Biocare Medical, Concord, CA) in a steamer for 30 min at 
95-98°C, followed by a 20 min cool down period. Subsequent steps were automated 
using an immunohistochemical staining platform (Nemesis, Biocare). Endogenous 
peroxidase activity was quenched by slide immersion in 3% hydrogen peroxide solution 
(Peroxidazed, Biocare) for 10 min followed by TBST rinse. A serum-free blocking 
solution (Rodent Block M, Biocare Medical, Concord, CA) was placed on sections for 20 
min. Blocking solution was removed and slides were incubated in primary antibody 
diluted in 10% blocking solution/90% TBST. Mouse monoclonal antibodies from Peter 
Davies were applied at the following dilutions: CP13 1:1,000, MC-1 1:800 and PHF1 
1:1,500, mouse monoclonal PHF-Tau: clone AT8 (Thermo Scientific #MN1020) 1:1,000. 
Sections were incubated in primary antibody for 60 min at room temperature followed by 
TBST rinse and detection with biotinylated anti-mouse secondary (Vector Laboratories 
#BP-9200, dilution 1:200) for 30 minutes followed by a TBST rinse. After the rinse, SA-
HRP (Biolegend #405210, RTU) was applied for 30 minutes. All slides then proceeded 
with TBST rinse and detection with diaminobenzidine (Covance, Dedham, MA). Slides 
were incubated for 5 min followed by TBS rinse then counterstained with CAT 
Hematoxylin (Biocare, Concord, CA) for 5 minutes. Slides were then dehydrated and 
coverslipped. Images were gathered using an Axioskop microscope (Zeiss, Germany) at 
40X magnification and a PixeLINK microscope camera (PL-A623C) with PixeLINK 
Capture SE software version 2.2 (Firewire camera release 4, Copyright © 2000-2006). 
Adobe Photoshop CS2 version 9.0 was used to match the color of different images of 
the same histological stain. Semi-quantitative analysis of images was conducted using a 
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‘+’ system (347). A blinded observer gave scores for three sections per sample 
indicating severity of pathology using ‘-’ for no positive labeling, ‘+’ for occasional 
positive labeling, ‘++’ for moderate positive labeling, ‘+++’ for prominent positive labeling. 
To summarize these results, the number of ‘+’ signs was counted for each animal and 
region, and multiple linear regression analyses were conducted using R statistical 
programming language to test for differences between rTg4510, rT2/T2, and rT2.  
 
Whole-genome sequencing and sequence analyses 
 Genomic DNA was extracted from a non-activated Tg4510 mouse harboring the 
0N4R human tau transgene using the DNeasy Blood & Tissue kit (Qiagen) according to 
the manufacturer’s instructions. Genomic DNA was analyzed by nanodrop and agarose 
gel to verify the quality (O.D. 260/280 ratio > 1.8) and quantity (300 ng for library 
construction). 
Sequencing was performed on Illumina HiSeq 2500 High-Output system using 
rapid SBS chemistry at the University of Minnesota Genomics Center, Minneapolis, MN.  
Following quality control, a TruSeq Nano DNA library was prepared from the genomic 
DNA sample and was sequenced on a single Illumina lane to generate 2x125 bp paired-
end reads. The average insert length in the library was 350 bp.   
All sequence analyses were conducted using the University of Minnesota’s 
installation of the Galaxy web-based suite of software (353). We isolated individual 
sequence reads that spanned the end of the transgene using the BLAT alignment tool 
(354) and mapped paired sequence reads to the transgene sequence using Bowtie2 
(355). We screened these data sets and identified unmapped reads in which the paired 
read mapped to the transgene sequence and then further analyzed these screened sets, 
in part using the Integrative Genomic Viewer (IGV) (356), to find the genomic insertion 
points and a single 5’ -5’ transgene fragment junction. Bowtie2 mapping of the sequence 
data to the Fgf14 genomic or Vipr2-Ptprn2 data (as appropriate) indicated that roughly 
half as many reads mapped to the unique sequences between the insertion points as 
mapped outside of this region, indicating that the Tg4510 mice have only a single copy 
of this portion of the Fgf14 genomic sequence. To estimate transgene copy number, we 
used sets of closely linked SNPs to distinguish between the PrnP sequence in the 
transgene and that in the FVB genome (357), and found that the dataset contains more 
than 35-fold more reads generated from transgene PrnP sequences than from the 
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diploid mouse PrnP sequence on chromosome 2, indicating that more than 70 copies of 
transgene sequence are inserted at the Fgf14 locus in the Tg4510 mice. Similar 
analyses were performed using polymorphisms in the CamKII genomic data to 
determine the copy number in the tTA transgene array. Sequences mapped to the 
reference Tg sequence were assemble into a consensus transgene sequence using 
SPADES (358).  
 
PCR and Sequencing 
Selected regions of Tg4510 and rT2/T2 genomic DNA were amplified by 
polymerase chain reaction (PCR) using Herculase II Fusion DNA polymerase (Agilent 
Technologies). For Tau transgene junctions in Tg4510 DNA, PCR and nested PCR 
reactions were run (Tables 2, 3 and 4). CaMKIIα-tTA transgene junctions were 
confirmed using rT2/T2 DNA (Tables 7 and 8). Gel bands were isolated from a low 
melting point agarose gel (NuSieve GTG, Lonza) and DNA was purified following 
digestion with β-agarase (New England Biolabs). Gel-purified PCR products were 
sequenced with classical Sanger sequencing at the University of Minnesota Genomics 
Center, Minneapolis, MN.  
 
Mouse cell culture and metaphase slide preparation 
Spleen from a Tg4510 mouse (28th generation backcross onto FVB genetic 
background) was minced into a single cell suspension and cultured for 24-28 hours with 
5ug/ml Concavalin A (mouse T-cell mitogen). Cultures were exposed to colcemid (Irvine 
Scientific) for 15 hrs overnight followed by harvest using standard cytogenetic 
protocols. Metaphase spread slides were prepared from methanol-acetic acid fixed cell 
pellets and FISH was performed the following day. 
 
Fluorescent in situ hybridization (FISH) 
DNA probes derived from the tau transgene sequence were labeled by nick 
translation reaction (Nick Translation Kit - Abbott Molecular) using Orange 552 dUTP 
(Enzo Life Science), ethanol precipitated and resuspended in hybridization buffer. The 
probe/hybridization buffer mix and slide were denatured, probe was applied to the 
metaphase slide, and slide was hybridized for 24 hours at 37°C in a humidified chamber. 
After hybridization, the FISH slides were washed in a 2xSSC solution and 
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counterstained with DAPI stain to enable chromosome identification by G-band 
patterning. Fluorescent signals were visualized on an Olympus BX61 microscope 
workstation (Applied Spectral Imaging, Vista, CA) with DAPI and Texas Red filter 
sets. FISH images were captured using an interferometer-based CCD cooled camera 
(ASI) and FISHView ASI software. 
 
Behavioral Experiments 
For nesting experiments, animals were not disturbed for at least 24 hours prior to 
testing. Each animal was placed in its own clean cage with a new nestlet placed in the 
center of the cage in the morning. Nests were photographed and scored 2 hours, 6 
hours and 24 hours after the start of the test. Scores of 0-7 were given as follows (75): 0- 
nestlet untouched, 1- <10% of nestlet was shredded, 2- 10-50% of nestlet shredded but 
no shape to nest (flat), 3- 10-50% of nestlet  shredded and there is shape to nest, 4- 50-
90% of nestlet shredded but no shape to nest (flat), 5- 50-90% of nestlet shredded and 
there is shape to nest, 6- >90% of nestlet shredded but no shape to nest (flat), 7- >90% 
of nestlet  shredded and nest had walls that were at least as tall as the mouse on 50% of 
the sides. Reported scores are the average of two individual blinded scorers.   
Open field testing was done two days after the conclusion of nesting 
experiments. Animals were not disturbed for at least 24 hours prior to testing and were 
placed in the testing room for 30 minutes prior to testing. The Open field setup was a 
plastic tub with opaque white walls, measuring 15 inches wide by 18.5 inches long by 12 
inches high. The arena floor was covered with new, pre-scented cage bedding. Each 
mouse was released in the center of the arena and allowed to freely explore for 10 
minutes. All trials were monitored using a computerized tracking system (Noldus 
Ethovision XT 10.0; Noldus Information Technology). All animals were tested in the 
morning to avoid activity differences from time of day. 
 
Statistical Analysis  
Analyses were conducted using GraphPad Prism version 6.00 software 
(GraphPad Software) and R statistical programming language. Gender differences were 
detected only in nest-building behavioral assays and analyses were conducted 
accordingly. In all cases, p<0.05 was considered to be statistically significant.  
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III. Results 
TAUP301L overexpression  
We used Flp/Frt recombination to target a single copy of the same tauP301L 
transgene used to generate Tg4510 into mouse embryonic stem cells at an intergenic 
site downstream of Collagen type I alpha I (Col1A1), a site previously demonstrated to 
promote transgene expression without dysregulating endogenous genes (359). Mice 
with this single targeted MAPT cDNA transgene insertion are designated T2. In order to 
match the expression pattern in rTg4510 mice, these new T2 mice are crossed to the 
same tTA-driver line (350) used to generate rTg4510 mice, resulting in rT2 mice. The 
rT2 mice are again crossed to T2 mice to generate mice homozygous for the tauP301L 
transgene (i.e., rT2/T2, as shown in Figure 20). 
 We find that rT2/T2 mice express two to three times as much human tauP301L 
mRNA and protein in the forebrain as hemizygous rT2 (Figure 2A-C). Despite 
expressing similar levels of tauP301L mRNA (0N4R isoform only) as rTg4510 (Figure 2A), 
rT2/T2 overexpress even higher levels of protein than rTg4510, however this trend was 
not statistically significant (Fig. 2B-C). 
  
TAUP301L-TgINDEL in Tg4510 disrupts Fgf14  
Preliminary results showed that tauP301L histopathology in rT2/T2 brains was not 
as robust as in rTg4510 at 5 months of age. To determine if an insertion mutation 
caused by the tauP301L transgene in Tg4510 could explain this phenotypic difference, we 
performed whole-genome sequencing on DNA from a Tg4510 responder mouse using 
the Illumina HiSeq2500 High-Output system. Assembly and analyses of these reads 
revealed that approximately 70 head-to-tail copies of the tau transgene form an array 
that replaces a 243,608bp region of Fibroblast growth factor 14 (Fgf14), the most 
telomeric gene on the long arm of chromosome 14 (Figure 3B). Within the insertion array 
the transgene orientation switches from a 3’→5’ orientation to a 5’→3’ orientation, 
however we are unable to determine precisely at which point in the array this switch 
occurs due to repetitive sequences in the reads (Figure 3B). We confirmed the 
transgene insertions sites by PCR amplifying and resequencing key junctions and by 
performing Fluorescence In Situ Hybridization (FISH) on Tg4510 genomic DNA (Figure 
4, Tables 2-4). The compiled tau transgene monomer sequence and all junction 
sequences have been submitted to GenBank.  
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Figure 2. Human tau expression in transgenic lines. (A) hTau mRNA was measured in 8-
week old mouse forebrains by RT-qPCR relative to housekeeping gene Hprt. A One-way ANOVA 
with Holm-Sidak’s multiple comparisons test showed significantly lower levels in rT2 compared to 
rT2/T2 and rTg4510 (F(2, 17) = 7.98, p = .0019). Of note, rT2 hTau expression was 58% and 
rTg4510 was 92% that of rT2/T2. (B) hTau protein overexpression relative to endogenous mouse 
tau in the tTA line was measured in 8-week old mouse forebrains by western blot. A One-way 
ANOVA with Holm-Sidak’s multiple comparisons test showed significantly lower levels in rT2 than 
rT2/T2 (F(2, 23) = 7.38, p = .0033). rT2 expression levels were 50% and rTg4510 were 70% that 
of rT2/T2. Overexpression of human relative to endogenous mouse tau was 8.5x in rT2, 17x in 
rT2/T2, and 11.8x in rTg4510. (C) A Simoa® ELISA system was used to confirm protein 
expression levels of samples in panel B, and showed by One-way ANOVA and Holm-Sidak’s 
multiple comparisons test that, again, rT2 levels were significantly lower than rT2/T2 (F(2, 22) = 
9.073, p = .0013). Samples were diluted one thousand-fold to be within range of detection for the 
assay and tTA controls were used to measure background signal. Data was adjusted to account 
for background and dilution. rT2 levels were 33% and rTg4510 were 71% of rT2/T2 by this 
method. (D) Western blots quantified by densitometry in panel B. Samples were treated with a 
phosphatase before being run through SDS-PAGE. Tau46 antibody, which recognizes human 
and mouse tau, was used to measure full-length (FL) tau levels. Amido black stain was used to 
normalize to total protein. Molecular weights for each blot in kDa are shown on the left, with sex 
of each mouse indicated above. Graphs show group means + SD with n’s in parentheses. 
**p<0.01. 
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Figure 3. Fgf14 is disrupted by a tau transgene array in Tg4510 mice. (a) Structure of the tau 
transgene monomer including the TRE promoter, prion protein (Prnp) sequences, tau cDNA ORF, 
Mapt 3’ UTR, and SV40 signal (see text for details). (b) Diagram of Fgf14 mRNA splice variants 
and disruption by the transgene array. Tg’, final transgene copy in the 3’→5’ orientation. Tg*, first 
transgene copy in the 5’→3’ orientation.  
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Figure 4. Confirmation of transgene insertion sites and array junctions in the Tg4510 
genome. (a) Diagram of the following key junctions: 1) the junction between the transgene array 
and the Fgf14 intron, 2) the junction between the transgene array and the Fgf14 promoter region, 
3) Tail-Head junctions between adjacent transgene copies (which occurred in three Types), and 
4) the Head-Head junction at the point in the array in which the transgene flips orientation. Note 
that the transgene copies at the Fgf14 intron, Fgf14 promoter region, and Head-Head junctions 
are truncated and therefore do not have aligned sequences. (b) Gel electrophoresis of PCR 
products shown in part a. The Fgf14 intron junction amplicon is 811 bp, the Tail-Head junction 
amplicon is 685 bp, the Head-Head junction amplicon is 626 bp, and the Fgf14 promoter region 
junction amplicon is 767 bp. (c) Metaphase chromosomes from a Tg4510 mouse were subjected 
to FISH, using DNA probes derived from the tau transgene sequence tagged with an Orange 552 
fluorescent label. Fluorescent signal is detected near the telomere on the long arm of 
chromosome 14, identified by its unique G-band patterning.  
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Table 2. Primer sequences used to amplify hTau transgene-Fgf14 junctions. 
Junction 
Product 
Primers Nested primers 
Forward Reverse Forward Reverse 
5’ 5’- 
CAGCATCAAGC
CCCAGAGAA -3’ 
5’- 
ACGCTATCTGTG
CAAGGTCC -3’ 
5’-
GCTCTGGATTTC
TGTGAGCCT -3’ 
5’-
GTAACCGGCCT
CTTCATCGG -3’ 
3’ 5’- 
TCTGGAACTCAC
CAGGTAATC -3’ 
5’- 
AACAAGGGTGG
TTTTCAAGAG -3’ 
N/A N/A 
Tail-Head 5’- 
TCTGGAACTCAC
CAGGTAATC -3’ 
5’- 
CATGGGTAGGC
TCACACAGT -3’ 
5’- 
ACCACGCTATCT
GTGCAAG -3’ 
5’- 
GGATGACTGCA
TCTGTCAAG -3’ 
Head-
Head 
5’- 
GAGCGAGGAAG
CCATCGTT -3’ 
5’- 
CAGATAGCGTG
GTCCGGC -3’ 
N/A N/A 
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Table 3. PCR cycling conditions used for non-nested PCR reactions for hTau transgene-Fgf14 
junctions. 
5’ 3’ Tail-Head Head-Head 
#  °C Time #  °C Time #  °C Time #  °C Time 
1 94 08:00 1 95 02:00 1 94 08:00 1 95 02:00 
33 94 01:15 35 95 00:20 33 95 00:20 35 95 00:20 
55 00:30 53.6 00:20 56 00:20 54 00:20 
72 01:00 72 00:30 72 00:36 72 00:30 
1 72 03:00 1 72 03:00 1 72 03:00 1 72 03:00 
(#) number of cycles, (°C) temperature, Time (minutes:seconds) 
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Table 4. PCR cycling conditions used for nested PCR reactions for hTau transgene-Fgf14 
junctions. 
5’ Nested Tail-Head Nested 
#  °C Time #  °C Time 
1 94 08:00 1 94 08:00 
33 94 01:15 35 95 00:20 
55 00:30 57.2 00:20 
72 01:00 72 00:30 
1 72 03:00 1 72 03:00 
1 4 ∞ 1 4 ∞ 
(#) number of cycles, (°C) temperature, Time (minutes:seconds) 
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Fgf14 expression is dysregulated in rTg4510 mice 
Although transcription of FGF14 has been reported to initiate at over unique 100 
start sites (360), at the time we began our analyses four representative splice variants of 
Fgf14 were present in GenBank, and we restricted our analyses to these variants: V1 
(NM_010201.4, encodes isoform 1a), V2 (NM_207667.3, encodes isoform 1b), X1 
(XM_011244952.1), and X2 (XM_006518549.2). The deletion in Tg4510 removes the 
first 219kb of V2 and terminates 266kb upstream of the transcription start site for V1. 
Overall, this removes the promoters and first exons of variants V2, X1, and X2, leaving 
the coding region of only variant V1 intact (Figure 3B). Available antibodies to Fgf14 
protein do not distinguish between the products of these splice variants, and as a result 
Western blot analyses of Fgf14 differences between these lines was uninformative with 
respect to altered ratios of Fgf14 isoforms (not shown). We performed quantitative real-
time PCR (qRT-PCR) of splice variants using RNA extracted from forebrain tissue of 
rTg4510, Tg4510, and non-transgenic (NT) mice and found that rTg4510 mice express 
5.6-fold higher mRNA levels of variant V1 than NT mice and 2.8-fold higher levels of V1 
than Tg4510 mice in their forebrains (Figure 5A, Tables 5-6). Both rTg4510 and Tg4510 
mice exhibit decreased expression of Fgf14 variants V2, X1, and X2, presumably due to 
haploinsufficiency (Figure 5B-D, Tables 5-6). This reflects a dramatic imbalance of the 
ratios of these variants in relation to one another in rTg4510 compared to NT mice 
(Figure 5E). We attribute the slight upregulation of Fgf14 V1 in responder Tg4510 brains 
to altered chromatin structure and/or effects of the non-coding Prnp sequences in the 
tauP301L transgene array (Figure 3A). 
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Figure 5. Dysregulation of Fgf14 mRNA splice variants in rTg4510 and Tg4510 mice. 
Expression levels in the rostral one-third of dissected forebrain hemispheres of Fgf14 variants V1 
(a), V2 (b), X1 (c), and X2 (d) in non-transgenic (NT), rTg4510, and Tg4510 mice (n for each 
group in parentheses). Data points represent duplicates of qPCR. Expression levels of each 
variant were determined by qRT-PCR relative to housekeeping gene Hprt. All samples were run 
in duplicate. Kruskal-Wallis tests were performed for V1 (H=13.2, df=2, p<0.0001), V2 (H=17.5, 
df=2, p<0.0002), X1 (H=12.3, df=2, p=0.0001), and X2 (H=6.9, df=2, p=0.026) groups, followed 
by Dunn’s multiple comparisons tests. All data were normalized to a positive calibrator, and are 
expressed as the group mean ± SEM. (e) Compiled group mean data for all variants. *p ≤0.05, 
**p≤0.01, ***p≤0.001 
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Table 5. Primer sequences used to measure hTau and Fgf14 mRNA relative to Hprt in RT-qPCR 
experiments. 
Target Primers 
Forward Reverse 
hTau 5’- CTACACCATGCACCAAGACC -3’ 5’- TGCTTTTACTGACCATGCGA -3’ 
Fgf14 
variant V1 
5’- CATCTTCGGCCTCAAGAAGC -3’ 
5’- TCAGAACACCTGAGGATCTGGC 
-3’ 
Fgf14 
variant V2 
5’- GGCCTCTTCTTTCTCAGGGT -3’ 5’- CATGCAAGGATGGTTCTCGG -3’ 
Fgf14 
variant X1 
5’- TGCTAGGCTGAGCAATGTAG -3’ 5’- CCTTGGATCTTCGATAGGGC -3’ 
Fgf14 
variant X2 
5’- ATGCTGCAGTGTCTTTGTGG -3’ 
5’- TCACAGGGGATGCTCAGAAG -
3’ 
Hprt 
5’- GCTGGTGAAAAGGACCTCT -3’ 
5’- 
CCACAGGACTAGAACACCTGCTA -
3’ 
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Table 6. PCR cycling conditions using for relative RT-qPCR to measure hTau and Fgf14 
expression.  
hTau Fgf14 variant 
V1 
Fgf14 variant 
V2 
Fgf14 variant 
X1 
Fgf14 variant 
X2 
# °C Time # °C Time  # °C Time # °C Time # °C Time 
1 95 10:00 1 95 10:00 1 95 10:00 1 95 10:00 1 95 10:00 
32 95 00:10 45 95 00:10 40 95 00:10 40 95 00:10 45 95 00:10 
55 00:10 56 00:15 52 00:15 57 00:15 56 00:15 
72 00:10 72 00:25 72 00:28 72 00:12 72 00:16 
(#) number of cycles, (°C) temperature, Time (minutes:seconds) 
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tTA-TgINDEL in rTg4510 and rT2/T2 disrupts five more genes 
We also performed whole-genome sequencing on DNA from an rT2/T2 mouse. 
We confirmed the expected configuration of the targeted tauP301L transgene insertion in 
this line and also defined the hemizygous tTA-TgINDEL mutation used to drive 
expression both in this line and in rTg4510. We found that approximately 7 head-to-tail 
copies of the tTA transgene form an array that replaces 508,119bp in a gene-rich region 
of mouse chromosome 12 near the immunoglobulin heavy chain complex (Figure 6). 
Similar to the configuration within the Fgf14 tau-TgINDEL allele, the transgene 
orientation within the tTA insertion array switches from a 3’→5’ orientation to a 5’→3’ 
orientation, although in this instance a cloning vector DNA fragment is also incorporated 
at this inversion point. The massive genomic deletion in the tTA-TgINDEL removes the 
3’ portion of Vasoactive intestinal peptide receptor 2 (Vipr2), the 5’ portion of Protein 
tyrosine phosphatase, receptor type, N polypeptide 2 (Ptprn2), and encompasses all of 
the annotated genes WD repeat domain 60 (Wdr60), Extended synaptotagmin-like 
protein 2 (Esyt2), and Non-SMC condensin II complex, subunit G2 (Ncapg2), as well as 
several predicted but uncharacterized genes (e.g. Gm20658). We confirmed the 
transgene insertions sites by PCR amplifying and resequencing key junctions (Figure 7, 
Tables 7-8). All junction sequences and the compiled tTA transgene monomer 
sequence, which includes a Ca2+-calmodulin kinase II (CaMKII) promoter fragment, have 
been submitted to GenBank.  
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Figure 6. The tTA transgene array in rTg4510 and rT2/T2 mice disrupts genes on 
chromosome 12. Diagram of the uninterrupted chromosomal region and its disruption by the 
tTA-TgINDEL mutation. Tg, transgenes are blue triangles, cloning vector in inversion point of Tg 
array is a green line, uninterrupted genes are filled arrows, and partially deleted gene fragments 
are white arrows. 
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Figure 7. Confirmation of the junctions in the tTA-TgINDEL allele. (a) Diagram of the 
following key junctions: 1) the junction between the transgene array and Vipr2, 2) the junction 
between the transgene array and Ptprn2, 3) Tail-Head junctions between adjacent transgene 
copies (which occurred in three Types), 4) TgHead-Vector, and 5) vector-TgHead. (b) Gel 
electrophoresis of PCR products shown in panel a.  
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Table 7. Primer sequences used to amplify CaMKIIα-tTA transgene-genome junctions. 
Junction Forward Reverse 
Vector-
TgHead 
5’ – 
AAGCCCTCCCGTATCGTAGTTAT – 
3’ 
5’ – GATGAAGACTTGACCTTGCCTC 
– 3’ 
TgHead-
Vector 
5’ – TCCACTAGGCTCCCAAGTCAT 
– 3’ 
5’ – AAGGCGATTAAGTTGGGTAACG 
– 3’ 
TgTail-
TgHead 
5’ – 
AGGAACCTTACTTCTGTGGTGTG – 
3’  
5’ – TCCACTAGGCTCCCAAGTCAT – 
3’ 
TgTail-
Ptprn2 
5’ – 
AGGAACCTTACTTCTGTGGTGTG – 
3’ 
5’ – 
CCCATTTACAGGGAAAATAAAGCC – 
3’ 
Vipr2-
TgTail 
5’ – 
CTCAGTGGGACAAGCTACCAAA – 
3’  
5’ – AAATAGCTTCTGCCGAGAGTCC 
– 3’ 
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Table 8. PCR cycling conditions used for CaMKIIα-tTA transgene-genome junctions. 
Vector-TgHead TgHead-Vector TgTail-TgHead TgTail-Ptprn2 Vipr2-TgTail 
#  °C Time #  °C Time #  °C Time #  °C Time #  °C Time 
1 95 02:00 1 95 02:00 1 95 02:00 1 95 02:00 1 95 02:00 
30 95 00:20 30 95 00:20 30 95 00:20 30 95 00:20 30 95 00:20 
52 00:30 52 00:20 52 00:20 52 00:20  52 00:20 
72 00:45 72 00:30 72 00:50 72 00:43  72 00:30 
1 72 03:00 1 72 03:00 1 72 03:00 1 72 03:00 1 72 03:00 
(#) number of cycles, (°C) temperature, Time (minutes:seconds) 
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Transgene expression and Fgf14-TgINDEL accelerate pathology 
We evaluated human tau histopathology in somatomotor cortex and 
hippocampus of 2-, 5-, and 7-month old male and female rTg4510, rT2/T2, and rT2 mice 
using MC1, AT8, CP13, and PHF1 antibodies as well as a Bielschowsky (Biels.) 
silver stain. Semi-quantitative analyses of stained sections (Figures 8-12) revealed 
similar pathological forms of tau in the first two of these three lines, although these 
accumulated at earlier ages and to a greater extent in rTg4510 than in rT2/T2 (Figure 
13). Western blot densitometry of phosphorylated tau (pTau) showed higher signal in 
transgene-positive than transgene-negative control mice, but not between rTg4510 and 
rT2/T2, possibly due to variability in the data (Figures 14-15). However, analyses of 
insoluble high-molecular-weight (HMW) tau was more consistent with the histopathology 
data (Figure 16). When we examined tissue samples from the rT2 line with less extreme 
tauP301L overexpression (8.5x endogenous mouse tau level in rT2 vs. 17x in rT2/T2, see 
Figure 2) we found only limited instances of pathological-associated forms of human tau 
protein in a few tissue samples from 7-month old mice (Figure 13). 
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Figure 8. Accumulation of MC1-positive neurons progresses more slowly in rT2/T2 than in 
rTg4510 brains. MC1 (Tau aa 7-9 and 326-330) antibody was used to detect an early-stage 
pathological change in tau conformation in the hippocampus (Hipp) and somatomotor areas of 
cortex (Ctx) of 2-month, 5-month, and 7-month old female (A) and male (B) rTg4510 and rT2/T2 
mice. Insets of hippocampal images show the CA1 region. MC1-positive tau deposits in rTg4510 
brains appear smaller than in rT2/T2 brains due to neuronal shrinkage. Scale bars in low 
magnification images represent 250 µm in hippocampus and 200 µm in cortex. Scale bars in high 
magnification insets represent 50 µm.  
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Figure 9. Accumulation of CP13-positive neurons progresses more slowly in rT2/T2 than 
rTg4510 brains. CP13 (Tau pSer202) antibody was used to detect an early-stage pathological 
phosphoepitope on tau in the hippocampus (Hipp) and somatomotor areas of cortex (Ctx) of 2-
month, 5-month, and 7-month old female (A) and male (B) rTg4510 and rT2/T2 mice. Insets of 
hippocampal images show the CA1 region. CP13-positive tau deposits in rTg4510 brains appear 
smaller than in rT2/T2 brains due to neuronal shrinkage. Scale bars in low magnification images 
represent 250 µm in hippocampus and 200 µm in cortex. Scale bars in high magnification insets 
represent 50 µm. 
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Figure 10. Accumulation of AT8-positive neurons progresses more slowly in rT2/T2 than 
rTg4510 brains. AT8 (Tau pSer202/pThr205) antibody was used to detect a pathological pre-tangle 
phosphoepitope on tau in the hippocampus (Hipp) and somatomotor areas of cortex (Ctx) of 2-
month, 5-month, and 7-month old female (A) and male (B) rTg4510 and rT2/T2 mice. Insets of 
hippocampal images show the CA1 region. AT8-positive tau deposits in rTg4510 brains appear 
smaller than in rT2/T2 brains due to neuronal shrinkage. Scale bars in low magnification images 
represent 250 µm in hippocampus and 200 µm in cortex. Scale bars in high magnification insets 
represent 50 µm. 
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Figure 11. Accumulation of PHF1-positive neurons progresses more slowly in rT2/T2 than 
rTg4510 brains. PHF1 (Tau pSer396/pSer404) antibody was used to detect a late-stage 
pathological phosphoepitope on tau in the hippocampus (Hipp) and somatomotor areas of cortex 
(Ctx) of 2-month, 5-month, and 7-month old female (A) and male (B) rTg4510 and rT2/T2 mice. 
Insets of hippocampal images show the CA1 region. PHF1-positive tau deposits in rTg4510 
brains appear smaller than in rT2/T2 brains due to neuronal shrinkage. Scale bars in low 
magnification images represent 250 µm in hippocampus and 200 µm in cortex. Scale bars in high 
magnification insets represent 50 µm. 
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Figure 12. Accumulation of neurofibrillary tangle-positive neurons progresses more slowly 
in rT2/T2 than rTg4510 brains. Bielschowsky silver stain was used to detect mature 
neurofibrillary tangles in the hippocampus (Hipp) and somatomotor areas of cortex (Ctx) of 2-
month, 5-month, and 7-month old female (A) and male (B) rTg4510 and rT2/T2 mice. Insets of 
hippocampal images show the CA1 region. Deposits in rTg4510 brains appear smaller than in 
rT2/T2 brains due to neuronal shrinkage. Scale bars in low magnification images represent 250 
µm in hippocampus and 200 µm in cortex. Scale bars in high magnification insets represent 50 
µm. 
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Figure 13. Slower progression of histopathology in rT2/T2 than rTg4510, and correlation of 
hTau expression level with severity. Summary of semi-quantitative analysis of 
tau histopathology progression in rTg4510 (n = 3 2M, 4 5M, 4 7M), rT2/T2 (n = 4 2M, 3 5M, 4 
7M), and rT2 (n = 4 2M, 2 5M, 3 7M) mice. Severity of histopathology was measured on a semi-
quantitative scale (‘-’ for no, ‘+’ for occasional, ‘++’ for moderate, and ‘+++’ for prominent positive 
labeling). For each stain in each region, ‘+’ signs were counted for each animal. Multiple linear 
regression analyses were conducted to test for differences between groups. A significant 
difference between rTg4510 and rT2/T2 y-intercepts was found for AT8 in the cortex (p=0.017) 
and between rTg4510 and rT2/T2 progression of pathology (slope) was for Biels. in the cortex 
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(p=0.024). A significant difference between rT2/T2 and rT2 y-intercepts was found for AT8 in the 
cortex (p=0.014) and between rT2/T2 and rT2 progression of pathology in MC1 in the 
hippocampus (p=0.0006), MC1 in the cortex (p=0.002), AT8 in the cortex (p<0.001), PHF1 in the 
hippocampus (p=0.03), PHF1 in the cortex (p=0.009), and Biels. in the hippocampus (p=0.02). A 
significant difference between rTg4510 and rT2 progression of pathology was found for MC1 in 
the hippocampus (p=0.0004), MC1 in the cortex (p=0.001), AT8 in the cortex (p<0.0001), PHF1 in 
the cortex (p=0.0007), Biels. in the hippocampus (p=0.004), and Biels. in the cortex (p=0.0006). 
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Figure 14. Quantification of pathological tau in rTg4510 and rT2/T2 forebrains relative to 
GAPDH. Western blots (a) and densitometric quantification (b) of pathological Tau relative to 
GAPDH (14C10) levels in rTg4510 (n = 3 2M, 4 5M, 4 7M), rT2/T2 (n = 4 2M, 3 5M, 4 7M), and 
sibling controls (rTg4510 n = 4 2M, 6 5M, 5 7M; rT2/T2 n = 2 2M, 6 5M, 2 7M). (a) Antibodies for 
pathological Tau included MC1 (Tau aa 7-9 and 326-330), AT8 (Tau pSer202/pThr205), CP13 (Tau 
pSer202), and PHF1(Tau pSer396/pSer404). Sibling controls showed little to no positive labeling, and 
the AT8 antibody gave a weak signal. Tau-hemizygous rT2/T2 samples were excluded from all 
analyses. (b) Mann-Whitney tests were conducted to compare TauP301L–expressing rTg4510 to 
rT2/T2 and revealed no significant differences for any age or any immunolabeling.  
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Figure 15. Quantification of pathological Tau in rTg4510 and rT2/T2 forebrains relative to 
human tau. Western blots (a) and densitometric quantification (b) of pathological Tau relative to 
human Tau (ab74391) levels in rTg4510 (n = 3 2M, 4 5M, 4 7M) and rT2/T2 (n = 4 2M, 3 5M, 4 
7M) mice. (a) Antibodies for pathological Tau included MC1 (Tau aa 7-9 and 326-330), AT8 (Tau 
pSer202/pThr205), CP13 (Tau pSer202), and PHF1(Tau pSer396/pSer404). Tau (ab74391, Abcam) 
immunoblots used for normalization are shown below the appropriate pathological Tau 
immunoblot. The AT8 antibody gave a weak signal. (b) Two-Way ANOVAs were conducted on 
MC1:Tau, AT8:Tau, CP13:Tau, and PHF1:Tau signal at 2, 5, and 7 months of age, and revealed 
no main effects of Age or Transgene for any measure. Graphs display group medians ± 95% 
confidence intervals. 
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Figure 16. High-molecular-weight (HMW) human tau in RIPA-insoluble, sarkosyl-insoluble 
fraction increases with age in both rTg4510 and rT2/T2. Protein from rTg4510 (n = 3 2M, 4 
5M, 4 7M), rT2/T2 (n = 4 2M, 3 5M, 4 7M), and sibling control mouse brains was extracted in 
RIPA buffer. RIPA-insoluble protein was solubilized in 1% sarkosyl, and the remaining pellet was 
kept as the RIPA-insoluble, sarkosyl-insoluble fraction. Top: Western blots showing tau (Tau13, 
BioLegend) and βIII-tubulin in the RIPA-insoluble, sarkosyl-insoluble fraction. High-molecular-
weight (HMW) tau consists of one bands above 50 kDa. Genotypes, age, and sex are shown for 
each sample. Bottom: The HMW tau band was quantified relative to βIII-tubulin by densitometry 
for sibling controls (sib CTL) and TauP301L –expressing mice. Hemizygous rT2 samples were 
excluded from all analyses. Mann-Whitney tests comparing rTg4510 to rT2/T2 showed no 
significant differences at any age.  
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Transgene expression and Fgf14-TgINDEL modulate severity of brain atrophy 
rT2/T2 mice do not exhibit the dramatic premature loss of brain mass shown by 
rTg4510, which lose ~20% of their forebrain mass by 7 months of age (Figure 17A, B). 
Gross forebrain atrophy, evident in rTg4510, is also absent in rT2/T2 at 7 months of age 
(Figure 17C).  
Our experimental design for the work described here included evaluating 
forebrain mass loss through 7 months, at which point rTg4510 mice exhibit severe 
forebrain mass loss and obvious gross forebrain atrophy (Figure 17). Although the 
rT2/T2 mice do not share these phenotypes by 7 months, we had sufficient animal 
numbers to continue these evaluations at 9 months, and then with fewer animals per 
time point at 10, 13, and 15 months (Figure 18). The few rT2/T2 animals examined at 13 
and 15 months in this pilot experiment each had severe forebrain mass loss and obvious 
gross forebrain atrophy that matched that of the few remaining background strain-
matched rTg4510 examined at similar ages. We used rT2 mice as controls that 
incorporated the effects of the tTA TgINDEL but with more moderate overexpression of 
tauP301L. We did not find severe forebrain mass loss or obvious gross forebrain atrophy 
by even 18 months in the rT2 mice, although brain mass may be trending lower in the 
oldest rT2 mice evaluated. Expected rTg4510 brain mass values based on accumulated 
data from the Ashe lab are shown for comparison (Figure 18B). 
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Figure 17. rT2/T2 do not exhibit gross forebrain atrophy by 7 months of age. (A) Forebrain-
hemispheres were dissected from 2-month (rTg4510 n=9, SD= 0.010; rT2/T2 n=10, SD=0.009), 
5-month (rTg4510 n=4, SD=0.005; rT2/T2 n=3, SD=0.005), and 7-month (rTg4510 n=3, 
SD=0.002; rT2/T2 n=4, SD=0.006) old mice and weighed. A one-way ANOVA was conducted 
(F(5, 27)=5.034, p=0.0022) with Bonferroni’s multiple comparisons test for 2-month (p>0.99, 
t=0.31, df=27, 95% CI [-0.008, 0.010]), 5-month (p>0.99, t=0.87, df=27, 95% CI [-0.010, 0.021]), 
and 7-month (p=0.0004, t=4.42, df=27, 95% CI [0.011, 0.0422]) groups. (B) Whole brains were 
dissected from 2-month (rTg4510 n=10, SD=0.022; rT2/T2 n=11, SD=0.023), 5-month (rTg4510 
n= 4, SD=0.020; rT2/T2 n=3, SD=0.032), and 7-month (rTg4510 n=4, SD=0.017; rT2/T2 n=4, 
SD=0.020) old mice and weighed. Bonferroni-corrected unpaired two-tailed t-tests were 
conducted for 2-month (p=2.56, t=0.1894, df=19, 95% CI [-0.02, 0.02]), 5-month (p=0.58, t=1.497, 
df=5, 95% CI [-0.08, 0.02]), and 7-month (p=0.046, t=3.359, df=6, 95% CI [-0.08, -0.01]) groups. 
(C) Frozen brains from a 7-month female wild-type (WT) (left), rTg4510 (middle) and rT2/T2 
(right) mouse were thawed and immersion-fixed in 10% formalin. Data in (A) and (B) are 
represented as connected means. *p ≤0.05, ***p≤0.001 
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Figure 18. The Fgf14 Tau-TgINDEL accelerates and tau expression level correlates with 
severity of brain mass loss. Forebrain-hemisphere (a) and whole brain (b) mass were 
measured for rT2/T2 (n=32), rT2 (n=120), rTg4510 F1 (FVB/129S6) (n=554), and rTg4510 N2 
(FVB x FVB/129S6) (n=32) mice at varying ages. Note that the genetic background of rTg4510 
N2 is matched to rT2/T2 and that of rTg4510 F1 is matched to rT2. Comparing rT2/T2 to rTg4510 
N2, a delay in the drop in brain mass is observed for both forebrain-hemisphere and whole brain 
measurements. A comparison between rT2 and rT2/T2 reveals that a higher level of human tau 
expression results in a more severe loss in brain mass. Finally, these data suggest that a higher 
amount of FVB genetic background exacerbates brain mass loss when comparing rTg4510 N2 to 
rTg4510 F1 (b). Lines represent connected means. Thick dotted lines for rTg4510 F1 data 
represent 95% confidence bands while thin dotted lines represent 95% prediction bands. 
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Age-related behavior changes in rT2/T2 not seen in rTg4510  
The Morris Water Maze has been regularly used to detect memory impairment in 
rTg4510 mice (274,347), but we were unable to evaluate mice from the rT2/T2 line using 
this test because these mice develop an age-related high intensity flight response 
phenotype at ~7M, not present in either the rTg4510 or rT2 lines, that make them unable 
to perform this task. This flight response appears to become more similar to that of non-
domesticated mice as the rT2/T2 mice age. Nest building activity, which is a natural 
behavior in mice that has been used as a measure of behavior dysfunction in other 
mouse models of tauopathy (75), was severely impaired in the rT2/T2 mice by 8.5 
months whereas the rT2 mice exhibited normal nest building activity (Figure 19A, B). 
Additional evaluation of the behavior phenotype in 8.5-month old rT2/T2 mice using 
open field analysis suggest that these mice are hyperactive as indicated by distance 
traveled (Figure 19C), but do not spend more time moving (Figure 19D) and do not 
exhibit a higher level of anxiety (Figure 19E). As these mice age (12.5 months), distance 
traveled is reduced, but apparently primarily due to significant reductions in time moving 
(Figure 19C, D). We did not examine nest building activity or open field behavior in age-
matched rTg4510 mice. 
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Figure 19. Nesting and open field behavior in rT2/T2 mice. (155) At 8.5 months of age, rT2/T2 
(n=7), rT2 (n=12), and control littermates (Tau+/+tTA-/- n=7, Tau-/-tTA-/- n=12) were tested for their 
natural ability to construct a well-structured nest, which was scored 2, 6, and 24 hours after 
presenting the mice with a fresh nestlet. An overall sex effect was detected indicating that 
females tended to build better nests than males. Therefore, each sex was analyzed separately. 
An impairment in nesting was observed in both male and female rT2/T2 mice, with rT2 mice 
sometimes performing significantly better than rT2/T2 mice. For females (a), a Two-way 
Repeated Measures ANOVA revealed a significant main effect of genotype (F (3, 13) = 6.5, 
p=0.006). For males (b), a Two-way Repeated Measures ANOVA also revealed a significant main 
effect of genotype (F (3, 17) = 14.3, p<0.0001). Tukey’s multiple comparisons test were run to 
compare genotypes within time points. (c-e) rT2/T2 and control littermates were tested in the 
open field at 8.5 months of age (n=7 per group) and at 12.5 months of age (Tau+/+tTA+/- n=10, 
Tau-/-tTA-/- n=13). Two-way ANOVAs showed that rT2/T2 mice exhibit signs of hyperactivity in 
that they travel significantly farther in the open field than controls at 8.5 months (F(1, 33) = 9.395, 
main effect of genotype p=0.0043), however, this declines to normal distance by 12.5 months (c). 
This shorter distance traveled at 12.5 months is reflected in less time spent moving (F(1, 33) = 
7.748, main effect of genotype, p=0.0088) (d). rT2/T2 mice do not exhibit signs of anxiety, as they 
spend about the same amount of time in the center of the field as controls (e). Data represent 
mean ± standard deviation. 
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Figure 20. Overview of mouse lines and key phenotypic differences. The tauP301L transgene 
array in Tg4510 and the tTA (Tet-Off) transgene array in the expression driver line, both of which 
replace large segments of the mouse genome, can only be maintained as hemizygous alleles, as 
depicted. The single-copy targeted insertion of the same tauP301L transgene generated for the 
work described here does not disrupt any endogenous genes and was used as either a 
hemigyous (T2) or homozygous (T2/T2) allele, as shown. Expression from the tauP301L transgene 
requires the tTA transcription activator protein from the driver transgene, and bi-transgenic lines 
that carry both the driver and responder transgenes are designated as rTg4510, rT2 or rT2/T2 (“r” 
= regulatable). Our work demonstrates that the Fgf14 tau-TgINDEL mutation is necessary to 
cause the rapidly progressive tauopathy phenocopy in rTg4510 (rTg4510 vs rT2/T2), and that key 
hallmarks of this phenocopy do not develop without extremely high levels of tauP301L 
overexpression (rT2 vs rT2/T2). The Vipr2-Ptprn2 tTA-TgINDEL allele alone without the tauP301L 
transgene is sufficient to cause significant neurodegeneration, and contributions from this allele 
must be controlled for in any line using this allele. 
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IV. Discussion 
Of more than 300 therapeutic agents that had been reported by 2011 to 
effectively treat deficits in transgenic mouse models of Alzheimer’s disease, none had 
shown significant clinical benefit in human clinical trials (361). An expert advisory panel 
of academic, industry, and government scientists convened to address this failure 
recommended in its ‘best practices’ report “choosing models for preclinical studies that 
exhibit significant and well-characterized pathology relevant to the disease process of 
interest (that is, amyloid plaques, tau pathology, neuronal loss, oxidative 
stress/inflammatory changes, and so on)” (361). Perhaps due in part to this 
recommendation, the rTg4510 mouse model of tauopathy, which exhibits profound 
premature neurodegeneration and neurofibrillary tangles, has become widely used for 
both basic and preclinical studies. Among models of tauopathy, rTg4510 mice display 
the most dramatic loss of neurons, and this loss progresses rapidly in young animals (2-
7 months) (Figure 17). However, we have now found that overexpression of the 
pathogenic tau variant in these mice is not sufficient to cause this premature and robust 
age-related loss of forebrain mass and gross forebrain atrophy, as originally and 
currently thought. 
Two distinct mutant alleles are combined in rTg4510 mice: 1) the tauP301L-
TgINDEL, and 2) the tTA-TgINDEL needed to drive expression from the tauP301L 
transgene allele. Both of these mutations were generated by pronuclear injection of 
synthetic mini-gene constructs into mouse single-cell embryos and were selected from 
among the many random integration events that occurred by screening for alleles that 
conferred the desired phenotype. In neither case, however, were the selected mutations 
themselves mapped or characterized. Our work presented here together with growing 
evidence from other groups indicates that the attractive rTg4510 tauopathy phenocopy 
found by screening for pathology similar to those found in human tauopathies arises 
from unintended dysfunctions conferred by the tauP301L and tTA TgINDEL mutations.   
Precisely defining the effects of the Vipr2-Ptprn2 tTA-TgINDEL allele on the 
tauopathy phenocopy of rTg4510 is complex and in some ways problematic. The 
pronuclear injection experiment used to make this tTA allele, which is nominally 
expressed from a CamKII promoter fragment, generated lines with a wide array of 
expression patterns (350) and the primary phenotype originally used to select this 
particular tTA-TgINDEL allele was functional tTA-driven overexpression selectively in 
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mouse forebrain neurons (350). Since genomic regulators retained in flanking 
sequences at each insertion site dictate the unique temporal and spatial expression 
pattern of tTA from each mutant allele, we were not surprised to find that four of the five 
annotated genes disrupted by this particular recombination event (Vipr2, Ptprn2, Wdr60, 
and Esyt2, Figure 6) have prominent forebrain expression patterns 
(https://www.ncbi.nlm.nih.gov/gene/) (362). We note that loss of both copies of the fifth 
annotated gene, encoding the chromosome condensin Ncapg2, results in embryonic 
lethality (363). If nothing else, the unique tTA expression pattern generated from the 
combination of the CamKII promoter fragment within the context of the Vipr2-Ptprn2 tTA-
TgINDEL mutation defines the tauP301L expression pattern in rTg4510, and likely defines 
the tissue specificity of the tauopathy phenocopy as well. Because we did not generate 
an alternative targeted insertion of a tTA transgene for our current work, we cannot 
determine if the loss of the genes disrupted by the Vipr2-Ptprn2 tTA-TgINDEL directly 
affect the tauopathy phenocopy of rTg4510. 
Because the tau transgene is expressed from a synthetic tTA-responsive 
promoter, tTA activity and tau expression are intrinsically linked, and as a result 
conclusively extricating the impacts of tauP301L from those of tTA activity on phenotypes 
in rTg4510 may not be possible. The Vipr2-Ptprn2 tTA-TgINDEL allele alone has been 
shown to be sufficient to cause a progressive neuron loss that leads to obvious 
degeneration of the dentate gyrus (364). Suppression of tTA activity during the first six 
weeks of postnatal development with doxycycline (Dox) has been shown to eliminate 
this observed neuron loss (364), presumably by eliminating tTA binding and subsequent 
unintended activation of non-target gene expression at undefined loci in the genome. We 
note that the 490+ cognate tTA binding sites within the Fgf14 tau-TgINDEL would also 
be expected to modify binding of excess tTA to and transcription activation at 
noncognate genomic sites, potentially complicating the interpretation of direct 
comparisons between rTg4510 mice and tTA-only littermates. For example, neuron loss 
in rTg4510 mice is less obvious in the dentate gyrus than in other regions of the 
hippocampus and cortex (347), suggesting that the course of the documented tTA-driven 
neuronal toxicity is significantly altered in rTg4510 mice and may not contribute 
significantly to neuron loss. The design of the rTg4510 model precludes testing the 
alternative but not mutually exclusive hypotheses that overexpression of tauP301L or tTA 
in this early developmental window is necessary to cause neuron loss.  Administering 
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Dox to rTg4510 mice from conception to 6 weeks, followed by removal of Dox resulted in 
robust tau histopathology by 54 weeks of age; neuron loss was reported to be absent, 
but data for neuron loss was not shown (365). In addition, Dox suppression during 
development has been shown to result in a lower level of transgene overexpression in a 
model in which the Vipr2-Ptprn2 tTA-TgINDEL allele drives expression of a CamKII 
target transgene (366). If this is also true for expression from the Fgf14 tau-TgINDEL, 
then the post-suppression level of transgene overexpression following Dox suppression 
during development (365) may not be sufficient to drive neuron loss.  
The fact that the Vipr2-Ptprn2 tTA-TgINDEL allele is not genetically linked to the 
Fgf14 tau-TgINDEL in rTg4510 has allowed us to use this same allele to drive 
expression in our new targeted-insertion rT2/T2 mice, and thereby matching the pattern 
of transgene expression and incorporating Vipr2-Ptprn2 tTA-TgINDEL-linked 
confounding effects essentially identical to those found in rTg4510. Our new targeted-
insertion rT2/T2 mice overexpress tauP301L at levels even higher than in rTg4510 mice 
(Figure 2B, C) from the same basic transgene construct (Figure 3A), but only the 
rTg4510 mice exhibit robust age-related loss of forebrain mass and gross forebrain 
atrophy prior to one year of age (Figure 17). This result clearly demonstrates that a 
functional contribution from the Fgf14 tau-TgINDEL mutation other than tauP301L 
overexpression is a necessary cause of this premature overt atrophy. By comparing 
tauP301L histopathology in tissue samples from rT2/T2 and rTg4510 mice (Figures 8-16), 
we are also able to conclude that confounding contributions from the Fgf14 tauP301L-
TgINDEL mutation accelerate the rate at which and the extent to which tauP301L 
histopathology develops in rTg4510. Finally, we found that mice from the rT2/T2 line 
develop an age-related high intensity flight response phenotype that make them unable 
to perform the Morris Water Maze, the task that has been used to measure memory 
impairment in rTg4510 mice (274,347). 
We found that the random recombination event that integrated the tauP301L 
transgene array into the mouse genome in Tg4510 deleted 244kb of the Fgf14 gene 
(Figure 3B, Figure 4), and that this disruption results in the dysregulation of the ratios of 
Fgf14 splice variants in mice that carry this mutation (Figure 5). Unfortunately for anyone 
attempting to determine molecular mechanisms of tau-related dysfunctions using 
rTg4510, confounding dysfunctions in Fgf14 have the potential to impact almost every 
aspect of neurobiology including synaptic transmission, plasticity and neurogenesis 
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(367). The splice variants of the internal growth factor Fgf14 differ in their N-terminal 
amino acid sequences, which contribute to their subcellular localization and their ability 
to regulate the voltage-gated sodium channels with which they interact (367-375). The 
fact that unbiased transcriptome analyses of the extent of alternative promoter usage in 
adult human brains identified FGF14 as one of the few outlier genes with more than 100 
transcription start sites strongly suggests that differential regulation of this gene is critical 
for establishing and maintaining normal brain function (360). The deletion of 244kb of 
this gene in the Fgf14 tauP301L-TgINDEL mutation would severely compromise the 
differential regulation of these functionally distinct Fgf14 isoforms by removing a large 
percentage of these transcription start sites and alternative N-terminal coding sequences 
(Figures 3 and 5). A translocation within a region of the human FGF14 gene that is 
nearly identical to the syntenic segment of Fgf14 disrupted by the tau transgene in 
rTg4510 has been reported to be linked to phenotypes ranging from ataxia (mother) to 
microcephaly and severe mental retardation (proband) (376), suggesting that these 
types of FGF14 disruptions may increase susceptibility to significant loss of brain mass 
and function.  
Comparisons between homozygous rT2/T2 and hemizygous rT2, which 
overexpress tauP301L at 50% that of rT2/T2 (Figure 2), has allowed us to determine that 
high transgene overexpression is a third critically important contributor to the tauopathy 
phenocopy in rTg4510 mice. By comparing tauP301L histopathology in tissue samples 
from rT2 to those from rT2/T2 mice (Figure 13) we are able to conclude that pushing the 
level of tauP301L overexpression to match or exceed that found in rTg4510 dramatically 
accelerates the rate and extent to which tau histopathology develops. The obvious age-
related high intensity flight response phenotype observed in rT2/T2 but not rT2 mice is 
also a phenotype that appears to be linked to the hyperexpression level of tau 
overexpression in these models. Open field analysis (Figure 19C-E) revealed that the 
rT2/T2 mice traveled a greater distance than controls, but did not move more often, 
indicating that the true difference was the speed at which these mice moved. A similar 
increase in distance traveled in open field analysis was also seen in a mouse tauopathy 
model in which tauP301L was overexpressed from an adeno-associated virus (AAV) 
vector, although in that model the increase in distance traveled paralleled a similar 
increase in time moving (377). Similar to our findings with rT2/T2, the AAV1-tauP301L 
overexpression model exhibited widespread accumulation of tau histopathology by 6 
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months without overt loss of neurons (377). The overt atrophy that we did observe in 
limited numbers of aged rT2/T2 mice (>12 months), also appears to be a phenotype 
linked to hyperexpression of transgene, since we did not observe signs of overt atrophy 
in aged rT2 mice (Figure 18). We note that the overt atrophy that appears to develop in 
aged rT2/T2 mice is similar to the ages at which neuron loss is seen in another 
tauopathy mouse model (319). Further studies with additional control lines (e.g., rT1 
without the P301L mutation in the tau transgene) will be needed to conclude whether 
these impacts of transgene hyperexpression on phenotype in rT2/T2 are due specifically 
to extremely high levels of tauP301L in particular, or to less specific cellular stresses 
caused by extreme overexpression of an exogenous gene in general. Our finding that 
high levels of tauP301L overexpression directly leads to measureable dysfunctions in this 
protein product parallel findings in which overexpression of amyloid precursor protein 
causes additional phenotypes not found in models based on endogenous App 
expression levels (378,379). Although massive overexpression of a transgene has been 
used as a means of inducing dysfunctions in many mouse models and is rationalized as 
accelerating dysfunctions that also might develop more slowly at physiological levels of 
expression, we need to remain cognizant of the fact that the mechanisms underlying 
these hyperexpression-induced dysfunctions may be unrelated to those that cause 
disease in patients.   
Our work highlights the critical importance of identifying and using proper control 
lines in any experiments involving transgenic animal models. The classic controls for 
confounding contributions from the genomic position effects of randomly integrated 
transgenes has been to characterize populations of experimental lines (e.g., transgene 
with a mutation) and of control lines (e.g., transgene without a mutation), and then either 
continue to work with small populations of these lines (>3 lines) with phenotypes that are 
representative of the average phenotypes of these characterized lines, or in most cases, 
with only single representative lines from each population. In almost every instance, 
lines with outlier phenotypes will have confounding contributions from their unique 
TgINDEL mutation. Although it may eventually be possible to reproduce the full range of 
premature tauopathy-like phenotypes found in rTg4510 by using targeted genomic 
modifications to generate control lines that more precisely and reproducibly generate the 
confounding contributions from the Fgf14-TgINDEL mutation (e.g., similar Fgf14 
dysregulation), this would be a new experimental system, and key findings from rTg4510 
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would need to be reproduced in this new system. Given the high cost in time and 
resources involved in making such a replacement, the onus of pursuing that work would 
have to fall on any group proposing to continue to use rTg4510 in their research. At this 
point, the targeted insertion mouse models we are developing offers a system in which 
the Fgf14-TgINDEL mutation and the potential confounding contributions from this 
mutation are eliminated. If crossed to mice that carry the Vipr2-Ptprn2 tTA-TgINDEL, as 
described here, these mice will still have confounding contributions from this activator 
allele, but this artificial environment would be matched in all mice in the series, with the 
only difference between lines being the particular tau variant specifically introduced into 
the targeted tau transgene. Nonetheless, mechanistic studies using our transgenic 
models would still need to account for possible contributions from the Vipr2-Ptprn2 tTA-
TgINDEL and from non-physiological levels of transgene overexpression. 
For more than a decade rTg4510 mice have been widely used as a model of 
human tauopathy but without recognizing the necessary confounding contributions from 
the Fgf14 tauP301L-TgINDEL, and with only recent and inconsistent attempts to control for 
the contributions from the previously undefined Vipr2-Ptprn2 tTA-TgINDEL allele (364). 
We are explicitly not asserting that any hypotheses regarding tau pathophysiology 
generated from these studies using the rTg4510 model are incorrect. However, we 
believe that in all of these studies it is critical to account for possible contributions from 
the confounding effects that we have now defined. In particular, we caution against the 
use of rTg4510 for testing potential disease therapies, as we now know that a 
therapeutic agent could significantly improve or even eliminate tauopathy-like 
phenotypes in rTg4510 by incidentally correcting effects such as the contributions from 
the Fgf14 tauP301L-TgINDEL mutation (i.e., as in rT2/T2) without modifying the intended 
drug target. 
Although we have restricted our work to characterizing rTg4510, we believe that 
our findings are indicative of a much broader and deeper problem. Classic pronuclear 
injection technology generates mice in which a transgene construct is typically arrayed 
as multimers in unpredictable and irreproducible configurations (see Figure 3B and 
Figure 6) inserted in random locations into the mouse genome. Genomic position effects 
on transgene expression patterns as well as gene disruption and dysregulation caused 
by these random insert events invariably result in dramatic phenotypic variation between 
the mouse lines generated by this technology. All too often the mouse line selected for 
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detailed characterization from among these many lines has been the line that exhibits 
the most “significant… pathology relevant to the disease process of interest” (361), as 
was the case with rTg4510. Although such mouse lines are widely and routinely used, 
many of the TgINDEL mutations in these lines remain only marginally characterized at 
the genetic level. As we have shown here, advances in genomic DNA sequencing 
technology now allow us to fully define the TgINDEL mutations in these lines, enabling 
us to more accurately identify the confounding effects caused by these mutations and to 
account for their possible impacts on our work.  
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I. Introduction  
Tau is the main axonal microtubule-associated protein of the mammalian central 
nervous system. Though tau is principally found in neuronal axons where it aids in 
microtubule assembly (7) and regulates cargo transport along microtubules (184), it has 
other ‘atypical’ functions in different regions in an isoform-dependent manner (202) such 
as growth factor signaling (232), receptor anchoring (211), and DNA protection (218). 
Perhaps because of the complex and multifunctional role of tau in neuron biology, tau 
dysfunction in a family of neurodegenerative diseases called tauopathies can result in a 
wide spectrum of clinical and neuropathological phenotypes.  
The mechanisms underlying tau pathogenicity remain unclear, in part due to 
extreme variability in phenotypes of tauopathy mouse models. The P301L mutation is 
frequently used to model human disease because it is the most common MAPT mutation 
(AD & FTD mutation database). Although in vitro studies indicate that this mutation 
confers pathogenic properties to the tau protein such as reduced microtubule binding 
(34), this idea is inconsistently replicated in mouse models. Transgenic mice harboring 
the P301L mutation exhibit diverse phenotypes such as severe early neuropathology 
(274), late-onset tauopathy (380), progressive motor impairments (348), mild or absent 
phenotypes (277,381), or even improvements in cognition (382). Mouse models 
expressing non-mutant (NM) human tau should be used as controls for P301L models, 
however, NM tau mouse models also have a range of phenotypes including mild 
phenotypes (383,384), developmental neuropathology (385,386), progressive synaptic 
and cognitive impairments (387), neurodegeneration (319), progressive tauopathy (388-
390), glial pathology (391,392), and axonopathy associated with motor deficits 
(385,393,394).  
Variability in tauopathy mouse models can be attributed to differential tau 
isoforms, expression levels, promoters, and disruption of endogenous genes (395). We 
recently found that in a popular tauopathy mouse model, rTg4510, two transgene 
insertion-deletion (INDEL) mutations disrupt genes important for brain function, calling 
into question the precise role of tau in that phenotype (396). If confounding variables 
such as those associated with random genome disruption are not specifically accounted 
for, it is difficult to draw conclusions about the biological role of tau in tauopathies. 
In this study, our goal was to characterize phenotypes associated with the P301L 
mutation by systematically comparing a novel P301L mouse model to a genetically 
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matched non-mutant (NM) mouse line with the same human tau (hTau) isoform, 
expression pattern, and transgene insertion sites in the genome. These lines harbor a 
single copy of a ‘responder’ human tau transgene in the same non-disruptive genomic 
locus. To activate hTau expression, they are crossed to the same ‘activator’ tTA line 
used in our previous publication, which has a transgene INDEL mutation that disrupts 
several forebrain genes and causes dentate gyrus degeneration (364,396). 
Unfortunately, these studies began before we were aware of the genomic disruption in 
the tTA line, however, we control for this confound because the lines are genetically 
identical except for the P301L mutation.  
Unexpectedly, we found that the NM mouse line we intended to use as a control 
exhibited a robust and early phenotype, which was absent in the P301L line. Our 
findings indicate that overexpression of the 0N4R isoform of NM hTau is pathogenic 
during postnatal development, in a manner distinct from classical aging-related 
tauopathy. We show that developmental toxicity of NM hTau is associated with strong 
microtubule binding, which we hypothesize is a pathological trigger that leads to a 
disruption of cellular processes and eventual cognitive dysfunction.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 84 
II. Materials and Methods 
Animals 
An ES cell line generated in the Koob lab was used for this work (396). A 
construct was generated that was essentially identical to the construct used to generate 
Tg4510, but incorporated a Flp-In promoter cassette (PGK promoter-ATG-FRT), and 6 
µg this construct and 0.5 ug pCAGGS-FlpE (Gene Bridges cat# A201) were transfected 
into the V6.5Col1a#15 ES cell line. Hygromycin selection at 140ug/mL was added day 2 
through day 6, and Hygro resistant ES clones were picked on day 7. DNA was analyzed 
for 5’ (5ArmCol1A assay primer + TRE start Rev) and 3’ (AMP R Reverse + Hygro 
Connection) junctions, internal Tau (TAU assay F and R), and multiple integration assay 
(AMP R Reverse + TRE start R) by PCR. Clones that passed all assays were expanded 
and karyotyped, and T1 (non-mutant) and T2 (P301L) responder mice were generated 
by injection into blastocysts. These mice were back-crossed five times to FVB prior to 
generating the rT1 and rT2 lines. 
 
ES Cell Assay Primer sequences: 
5ArmCol1A pcr assay 5’-CAGGTGCACAGCATTGCGGACATG-3’ 
TRE Start Rev 5’-ATTGCTCCAGGCGATCTGAC-3’ 
Amp R Reverse 5’-GGAATAAGGGCGACACGGAA-3’ 
Hygro Connecton 5’-ATCCACGCCCTCCTACATCGAA-3’ 
Tau Assay F 5’-GTTCGAAGTGATGGAAGATCACG-3’ 
Tau Assay R 5’-TTGGGTGGAGTACGGACCA-3’ 
 
PCR Probe Primers: 
Amp F 5’-CCTCCATCCAGTCTATTAATT-3’ 
Amp R 5’-TCCTTGAGAGTTTTCGCCCCG-3’ 
 
A human tau plasmid was used to generate T1 and T2 responders, which harbor 
a 0N4R human tau cDNA transgene flanked by non-coding regions of the murine Prion 
protein gene and regulated by a tetracycline response element (TRE). Activator mice 
harbor a tetracycline transactivator (tTA) transgene under the control of the CaMKIIα-tTA 
(tTA) promoter to drive expression specifically in forebrain excitatory neurons (350). 
Human tau expression is activated in bigenic hTau+/-tTA+/- rT1 and rT2 progeny of an 
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activator-responder cross. Responder T1 and T2 mice were maintained on an FVB/N 
background while activator mice were maintained on a 129S6 background. Littermates 
hTau+/-tTA-/-, hTau-/-tTA+/-, and hTau-/-tTA-/- genotypes were used as controls. Both male 
and female mice were used, and were combined in statistical analyses after 
demonstrating the absence of significant gender effects (P > 0.05). All animal breeding 
was conducted conservatively assuming 8 pups per litter based on accumulated data 
from the Ashe lab colony. All experiments with animals described in this study were 
conducted in full accordance with the American Association for the Accreditation of 
Laboratory Animal Care and the Institutional Animal Care and Use Committee at the 
University of Minnesota. 
 
qRT-PCR  
mRNA expression levels of hTau were quantified relative to a reference gene, 
Hprt (Table 2). Total cellular RNA was extracted from homogenized forebrain tissue 
using RNeasy Lipid Tissue Kit (Qiagen) according to the manufacturer’s instructions. 
RNA samples were treated with DNaseI (New England Biolabs) to digest contaminating 
DNA, and subjected to cDNA synthesis using the iScript cDNA synthesis kit (Invitrogen) 
according to the manufacturer’s instructions. PCR reactions were set up in a 20-µl 
volume in 96-well plates, with 3 replicates per sample. Roche SYBR Green PCR master 
mix was used and reactions were run in the Roche LightCycler® 480 instrument (Table 
3). A final melting curve confirmed that single amplicons were present for each variant 
and reference reactions, and a basic relative quantification was performed using the 
∆∆CT-Method (LightCycler® 480 Software release 1.5.0 SP3). All data were normalized 
to a positive calibrator sample used in each experiment.  
 
Protein extraction from brain tissue in RIPA buffer 
Soluble and insoluble protein was extracted from mouse forebrain hemisphere 
tissue in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 0.5% Triton X-100, 
1% sodium deoxycholate, 0.3% SDS, 0.1 mM phenylmethyl sulfonyl fluoride, 0.2 mM 
1,10-Phenoanthroline Monohydrate, Phosphatase Inhibitor Cocktail A (Sigma), Protease 
Inhibitor Cocktail (Sigma), Phosphatase Inhibitor Cocktail 2 (Sigma)) by drawing up and 
expulsing tissue through 1 mL MonojectTM syringes (Covidien) first without and then with 
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20G BD PrecisionGlideTM needles. Homogenates were nutated for 1 hour at 4°C then 
centrifuged at 13,000 rpm for 90 minutes at 4°C, and the supernatant was collected.  
 
Protein extraction from brain tissue in TBS buffer 
Soluble protein was extracted from mouse left forebrain hemispheres in TBS 
buffer (25 mM Tris-HCl, pH 7.4, 140 mM NaCl, 3 mM KCl) using a Dounce Homogenizer 
(PolyScience) at setting 10 for 25 strokes. A series of protease inhibitors were added to 
buffer within 1 hour of use at the following final concentrations: 0.1 mM phenylmethyl 
sulfonyl fluoride, 0.2 mM 1,10-Phenoanthroline Monohydrate, Phosphatase Inhibitor 
Cocktail A (Sigma), Protease Inhibitor Cocktail (Sigma), Phosphatase Inhibitor Cocktail 2 
(Sigma). After homogenization, samples were centrifuged at 15.6 x g for 90 minutes at 
4°C. Supernatants were collected and diluted appropriately for ELISA. 
 
Subcellular fractionation of brain tissue 
Mouse right forebrain hemispheres were biochemically fractionated into cytosolic 
and light membrane (GAPDH-enriched, G-E), presynaptic (Synaptophysin-enriched, S-
E), and postsynaptic (PSD-95-enriched, P-E) fractions using a modified version of a 
previously published protocol (397). Briefly, to obtain the G-E fraction, tissue was gently 
homogenized in sucrose buffer (0.32 M sucrose, 25 mM HEPES, pH 7.4) using a 
Dounce Homogenizer (PolyScience) at setting 1 for 12 strokes. Homogenates were 
centrifuged at 3,000 x g for 5 minutes at 4°C. The supernatant was then centrifuged at 
10,000 x g for 12 minutes at 4°C, and the resulting supernatant was collected. To obtain 
the S-E fraction, pellets were washed in sucrose buffer and then resuspended in HBS 
(25 mM HEPES, 150 mM NaCl, pH 7.4). 80% Triton X-100 (Sigma) was added to the 
suspension for a final concentration of 2%. Samples were then incubated on ice for 30 
minutes, centrifuged at 10,000 x g for 20 minutes at 4°C, and the resulting supernatant 
was collected. To obtain the P-E fraction, pellets were resuspended in PBS (0.01 M 
phosphate buffer, 0.0027 M KCl, 0.137 M NaCl, pH 7.4). A series of protease inhibitors 
were added to all buffers within 1 hour of use at the following final concentrations: 0.1 
mM phenylmethyl sulfonyl fluoride, 0.2 mM 1,10-Phenoanthroline Monohydrate, 
Phosphatase Inhibitor Cocktail A (Sigma), Protease Inhibitor Cocktail (Sigma), 
Phosphatase Inhibitor Cocktail 2 (Sigma). 
 
 87 
Phosphatase treatment of brain extracts 
RIPA extracts (see above) were treated with calf intestinal alkaline phosphatase 
(CIP, New England Biolabs), and samples were resuspended in 10 µl CIP buffer (100 
mM NaCl, 50 mM Tris-HCl, 10 mM MgCl2, 1 mM dithiothreitol, EDTA-free protease 
inhibitor cocktail, pH 7.9) per 1 µg protein. One unit CIP per µg protein was added to the 
samples prior to incubation at 37°C for 30 minutes. Samples were then concentrated 
using 0.5mL 10K Amicon Ultra centrifugal filters (Millipore, UFC501096).  
 
Isolation of microtubules and associated proteins 
Microtubules (MTs) and microtubule-associated proteins were isolated using a 
previously published protocol (398), which was modified from two original publications 
(399,400). Mouse forebrains were flash frozen in liquid nitrogen and crushed into a 
powder using a mortar and pestle. The powder was resuspended in 1.5X volume of 
MES/glutamate buffer (0.1M pH6.8 2-(N-morpholino)ethanesulfonic acid, 0.5mM MgCl2, 
1mM EGTA, 1M glutamate) containing 1mM DTT. The suspensions were sonicated 5 
times for 10 seconds with 30-second rest intervals on ice (sonicator amplitude 20%, 1 
short burst per second done manually in Continuous mode) (Fisher Scientific 150E 
Digital Sonic Dismembrator, with model 4C15 cell disruptor). Samples were 
ultracentrifuged at 30,000 x g at 4°C for 15 minutes, and then supernatants were 
ultracentrifuged at 120,000 x g at 4°C for 1 hour (Beckman Coulter OptimaTM L-80 XP 
Ultracentrifuge with Type 70.1 Ti Fixed-Angle Titanium rotor and 4mL thick-walled 
polycarbonate tubes). 20µM Taxol (Paclitaxel, ApexBio #A4393) and 1mM GTP were 
added to the clarified supernatants, which were then incubated at 37°C for 30 minutes. 
Samples were gently layered onto a sucrose cushion (MES/glutamate buffer containing 
20% sucrose) and ultracentrifuged at 30,000 x g at 37°C for 30 minutes. The 
supernatants were then collected as the cytosolic fraction while MT/MAP pellets were 
resuspended in 50ul MES/glutamate buffer containing 20µM taxol and stored at -80°C.  
 
Sarkosyl extraction 
To obtain sarkosyl-insoluble fractions, a modified version of a previously 
published method was used (351). Briefly, RIPA-insoluble pellets were homogenized in 
1% sarkosyl and incubated at room temperature for 30 minutes with constant shaking. 
Samples were centrifuged for 1 hour at 100,000 xg at 20°C, and the supernatant and 
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pellet were separated and diluted in O+ buffer (62.5 mM Tris-HCl, pH 6.8; 10% glycerol; 
5% 2-mercaptoethanol; 2.3% SDS; 1 mM EGTA; 1 mM EDTA; 1 mM PMSF; 1 mM 
Na3VO4; 1 mM NaF; 10 μl/ml of protease inhibitor cocktail P8340; Sigma-Aldrich). 
Samples were boiled for 3 minutes and stored at -20°C.  
 
Western blot and analysis 
Total protein concentrations for each sample were determined by Pierce™ 
Bicinchoninic Acid protein assay (Thermo Scientific).  Equal amounts of protein for each 
sample were loaded and separated using SDS-PAGE on 10%, 10-20% or 10.5-14% 
CriterionTM pre-cast Tris-HCl gels (Bio Rad). Protein was transferred to nitrocellulose 
membranes (Bio Rad), which were blocked with 5% Bovine Serum Albumin (Sigma) in 
1X TBST buffer (10 mM Tris-Base (Sigma), 0.2 M NaCl (Macron Chemicals), 0.1% 
Tween-20 (Sigma) pH 7.4).  Protein was immunoblotted with Tau13 (1:60,000, 
BioLegend), GAPDH (14C10, Cell Signaling Technology, 1:4,000), Tau46 (4019T, Cell 
Signaling Technology, 1:10,000), β-III tubulin (79-720, ProSci, 1:10,000), Synaptophysin 
(SY38 ab8049, Abcam, 1:10,000), PSD-95 (2507S, Cell Signaling Technology, 
1:10,000), CP13 (pSer202, Peter Davies, 1:1,000) , PHF1 (pSer396/404, Peter Davies, 
1:1,500), rabbit anti-human tau (ab74391, Abcam, 1:10,000), α-tubulin (ThermoFisher, 
DM1A 62204, 1:10,000), MAPK (05-481, Millipore, 1:250) and JNK/SAPK1 (06-748, 
Millipore, 1:5,000) antibodies. For total protein analysis, Li-Cor REVERTTM total protein 
stain kit (product #926-11010) was used to obtain normalized phospho-tau to total tau 
ratios on separate western blots, after ab74391 was discontinued. To visualize 
immunoreactivity using a LiCor imaging system, IRDye-linked goat anti-mouse 800CW 
and goat anti-rabbit 680LT secondary antibodies were used (LI-COR 
Biosciences,1:100,000). Immunoreactivity was quantified by densitometry using 
OptiQuant version 3 software. 
   
ELISA 
Samples were run in duplicate in the Human Total Tau V-PlexTM ELISA kit (Meso 
Scale Discovery) according to the manufacturer’s instructions. To be within the range of 
detection for this assay, extracts were diluted in Diluent 35 at the following ratios: TBS 
1:10,000, G-E 1:5,000, S-E 1:2,000, and P-E 1:150.  
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Half-life measurements 
Doxycycline chow (DOX) (Diet 7013, 200mg/kg) was administered to 8-week old 
rT1 and rT2 mice 3 times per week for 0, 1, 3, 6, 11, 16, and 21 days resulting in 
suppression of hTau mRNA expression for 0, 2, 5, 10, 15, and 20 days, because it takes 
24 hours to suppress hTau suppression in these mouse lines (data not shown). hTau 
protein levels measured by ELISA (ng hTau / mg brain mass) were Log transformed and 
plotted over days on DOX chow. Simple linear regressions were used to determine the 
slopes (k’) of rT1 and rT2 lines and the half-life (t1/2) was determined based on the 
integrated rate law of first-order chemical reactions: k = 2.303 * k’ ; and t1/2 = 0.693 / k 
(401).  
 
Morris Water Maze 
The investigators were blinded to the group allocation and mice were randomized 
to control for potential age, gender and litter effects. Sample sizes were estimated based 
on our unpublished data. Spatial reference memory was measured by using a modified 
Morris water maze with a protocol tailored for rapid learning in the 129/FVB F1 mice 
(402). Mice were prehandled for 5 sessions during the week preceding testing to 
gradually introduce the animals to handler manipulations and exposure to the 
transportation devices (beaker and scoop). In addition, there was a gradual increase in 
the time that mice were in home cages without micro-isolator lids and then outside of 
their cage in an open field and under brighter light conditions without exposure to water. 
Mice received visible-platform training for 5 d, with three trials per day, followed by 
hidden-platform training for 8 d, with two trials per day. The path lengths to the hidden 
platform were averaged over two-day periods (two trials per day, four trials total) for 
statistical analysis. There was a 3-d rest period between the visible- and hidden-platform 
training sessions. Three probe trials of 30 s duration each, during which the platform was 
removed from the pool, were performed 72 h after the 8th, 12th and 16th trials of hidden-
platform training, after days 4, 6, and 8 of hidden training, respectively. Hidden training 
continued immediately after the first and second probe trials. Accordingly, there was 72-
h interval between hidden trials 8 and 9 (days 4 and 5) and between trials 12 and 13 
(days 6 and 7). The quadrant occupancy scores of the three probe trial scores were 
averaged for statistical analysis. For developmental suppression experiments, DOX 
chow (40 mg/kg, Envigo) was administered 3 times per week to either pregnant T1 and 
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T2 dams (Diet 5015) upon separation from sires or to weaned litters (Diet 7013). This 
dosage of DOX was chosen because higher doses cause placental abnormalities and 
fetal loss (403). rT1 and rT2 hTau+/-tTA+/- mice in addition to hTau-/-tTA-/- and hTau-/-tTA+/-  
littermates included in this study all received the DOX chow diet. Upon switching diets 
between DOX and regular chow, clean cages were used. All trials were monitored, and 
performance measures were extracted using a computerized tracking system (Noldus 
EthoVision XT 10; Noldus Information Technology). hTau-/-tTA-/- and hTau+/-tTA+/- mice of 
the same line underwent water maze training at the same time to control for batch 
effects. 
 
Mitochondrial length and transport measurements 
Mitochondria were examined using methods validated previously (404). Primary 
hippocampal cultures were established using postnatal day 0 pups. The hippocampus 
was dissected in cold Earle’s balanced salt solution (Gibco) and digested with 10 U/ml 
papain (Worthington Biochemical Corporation) in Earle’s balanced salt solution at 37°C 
for 15 min. Low ovomucoid solution containing 0.15% BSA (Sigma-Aldrich), 0.15% 
trypsin inhibitor (Sigma-Aldrich) in Dulbecco’s phosphate-buffered saline (DPBS) with 
calcium and magnesium (Gibco), and 66.6 U/ml deoxyribonuclease I (Sigma-Aldrich) 
was added to stop the digestion reaction. After 5 min, cells were suspended in fresh low 
ovomucoid solution. Debris was removed with a BD 70-μm nylon strainer, and the cells 
were spun at 341x g for 7 min. Cell pellets were then resuspended in warm Neurobasal 
A medium (Gibco) containing 2% B27 (Gibco), 0.5 mM GlutaMAX (Gibco), and 100 U/ml 
penicillin/streptomycin (Gibco).  
Hippocampal primary neurons were plated on glass-bottom microwell dishes 
(MatTek Corporation) that had been coated overnight with 0.5 mg/ml poly-L-lysine 
(Sigma-Aldrich) in borate buffer and for 1-2 h with 0.005 mg/ml laminin in neurobasal A. 
Hippocampal cells were plated at a density of 350,000 cells per 10-mm microwell dish. 
After 24 h, 5-fluoro-2’-deoxyuridine (Sigma-Aldrich) was added at a final concentration of 
7.15 μg/ml to inhibit glial growth. Half-medium changes were performed every 7 d to 
maintain culture health. 
Transfections of hippocampal cultures were performed on DIV 8-11. Plasmids 
used (provided by K. Vossel, University of MN) included an FUGW EGFP construct 
(405) and mito-RFP, which was constructed by fusing the mitochondrial-targeting 
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sequence of human isovaleryl coenzyme A dehydrogenase to the N terminus of RFP 
within the pDsRed1-N1 vector backbone containing a CMV promoter (Takara Bio Inc.) 
(406). After removal of conditioned medium, cells were washed once with warm DPBS 
without calcium or magnesium (Gibco) and immediately placed into 500 μl warm 
transfection medium consisting of Neurobasal A (Gibco) with 0.5 mM GlutaMAX (Gibco), 
1 mM kynurenic acid (Sigma-Aldrich) and 10 mM magnesium chloride (Sigma-Aldrich). 
To prepare transfection complexes, Lipofectamine 2000 (Invitrogen) was added to 
OptiMEM reduced serum medium with GlutaMAX (Gibco) at a ratio of 1.35 μl 
Lipofectamine per 25 μl OptiMEM. In separate tubes, plasmid DNA was combined in 
amounts that were equimolar to 1 μg FUGW per 25 ml OptiMEM. After incubating 
separately 5 min, the Lipofectamine-OptiMEM and DNA-OptiMEM solutions were 
combined and incubated at room temperature while covered for 25 min. Then, 50 ml of 
combined transfection solution was added to each microwell dish. Neuronal cultures 
were then incubated for 30 min at 37°C. Finally, cells were washed twice with warm 
DPBS and immediately placed in ¾ conditioned medium and ¼ fresh medium.  
Live imaging of axonal mitochondria was conducted on DIV 10-13 with a Nikon 
inverted TiE deconvolution microscope system with Ibidi live cell environmental 
chamber, PFS Perfect Focus III focus lock technology, LED Light engine, motorized 
stage, Zyla 5.5MP sCMOS camera, and Nikon NIS-Elements Viewer imaging software 
version 5.10. Objective lenses were 10x (PlanFluor, NA 0.25), 20x (PlanFluor, NA 0.25 
ELWD), and 40x (Plan Apo, NA 0.95). EGFP and RFP were illuminated at wavelengths 
of 470 nm and 555 nm, respectively.  
At the beginning of each section, positions of neurons with easily identifiable 
axons were recorded at 10x magnification, using FUGW (EGFP) as a morphology 
marker. Cells exhibiting axonal beading were excluded from imaging sessions. Axons 
were distinguished as the longest neurite (≥3 times longer than other neurites), validated 
previously (404). Imaging of axonal mitochondria using mito-RFP was performed for 
each axon with a 40x objective. Images were acquired every 1 s for 150 s, with an 
exposure time of 100 ms per frame.  
Images were processed in Fiji using the Multiple Kymograph and tsp050706 
plugins. Moving mitochondria were defined as showing displacement of at least 2 μm, 
which was the average length of mitochondria observed previously (404). Velocity was 
measured for each moving mitochondrion by averaging its total velocity, including brief 
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pauses, while in the image frame. Lengths of mitochondria were measured on the 
kymographs. Pixels were converted to μm based on the calibration of the objective. 
 
Fluorescent immunohistochemistry, imaging, and analysis  
At two months of age mice were transcardially perfused with 50ml phosphate-
buffered saline followed by 50ml 4% paraformaldehyde. Brains were removed, post-fixed 
overnight in 4% paraformaldehyde, and cryoprotected for 48hr in 30% sucrose. Brains 
were coronally cryo-sectioned at 40 microns, and all subsequent incubations and 
washes were performed free-floating in 24-well plates. 
Following three washes of PBS+ .1% TritonX-100, sections were placed in 1% 
NaBH for 20 min at room temperature.  Sections were washed 5x15minutes in PBS+ 
.1% TritonX-100. Sections were incubated in an antigen retrieval sodium citrate buffer 
(Reveal Decloaker, Pacheco, CA) for 30 minutes at 80° and allowed to cool for 30 
minutes. Sections were washed 3x15min in PBS+ .1% TritonX-100 and transferred to 
blocking buffer of PBS + .5% triton X-100, 5% Normal goat serum. Sections were 
incubated for 48hr at 4° in primary antibody solution of PBS + .3% triton X-100, 3% 
Normal goat serum, at a 1:1,000 dilution (DNA/RNA Oxidative Damage Oh8dG, QED 
Bioscience Inc. San Diego, CA). 
Following three washes of PBS+ .1% TritonX-100, sections were incubated for 
1hr at room temperature in secondary antibody solution of PBS + .3% triton X-100, 3% 
Normal goat serum, at a 1:1,000 dilution (Goat Anti-Mouse IgG H&L Alexa Fluor594, 
Abcam, Cambridge, United Kingdom). Sections were washed 3x15min in PBS and 
placed onto Superfrost slides. Sections were treated for 30 seconds with TrueBlack® 
Lipofuscin Autofluorescence Quencher and washed 3x15min with PBS.  Slides were 
coverslipped with Vectashield mounting media containing DAPI (Vector Laboratories, 
Burlingame, CA). Note that RNase treatment did not affect signal intensity in pilot 
experiments, and thus was not used for experimental tissue. 
After blinding the investigator, samples were imaged on a Nikon NiE C2 Upright 
Confocal microscope and 10x images were taken of the dentate gyrus of the 
hippocampus, CA1 region of the hippocampus, and the cortex. Analysis of the Alexa 
Fluor594 signal intensity was performed in Fiji/ImageJ. The pyramidal layer of the CA1 
region of the hippocampus, the granular cell layer of the dentate gyrus, and all cortical 
layers were outlined as the region of interest (ROI) using the polygon tool. The 
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integrated density (area x mean intensity) of the ROI was measured to account for 
differences in area between samples.  
 
Experimental Design and Statistical Analysis 
Power analyses on preliminary data were performed for pTau quantification, 
hTau ELISA, and Morris Water Maze. For pTau detection by western blot, it was 
determined that an n of 6 mice would be sufficient to have an 84% chance of detecting a 
39% difference in means at a significance level of 0.05. For ELISA experiments, it was 
determined that an n of 4 mice per line would be sufficient to have a 91% chance of 
detecting a 21% difference in means. Therefore, a group size of 6 was chosen for tau 
quantification experiments by western blot and ELISA. For behavioral experiments, it 
was determined that a sample size of 12 would be sufficient for a 64% chance of 
detecting a 41% difference in group means.  
 For half-life experiments, R programming language was used to conduct multiple 
linear regressions for detecting differences between linear regression slopes. Statistical 
analyses for all other data were conducted using GraphPad Prism version 7.00 software 
(GraphPad Software). Unpaired two-tailed t-tests were used to detect differences 
between rT1 and rT2 hTau mRNA, protein (by western blot and ELISA), phosphorylated 
hTau at 8 weeks of age, and NM vs. P301L hTau levels in microtubule-binding 
experiments. Two-way ANOVAs with Sidak’s multiple comparisons test were used for 
comparing human and mouse tau levels in rT1 and rT2 mice, as well as hTau levels and 
phosphorylation with or without DOX suppression. Simple linear regression was used to 
calculate slopes, y-intercepts, and R2 values for NM and P301L hTau half-life data. 
Bonferroni-corrected unpaired two-tailed t-tests were used to compare phosphorylation 
levels of hTau in rT1 and rT2 at 3, 5, and 7 weeks of age. Two-way ANOVAs with 
Tukey’s multiple comparisons test were used to detect differences in hTau levels and 
phosphorylation with 4 or 12 weeks of DOX suppression in rT1 and rT2. 
Two-way repeated measures ANOVAs with Sidak’s multiple comparisons tests 
were used for Morris Water Maze visible and hidden trial data to determine if rT1, rT2, 
and non-transgenic littermate path lengths changed over time. Two-Way repeated 
measures ANOVAs with Tukey’s multiple comparisons tests were used for Water Maze 
visible and hidden data to determine if rT1 and rT2 path lengths differed from 4-week 
and 12-week DOX suppression groups. One-way ANOVAs followed by Holm-Sidak’s 
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multiple comparisons tests with target (T) as the control column were to assess search 
bias in Water Maze probe trial data to separately determine if each group spent more 
time in the target than the other 3 quadrants (407). One-way ANOVAs followed by Holm-
Sidak’s multiple comparisons tests were also used to compare 0-, 4-, and 12- week 
suppression groups and to compare hTau-/-tTA-/-, hTau-/-tTA+/-, and hTau+/-tTA+/- 
genotypes in time spent only in the target quadrant. Two-tailed Mann Whitney tests were 
used to directly compare the percent time spent only in the target quadrant between rT1 
or rT2 and non-transgenic littermates. A Kruskal-Wallis test with Dunn’s multiple 
comparisons test was used to analyze mitochondrial length data. Two-way ANOVAs with 
Sidak’s multiple comparisons tests were used to determine whether there were 
differences in oxidative stress between rT1 and rT2 and between each of the genotypes 
in each brain region. Two-way ANOVAs with Sidak’s multiple comparisons test were 
used to test if postnatal brain mass differed between genotypes, if rT1 brain mass 
differed from rT2, and to test if DOX suppression affected rT1 and rT2 brain mass. In all 
cases, p<0.05 was considered to be statistically significant.  
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III. Results 
Elevated steady-state levels of 4R NM compared to P301L hTau 
Responder T1 and T2 mice were generated using site-specific targeting of a 
human tau (hTau) transgene downstream of the Col1A1 3’ untranslated region in 
modified embryonic stem cells. Correct single-copy integration was confirmed using 
PCR assays and whole-genome sequencing (396). The transgene consists of the cDNA 
sequence for the 0N4R isoform of hTau, flanked by non-coding regions of the murine 
Prion protein gene to enhance brain expression (274), and regulated by a tetracycline 
response element (TRE) promoter. T1 mice harbor a non-mutant hTau transgene while 
T2 harbor a P301L mutant hTau transgene. Responder T1 and T2 mice are crossed to 
the CaMKIIα-tTA line (350) to generate Tet-OFF bigenic rT1 and rT2 (r = regulatable) 
progeny that express 0N4R hTau selectively in forebrain neurons, except in the 
presence of doxycycline.  
hTau transgene expression was not ‘leaky’ in the absence of the activator 
transgene in T1 and T2 responder lines (Figure 21A, Table 10). Despite expressing 
similar levels of hTau mRNA in the forebrain (Figure 21A, Table 10), rT1 mice had 
elevated steady-state levels of hTau protein at 8 weeks of age (t(21) = 4.60, p = .0002, 
95% CI [-1.10 , -.42]) (Figure 21B). A difference in electrophoretic mobility also 
suggested a difference in post-translational modifications (Figure 21C). A human tau 
ELISA (Meso Scale Discovery) confirmed the difference in hTau steady-state levels 
(t(10) = 5.06, p = .0005,  95% CI [-112.3 , -43.66]) (Figure 21D). To quantify fold-
overexpression of hTau relative to endogenous mouse tau, phosphatase-treated 
extracts from rT1 and rT2 were compared to activator-only (tTA) brains using a pan-tau 
antibody, which revealed 12.6-fold overexpression in rT1 and 6.2-fold in rT2 (tTA vs. 
hTau F(1, 20) = 73.71, p < .0001; rT1 vs. rT2 F(1, 20) = 12.01, p = .0024) (Figure 
21E,F). rT1 hTau overexpression was significantly higher than that of rT2 (p = .0002).  
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Figure 21. hTau expression in rT1 and rT2 mice. (A) Relative RT-qPCR shows similar hTau 
mRNA expression in 8-week old rT1 and rT2 forebrains. hTau mRNA was not detected in T1 or 
T2 responders, demonstrating a lack of leaky transgene expression in the absence of the 
activator transgene (data not shown). (B) Densitometric analysis of western blots shows higher 
steady-state levels of NM than P301L hTau in forebrains of 8-week old mice. (C) Representative 
immunoblots for hTau (Tau13 antibody) and GAPDH protein for data in B. Proteins were 
extracted in RIPA buffer and run on a 10-20% Tris-HCl gel. (D) Soluble tau extracted in TBS 
buffer and measured by human tau ELISA also shows higher steady-state levels of NM than 
P301L hTau in 8-week old forebrains. (E) Quantification of full-length (FL) human and mouse tau 
in phosphatase-treated samples from 8-week old forebrains, showing higher overexpression of 
hTau in rT1 (12.6-fold) than rT2 (6.2-fold) relative to tTA+/- mice. (F) Representative immunoblots 
for human and mouse tau (Tau46) and β-III tubulin for data in E. Proteins were extracted in RIPA 
buffer, treated with phosphatase, and run on a 10.5-14% Tris-HCl gel. n’s for each group in 
parentheses. Graphs display group means + SD. ***p<0.001 
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Longer half-life of 4R NM than P301L hTau 
Because hTau mRNA levels are similar between rT1 and rT2, it is unlikely that 
hTau protein is higher in rT1 due to a higher rate of production. We therefore tested the 
hypothesis that the elevation in 4R NM hTau steady-state levels was due to a slower 
rate of degradation by measuring the half-life in 8-week old rT1 and rT2 mice in a 
manner similar to a previous study (401), taking advantage of doxycycline (DOX)-
mediated suppression. Using ELISA measurements, we found that hTau levels declined 
with longer periods of transgene suppression (F(3, 80) = 443.9, R2 = 0.94, p < .000), and 
that the clearance rate of soluble hTau was slower in 8-week old rT1 than rT2 forebrains 
(Figure 22A, Table 9).  
To determine if clearance of 4R NM hTau was impaired in a specific subcellular 
compartment, forebrains were fractionated into GAPDH-enriched (G-E), synaptophysin-
enriched (S-E), and PSD-95-enriched (P-E) fractions (Figure 22B). Again, hTau levels 
declined with longer periods of transgene suppression in the G-E (F(3, 80) = 147.6, R2 = 
0.85, p < .000), S-E (F(3, 80) = 115.9, R2 = 0.81, p < .000), and P-E fractions (F(3, 80) = 
125.5, R2 = 0.83, p < .000) (Table 9). In addition, NM hTau degradation was significantly 
slower than P301L in the P-E fraction (Figure 22C, Table 9). The half-life of NM hTau 
was consistently longer than for P301L hTau in all fractions tested (Table 9). These 
results demonstrate that hTau steady-state levels are higher in rT1 than rT2 because of 
a slower clearance rate, and suggest that hTau degradation is impaired primarily in the 
postsynaptic compartment. Although only a small fraction of total hTau is localized to the 
postsynaptic compartment, reduced clearance may begin early and compound over time 
to cause elevated levels by 8 weeks of age. 
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Figure 22. Slower clearance rate of 4R NM than P301L hTau. (A) The clearance rate of 
soluble NM hTau is slower than P301L hTau (see also Table 1). (B) Validation of biochemical 
fractionation method into GAPDH-enriched (G-E), Synaptophysin-enriched (S-E), and PSD-95-
enriched (P-E) compartments. Proteins were run on a 10% Tris-HCl gel. (C) The clearance rate of 
NM hTau is slower than P301L hTau in the P-E fraction (see also Table 1). Symbols on graphs 
are group means ± error, solid lines represent linear regressions with standard error as dotted 
lines. n’s in parenthesis. *p<0.05, **p<0.01 
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Table 9. Summary of 4R NM and P301L hTau half-life and regression data. Half-lives of NM 
and P301L hTau as measured by the experiment shown in Figure 2 in rT1 and rT2 mice were 
calculated using the integrated rate law for first-order chemical reactions (t1/2 = 0.693 / (2.303 x k’) 
(401), where k’ is the slope of the log-transformed values of tau plotted over time on DOX. 
Cofficients of determination (R2) values, y-intercepts, and slopes from simple linear regressions 
(SLR) are listed. Multiple linear regressions (MLR) were used to test for differences between 
slopes, and p-values are shown.  
Fraction 
NM hTau 
half-life 
(days) 
P301L hTau 
half-life 
(days) 
SLR R2 
(NM, 
P301L) 
SLR Y-
intercept (NM, 
P301L) 
SLR slope 
(NM, P301L) 
MLR p-
value 
Soluble 15.0 12.5 0.92, 0.96 2.56, 2.53 -0.020, -0.024 0.00292 
G-E 12.6 11.1 0.86, 0.83 2.14, 2.08 -0.024, -0.027 0.1762 
S-E 18.5 15.6 0.78, 0.80 1.68, 1.61 -0.016, -0.019 0.14309 
P-E 12.5 9.7 0.78, 0.84 0.047, 0.00014 -0.024, -0.031 0.0214 
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Hyperphosphorylation of 4R NM hTau compared to P301L hTau 
We observed altered electrophoretic mobility of NM compared to P301L hTau, 
suggesting a difference in post-translational modifications (see Figure 21C). In addition, 
some studies indicate that NM tau has a higher propensity to become phosphorylated 
than P301L tau (313,381,385,386). Therefore, we next determined whether 4R NM hTau 
was hyperphosphorylated compared to P301L hTau in 8-week old rT1 and rT2 
forebrains by immunoblotting with a series of antibodies that recognize well-known tau 
phosphoepitopes in human tauopathy post-mortem tissue.  
While some antibodies showed no differences between rT1 and rT2, including 
AT8 (pSer202/pThr205) and PG5 (pSer409) (data not shown), CP13 (pSer202) and 
PHF-1 (pSer396/pSer404) revealed significantly higher phosphorylation levels of NM 
than P301L hTau (CP13: t(10) = 11.47, p < .0001, 95% CI [-.27 , -.18]; PHF-1: t(10) = 
6.18, p = .0001, 95% CI [-.17 , -.08]) (Figure 23A, B). NM hTau was also 
hyperphosphorylated compared to P301L hTau in the biochemically isolated 
postsynaptic fraction (CP13: t(10) = 3.32, p = .0078, 95% CI [-.31 , -.062]; PHF-1: t(10) = 
6.35, p < .0001, 95% CI [-.31 , -.15]) (Figure 23C, D). To determine how early this 
phosphorylation could be detected, we performed experiments in 3-, 5-, and 7- week old 
rT1 and rT2. First, we confirmed expression of hTau and tTA mRNA and hTau protein in 
postnatal mice (Figure 24, Table 10). We found that NM hTau hyperphosphorylation 
compared to P301L hTau could be detected as early as 5 weeks of age (CP13: t(6) = 
4.76, p = .0093, 95% CI [-.402 , -.13]; PHF-1: t(6) = 6.61, p = .0018, 95% CI [-.33 , -.15]), 
and continued at 7 weeks (CP13: t(5) = 7.38, p = .0021, 95% CI [-.37 , -.18]; PHF-1: t(5) 
= 4.11, p = .028, 95% CI [-.44 , -.10]), suggesting that this could be a 
neurodevelopmental phenomenon (Figure 23E, F). 
There is much overlap between the sites highly phosphorylated on tau during 
development and in aging-related neurodegenerative diseases, but normal 
developmental phosphorylation is insufficient to induce tau aggregation and insolubility 
(250). To determine whether phosphorylation of 4R NM hTau in young mice was 
associated with insolubility, protein from forebrains of 8-week old mice was extracted in 
sarkosyl. No high-molecular-weight hTau species above 55 kDa were observed (data 
not shown), indicating that the phosphorylation in rT1 brains does not induce the 
formation of insoluble aggregates. 
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Figure 23. 4R NM hTau is hyperphosphorylated compared to P301L hTau by 5 weeks of 
age. Phosphorylation of hTau was greater in rT1 than in rT2 forebrains (A, B) and in the 
biochemically isolated PSD-95-enriched (P-E) fraction (C, D) at 8 weeks of age. Top panels: 
graphs summarizing densitometric analyses of western blots immunoblotted with CP13 
(pSer202), PHF-1 (pSer396/Ser404), and ab74391 (hTau), with n’s for each group in 
parentheses. Bottom panels: representative western blots for data in top panels with sex of the 
animals indicated above. NM hTau becomes hyperphosphorylated as early as 5 weeks of age at 
both pSer202 (E) and pSer396/404 (F) (rT1: n = 4 3wk, 6 5wk, and 5 7wk; rT2: n = 6 3wk, 2 5wk, 
and 2 7wk). Densitometric quantification in E and F are in left panels with representative blots on 
the right, ages of animals indicated above. Proteins were extracted in RIPA buffer and run on 
10% Tris-HCl gels. Graphs display group means ± SD. *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001 
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Figure 24. hTau and tTA expression in postnatal rT1 and rT2. Forebrain mRNA analysis in 3- 
, 5- , and 7- week old rT1 and rT2 (n = 2-6 per group) confirmed both tTA (A) and hTau (B) mRNA 
expression at these young ages and revealed no differences between the two lines. There was a 
trend indicating a steady rise in tTA mRNA as the mice get older (Two-way ANOVA: F (2, 18) = 
3.24, p = 0.063). Forebrain protein analysis also confirmed hTau protein expression at these 
young ages (n = 2-6 per goup) and showed that by 7 weeks, there was still no difference hTau 
steady-state levels between the two lines or a change in levels over time (C). (D) Representative 
western blots for quantitative densitometry in panel C.   
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Developmental transgene suppression temporarily reduces NM hTau levels and 
phosphorylation 
The predominance of 3R tau isoforms in the developing mouse brain (33) is 
essential for neurite polarity establishment (194) and neurite outgrowth (195,201). We 
therefore hypothesized that overexpression of 4R tau during a developmental period in 
which 3R normally predominates causes the abnormal molecular phenotype of NM 
hTau. We found that there was no effect of hTau expression on endogenous mouse tau 
(mTau) in postnatal mice at the mRNA level (Figure 25, Table 10). Still, 
overrepresentation of 4R hTau caused by overexpression could disrupt developmental 
processes, even in the presence of normal levels of 3R and 4R mTau isoforms. To 
determine whether the elevation in steady-state levels and hyperphosphorylation of NM 
compared to P301L hTau was due to overexpression during development, and whether 
pathogenicity of NM hTau is established during a specific developmental window, we 
suppressed hTau and tTA expression with DOX for either the first 4 or 12 weeks of life. 
Following suppression, mice were taken off of DOX chow for 4 or 8 weeks, and brain 
tissue was collected. Importantly, hTau expression and tTA toxicity in these models are 
intrinsically linked. Suppression of tTA during development prevents the observed 
reduction of dentate gyrus granule cells in that line (364), presumably by preventing off-
target binding of the overexpressed tTA protein during this vulnerable period. However, 
we reiterate that this phenomenon is matched between rT1 and rT2.  
Pilot experiments in rT2 mice showed that DOX suppresses hTau mRNA by 24 
hours, and that hTau mRNA and protein return to normal levels following developmental 
suppression (Figure 26). Oddly, tTA mRNA expression following suppression surpassed 
normal levels, perhaps due to confounding effects of DOX on cell biology (408,409). 
Developmental suppression followed by 4 weeks of hTau and tTA expression lowered 
NM hTau levels (F(2, 29) = 6.96, p = .0034), pSer202 phosphorylation (F(2,29) = 24.96, 
p < .0001), and pSer396/404 phosphorylation (F(2,29) = 9.45, p = .0007), while 
suppression had no effect on P301L hTau biochemistry (Figure 27). There were also 
significantly higher levels of pSer202 phosphorylation of NM hTau than P301L hTau in 
non-suppressed control mice (F(1, 29) = 46.96, p < .0001) (Figure 27). After 8 weeks of 
post-suppression expression, there was no effect of suppression and no difference 
between rT1 and rT2 except for pSer202 phosphorylation, which remained reduced in 
suppressed mice (F(2,29) = 8.88, p = .001) and remained higher in rT1 than rT2 (F(1,29) 
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= 31.41, p < .0001). In conclusion, suppression of hTau and tTA for either 4 or 12 weeks 
reduced 4R NM hTau steady-state levels and phosphorylation to levels comparable to 
P301L hTau. However, these molecular phenotypes were partially or fully reversed after 
8 weeks of expression, indicating that the effect of developmental transgene 
suppression on NM hTau regulation is only temporary. 
Of note, we were not able to replicate differences in hTau steady-state levels 
(Figure 21) and pSer396/404 phosphorylation (Figure 23) in the 8-week old non-
suppressed controls included in the DOX-suppression experiment (Figure 27). As these 
were different groups of mice, we attribute these observations to litter effects. However, 
the pSer202 observation remained quite robust in the suppression experiment (Figure 
27), suggesting that this phosphorylation event occurs first and increases propensity for 
phosphorylation at pSer396 and pSer404 (253,254), leading to elevated stability 
(410,411). Our observations indicate that the timing of these events is highly variable in 
different litters of mice, and took longer in the mice included in the suppression 
experiment. 
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Figure 25. No effect of hTau expression on endogenous mTau mRNA. Forebrain mRNA 
analysis of endogenous mTau expression was performed in 3- , 5- , and 7- week old rT1 and rT2 
mice (n = 2-6 per group). While, there was no difference between rT1 and rT2, we detected an 
effect of sex (t(36) = 2.59, p = .014) in that females expressed more mTau mRNA than males. 
Overall there was no effect of age or genotype for either females (A) or males (B) indicating that 
hTau expression does not affect mTau mRNA expression. To assess mTau splice variants 
individually in a qualitative manner, PCR was run on cDNA from rT1 and rT2 forebrains using 
forward (F) and reverse (R) primers flanking alternatively spliced mouse exon (ME) 10 
(ME9F11R), flanking alternatively spliced exons 2, 3, and 4 (ME1F5R), or for total Gapdh as a 
control (412). This showed no obvious differences in relative levels of mTau splice variant mRNA 
expression in postnatal rT1 (C) or rT2 (D) whether or not hTau was being expressed. Note that 
for ME9F11R reactions, the 297 base-pair (bp) product is 3R (exon 10-) while the 390bp product 
is 4R (exon 10+) mTau. For ME1F5R reactions, the 260bp product is 1N mTau (exon 4+, exon 2- 
and exon 3-). PCR products were sequenced to confirm the correct splice variants. 
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Table 10. Primer sequences used for relative RT-qPCR and PCR experiments. Forward and 
reverse primers used to quantify hTau and Hprt mRNA in qPCR experiments are shown. Mouse 
exon (ME) forward (F) reverse (R) 
Target Primers 
Forward Reverse 
hTau 5’- CTACACCATGCACCAAGACC -3’ 5’- TGCTTTTACTGACCATGCGA -3’ 
tTA 5'- ACTACTGATAGTATGCCGCCATT 
-3' 
5'- CAGGCCCTCGATGGTAGA -3' 
Hprt 
5’- GCTGGTGAAAAGGACCTCT -3’ 
5’- CCACAGGACTAGAACACCTGCTA 
-3’ 
Gapdh 5'- TGTCAGCAATGCATCCTGCA -3’ 5’- CCGTTCAGCTCTGGGATGAC -3’ 
ME9F11R 5’- CACCAAAATCCGGAGAACGA -3’ 5’- CTTTGCTCAGGTCCACCGGC -3’ 
ME1F5R 5’- TCCGCTGTCCTCTTCTGTC -3’ 5’- TTCTCGTCATTTCCTGTCC -3’ 
XBP1 5’- GAACCAGGAGTTAAGAACACG -
3’ 
5’- AGGCAACAGTGTCAGAGTCC -3’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 107 
 
Figure 26. DOX pilot experiments in rT2 mice for hTau half-life and developmental 
suppression experiments. Forebrain mRNA analyses showed that DOX 40mg/kg (A) and DOX 
200mg/kg (B) diets fully suppressed hTau expression by 24 hours after administration (n = 2-4 
per group). Further forebrain mRNA analyses showed that with 3 weeks of developmental 
suppression using DOX40, tTA expression steadily rises and surpasses that of mice that have not 
been suppressed (C). After developmental suppression with DOX40, hTau mRNA in the forebrain 
returns to levels comparable to those of non-suppressed mice (D). Similarly, hTau protein returns 
to normal levels after developmental DOX40 treatment (E). (F) Representative western blot 
densitometrically quantified in panel E. Interestingly, after 1 week of post-suppression expression, 
hTau expression in females (pink dots) is higher than that of males (blue dots) in terms of both 
mRNA (D) and protein (E-F). 
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Figure 27. Developmental suppression temporarily reduces 4R NM hTau levels and 
phosphorylation in rT1 forebrains. Quantitative data from densitometry of western blots for 
human tau normalized to total protein, and phospho-hTau at pSer202 and pSer396/404 
normalized to total protein, represented as ratios to normalized total hTau levels (phospho-
hTau:total protein::hTau:total protein). hTau was suppressed for either the first 4 weeks (OFF 4W 
→ ON) or 12 weeks (OFF 12W → ON) of life followed by expression for 4 (top row) or 8 (bottom 
row) weeks. Non-suppressed controls aged 4 or 8 weeks (ON) are included to match the 
expression period of suppressed mice. n = 5-6 per group. “ * ” symbols indicate effect of DOX 
treatment while “ # ” symbols indicate differences between rT1 and rT2. Graphs display group 
means + SD. *p<0.05, **p<0.01, ***p<0.001, **** or #### p<0.0001.   
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rT1 but not rT2 mice exhibit cognitive impairments 
Behavioral studies to assess cognition in these lines were conducted before we 
were aware of the abnormal molecular phenotype of 4R NM hTau. Therefore, we 
originally predicted that the P301L mutation would be associated with spatial learning 
and memory deficits in the Morris Water Maze in 5-month old rT2 mice. Non-transgenic 
littermates were used as internal controls for ‘batch effects’ such as effects of season, 
times of day and week, and animal husbandry schedules in these experiments. 
However, cognitive phenotypes in rT1 and rT2 should be considered in relation to one 
another rather than to non-transgenic animals, which lack both hTau and tTA 
transgenes. 
Both rT1 (main effect of Day: F(4, 88) = 35.80, p<.0001) and rT2 (main effect of 
Day: F(4, 88) = 43.76, p<.0001) path lengths to the visible platform were significantly 
reduced as training progressed, indicating sensorimotor acquisition of the task in both 
lines (Figure 28A). Path lengths to the hidden platform also decreased as training 
progressed for both rT1 (main effect of Day: F(3, 66) = 7.521, p=.0002) and rT2 (main 
effect of Day: F(3, 66) = 9.752, p<.0001), indicating improvements in spatial navigation 
(Figure 28B). However, when compared to non-transgenic littermates, we were 
surprised to find that 5-month old rT1 but not rT2 mice exhibited learning deficits during 
visible-platform training (main effect of Genotype: F(1, 22) = 18.46, p = .0003) and 
hidden-platform training (main effect of Genotype: F(1, 22) = 23.76, p < .0001) (Figure 
28A, B).  
rT1 mice also exhibited deficits in spatial reference memory during probe trials. 
Search bias was detected in Tau-/-tTA-/- mice (F(3,44) =15.79, p<.0001) but not in Tau+/-
tTA+/- rT1 mice (F(3,44) =3.72, p=.018) (Figure 28C). In addition, Tau+/-tTA+/- rT1 mice 
spent significantly less time in the target quadrant than non-transgenic littermates (U = 8, 
p < .0001) (Figure 28C). This indicates either a pure learning deficit or a combined 
learning and spatial memory deficit in rT1 mice, associated with the abnormal molecular 
phenotype of 4R NM hTau. In contrast, 5-month old rT2 mice exhibited no such deficits 
(Figure 28D, E, F), suggesting that the low levels of P301L hTau phosphorylation at this 
age are insufficient to cause cognitive deficits in rT2.  
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Figure 28. Cognitive deficits in rT1 are prevented with developmental suppression. The 
Morris water maze was used to measure cognitive function in rT1 and rT2 mice. 5-month old rT1 
mice exhibit learning deficits in visible-platform training (A), in hidden-platform training (B), and in 
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spatial reference memory during probe trials (C). Probe trial data shows time spent in left (L), 
opposite (O), target (T), and right (R) quadrants to assess search bias. (D-F) Five-month old rT2 
mice are indistinguishable from non-transgenic littermates in all trials. With doxycycline-mediated 
suppression of hTau during the first 4 weeks or 12 weeks of life, followed by hTau expression for 
5 months, (OFF 4W → ON 5M and OFF 12W → ON 5M, respectively) rT1 performance improves 
in all aspects of the task when compared to 5-month old animals (ON 5M) (G-I). “ * ” indicates 
differences between ON 5M and OFF 4W groups while “ # ” indicates differences between ON 
5M and OFF 12W groups (G, H). DOX treatment had no effect on rT2 cognition (J-L). rT1 and rT2 
performance was comparable to hTau-/-tTA-/- and hTau-/-tTA+/- littermate controls with both 4 
weeks (M-R) and 12 weeks (S-X) of suppression. “ * ” indicates differences between hTau-/-tTA-/- 
and hTau-/-tTA+/- while “ # ” indicates differences between hTau-/-tTA-/- and hTau+/-tTA+/- (T,V). For 
all probe data, “ * ” indicates tests for search bias while “ $ ” indicates differences in time spent in 
target quadrant (T) between groups. n’s for each group in parentheses. Graphs display group 
means ± SD. All probe data represent the average values for three probe trials. Symbols to right 
of Visible and Hidden graphs indicate main effect of Genotype (A-F, M-X) or DOX treatment (G-
L). *, #, or $ p<0.05; ** or ## p<0.01; *** or ### p<0.001; $$$$ or ****p<0.0001 
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Developmental transgene suppression prevents cognitive impairments in rT1 
Developmental transgene suppression temporarily reduced 4R NM hTau steady-
state levels and phosphorylation levels compared to P301L hTau (see Figure 27). To 
determine whether developmental suppression also prevents the cognitive deficits in rT1 
mice, and whether pathogenicity is established during a specific developmental window, 
we again suppressed hTau and tTA expression with DOX for either the first 4 or 12 
weeks of life. Following developmental suppression, hTau and tTA were expressed for 5 
months so as to match the expression period of impaired rT1 mice. Data from non-
suppressed mice are included for comparison, and therefore the same data from hTau+/-
tTA+/- mice in Figure 28A-F are included in Figure 28G-L and 28M-X. 
Both 4 weeks and 12 weeks of suppression prevented rT1 impairments in visible-
platform training (F(2, 33) = 12.9, p < .0001) and hidden-platform training (F(2, 33) = 
6.89, p = .0032) compared to non-suppressed rT1 mice (Figure 28G, H). Developmental 
suppression of hTau also improved spatial reference memory in probe trials. Search bias 
was detected in both the 4-week suppression (F(3,44) = 18.45, p<.0001) and 12-week 
suppression (F(3,44)=15.33, p<.0001) groups (Figure 28I). In addition, suppressed rT1 
spent significantly more time in the target quadrant than non-suppressed mice (F(2, 33) 
= 10.37, p = .0003). In contrast, suppression of hTau and tTA had no effect on rT2 
cognition (Figure 28J, K, L).  
Suppressed rT1 and rT2 mice were also compared to hTau-/-tTA-/- and hTau-/-
tTA+/- littermates. In the 4-week suppression group, rT1 mice improved as visible training 
(F(4, 132)=46.8, p<.0001) and hidden training (F(3, 99=21, p<.0001) progressed, and no 
differences were detected between genotypes (Figure 28M, N). All rT1 genotypes 
exhibited search bias in probe trials: hTau-/-tTA-/- (F(3,44)=32.41, p<.0001), hTau-/-tTA+/- 
(F(3,44)=14.43, p<.0001), and hTau+/-tTA+/- (F(3,44)=17.6, p<.0001) (Figure 28O). rT1 
hTau+/-tTA+/- spent less time in the target quadrant than hTau-/-tTA-/- mice (F(2,33)=3.89, 
p<.031), but were comparable to hTau-/-tTA+/- littermates (Figure 28O). With 4 weeks of 
suppression, all rT2 genotypes also improved during visible (F(4,132)=87.15, p<.0001) 
and hidden (F(3,99)=18.28, p<.0001) training with no differences between genotypes 
(Figure 28P, Q). All rT2 genotypes also exhibited search bias in probe trials: hTau-/-tTA-/- 
(F(3,44)=17.41, p<.0001), hTau-/-tTA+/- (F(3,44)=17.45, p<.0001), and hTau+/-tTA+/- 
(F(3,44)=18.45, p<.0001) (Figure 28R). There was no difference in time spent in the 
target quadrant between rT2 genotypes (Figure 28R).  
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In the 12-week suppression group, rT1 performance was comparable to hTau-/-
tTA-/- and hTau-/-tTA+/- littermates in visible (F(4,128)=57.19, p<.0001) and hidden 
(F(3,96)=32.32, p<.0001) training (Figure 28S, T). A main effect of genotype 
(F(2,32)=3.66, p=0.037) in hidden training arose due to slight differences on Day 1 
(Figure 28T). All rT1 genotypes exhibited search bias in probe trials: hTau-/-tTA-/- 
(F(3,44)=17.71, p<.0001), hTau-/-tTA+/- (F(3,44)=12.35, p<.0001), and hTau+/-tTA+/- 
(F(3,44)=12.94, p<.0001) (Figure 28W). No differences between rT1 genotypes were 
detected in terms of time spend in the target quadrant (Figure 28W). rT2 mice 
suppressed for 12 weeks also improved as visible (F(4,132)=100.9, p<.0001) and hidden 
(F(3,99)=33.3, p<.0001) training progressed (Figure 28V, W). A main effect of genotype 
(F(2,33)=3.29, p=0.050) arose due to slight differences between genotypes on Day 1 of 
visible training (Figure 28V). All rT2 genotypes also exhibited search bias in probe trials: 
hTau-/-tTA-/- (F(3,44)=33.1, p<.0001), hTau-/-tTA+/- (F(3,44)=18.82, p<.0001), and hTau+/-
tTA+/- (F(3,44)=15.33, p<.0001) (Figure 28X). There was no difference in time spent in 
the target quadrant between rT2 genotypes (Figure 28X). Taken together, these data 
show that developmental transgene suppression prevented the cognitive impairments in 
rT1 mice.  
 
Higher ratios of microtubule-bound to –unbound 4R NM hTau than P301L hTau 
If developmental overexpression of 4R tau is toxic, why are abnormal molecular 
phenotypes and cognitive dysfunction present only in rT1 mice and not also rT2? A 
major consequence of the P301L mutation, which lies in tau’s second microtubule (MT) 
binding domain encoded by the alternatively spliced exon 10, is a reduction in the ability 
of tau to bind MTs (34). We hypothesized that this loss of function conferred by the 
pathogenic P301L mutation is protective against molecular and cognitive phenotypes 
associated with 4R NM hTau. 
To quantify MT -bound vs. -unbound hTau in 8-week old rT1 and rT2, we isolated 
microtubules (MTs) and microtubule-associated proteins, MAPs, (290) from forebrains 
(Figure 29A). P301L hTau was found to be more abundant in the cytosol (t(12) = 5.60, p 
= 0.0001) while NM hTau was more abundant in the MT/MAP pellet (t(12) = 5.21, p = 
0.0002) (Figure 29B, C). The mean ratios of MT -bound to -unbound hTau were 1.46 for 
NM and 0.70 for P301L hTau, demonstrating that 4R NM hTau binds MTs significantly 
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stronger than P301L hTau. This also suggests that reduced MT-binding of P301L hTau 
protects against abnormal molecular and cognitive phenotypes. 
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Figure 29. 4R NM hTau binds microtubules more strongly than P301L hTau. (A) Validation of 
protocol to isolate microtubules (MTs) and microtubule-associated proteins (290) in the pellet (P), 
leaving cytosolic elements in the supernatant (S). The cytosolic fractions (B) and MT/MAP 
fractions (C) were run through SDS-PAGE and immunolabled with hTau, GAPDH, and β-III 
tubulin antibodies (representative images in right panels). Proteins were run on 10.5-14% gels. 
Fluorescent signal from western blots was quantified by densitometry, and values represent 
averages of two separate experiments (left panels). Graphs show group means + SD with n’s 
indicated in parentheses. ***p<0.001 
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Mitochondrial abnormalities and oxidative stress in rT1 
Overexpression of tau is known to cause a disruption of mitochondrial fission and 
fusion dynamics (413), which contributes to neurodevelopmental disorders (414). 
Therefore, we examined mitochondrial length in primary hippocampal neurons derived 
from P0 rT1 and rT2 mice. Active hTau expression was confirmed in our cultures (data 
not shown), which were transfected with an EGFP construct to identify axons and a 
mitochondria-specific RFP construct to visualize mitochondria within the axon, as done 
previously (404). We found that while there was no difference in mitochondria density 
(Figure 30B), mitochondria were longer in axons from rT1 (hTau+/-tTA+/-) than from 
control (hTau+/-tTA-/-) neurons (H = 10.9, p = 0.012) whereas there was no difference in 
mitochondrial length between rT2 and control neurons (Figure 30A, C). We also 
observed no differences in the percentages of moving mitochondria or the velocity of 
mobile mitochondria between groups (data not shown). Although we did not observe 
effects on mitochondrial transport, these findings are consistent with developmental 
pathogenicity of 4R NM hTau, and further suggest that impaired mitochondrial dynamics 
are part of that pathogenic pathway. 
 Disruptions in mitochondrial dynamics have been shown to be linked to oxidative 
stress (415). Therefore, we assessed oxidative damage to DNA and RNA using the 
marker 8-hydroxy-2’-deoxyguanosine (8OHdG) in 2-month old rT1, rT2, and littermate 
controls. We found that 8OHdG staining was more intense in rT1 than for other samples 
(Figure 31A). We also quantified the signal intensity and found that, indeed, oxidative 
stress was higher in rT1 than rT2 in the CA1 region of the hippocampus (F(1,30) = 
29.38, p<.0001) and in cortex (Ctx) (F(1,30) = 11.11, p=.0023) (Figure 31B, C). 
Interestingly, oxidative stress in the dentate gyrus (DG) was highest in non-transgenic 
littermates (F(2,30) = 16.93, p<.0001) (Figure 31D), which may be explained by a 
requirement for high levels of reactive oxygen species in the regulation of adult 
neurogenesis (416,417). This suggests that tTA and hTau expression may contribute to 
redox imbalance in the DG, which could have consequences for adult neurogenesis and 
therefore cognition. We note that the 8OHdG signal may represent not only nuclear and 
mitochondrial DNA, but also RNA.  
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Figure 30. Elongated mitochondria with no change in density in rT1 hippocampal axons. 
The length of mitochondria (A) and density of mitochondria (B) were measured in primary 
hippocampal neurons derived from rT1 and rT2 postnatal day 0 pups. hTau-only (hTau+/-tTA-/-) 
controls were included for comparison. The number of axons in which mitochondria were counted 
and measured are shown in parenthesis for each group. Neurons were taken from a total of 10 
rT1 hTau+/-tTA+/-, 7 rT1 hTau+/-tTA-/-, 7 rT2 hTau+/-tTA+/-, and 4 rT2 hTau+/-tTA-/- mice. (C) 
Representative images of axonal mitochondria in hippocampal neurons. Graphs display group 
means + SEM. *p<0.05 
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Figure 31. Elevated oxidative stress in 2-month rT1 brains. (A) Representative images 
showing 8-hydroxy-2’-deoxyguanosine (8OHdG, red), a marker for oxidative damage to DNA and 
RNA, in 2-month old rT1 and rT2 animals in addition to hTau-/-tTA-/- and hTau-/-tTA+/- littermate 
controls. Images are shown for the three areas assessed: hippocampal CA1, somatomotor areas 
of cortex (Ctx) and dentate gyrus (DG). DAPI is shown in blue. (B-D) Quantification of intensity of 
the red signal in terms of integrated density to account for differences in region of interest (ROI) 
areas. n = 3 males and 3 females per group. Graphs show group means + SD. Scale bars 
represent 500 μm. ***p<0.001, ****p<0.0001 
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Reduced brain mass in postnatal rT1 mice 
Knowing that aberrantly elongated mitochondria in neurodevelopmental disorders 
are accompanied by microcephaly (414), and that an excess of tau interferes with cell 
division, leading to aneuploidy and neuronal apoptosis (418,419), we postulated that rT1 
mice may have abnormal brain development. To test this, we simply weighed whole 
brains and compared brain mass of rT1, rT2, and littermates.  
Our analysis of brain mass showed that rT1, rT2, and tTA mice had reduced 
brain mass compared to hTau-/-tTA-/- and hTau+/-tTA-/- controls (F(3, 251) = 45.15, p < 
.0001), and that rT1 mice had reduced brain mass compared to rT2 (F(1, 251) = 19.27, p 
< .0001; rT1 mean = .429g, SD = 0.018; rT2 mean = 0.443g, SD = 0.021) (Figure 32A). 
Despite the contribution of tTA-induced toxicity, 4R NM hTau was associated with 
reduced brain mass compared to P301L hTau. This suggests that tTA interferes with 
normal brain development and that P301L hTau is protective from tTA toxicity, while NM 
hTau is not. In addition, 4 weeks and, to a greater extent, 12 weeks of developmental 
suppression of hTau and tTA was associated with increases in brain mass in rT1 (F(2, 
46) = 17.67, p < .0001), but had no effect on brain mass in rT2 mice (Figure 32B). 
Although we cannot exclude the possibility that the subtle difference in brain mass could 
be due to background strain variation in the breeding history of rT1 and rT2, the effect of 
developmental suppression was specific to rT1, suggesting that 4R NM hTau and tTA 
overexpression during postnatal development is associated with reduced brain size. 
Finally, as forebrain neurons are overexpressing high levels of hTau, we 
hypothesized that endoplasmic reticulum (ER) stress may be occurring in rT1 and rT2 
brains. We found no evidence of activation of the unfolded protein response (UPR), 
which occurs downstream of ER stress (Figure 33). This indicates that oxidative stress 
but not ER stress is ongoing in more so in rT1 than rT2 brains. 
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Figure 32. Reduced brain mass in postnatal rT1 mice. (A) Whole brains from rT1, rT2, and 
littermates between the ages of 3 and 5 weeks were weighed (rT1: n = 27 hTau-/-tTA-/-, 35 hTau+/-
tTA-/-, 28 hTau-/-tTA+/-, and 33 hTau+/-tTA+/-; rT2: n = 33 hTau-/-tTA-/-, 33 hTau+/-tTA-/-, 36 hTau-/-
tTA+/-, and 34 hTau+/-tTA+/-). “ * ” indicates differences between genotypes while “ # ” indicates 
differences between lines. (B) Brain mass was compared between 3 groups of Tau+/-tTA+/- rT1 
and rT2: 4 week-old animals (ON 4W, n = 12 rT1 and 7 rT2), hTau suppressed for 4 weeks 
followed by expression for 4 weeks (OFF 4W → ON 4W, n = 9 rT1 and 10 rT2), and 12 weeks of 
suppression followed by 4 weeks of expression (OFF 12W → ON 4W, n = 6 rT1 and 8 rT2). 
Graphs display group means + SD. *p<0.05, ** or ## p<0.01, ****p<0.0001.  
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Figure 33. No evidence of ER stress in rT1 or rT2 brains. An X-box binding protein 1 (Xbp1) 
splicing assay was run on cDNA from postnatal rT1 and rT2 forebrains. The presence of a faint 
lower band indicates mRNA processing of XBP1 by Inositol-requiring enzyme 1 (IRE1) to a 
shorter splice variant, which is indicates activation of the unfolded protein response (UPR). The 
short splice variant was detected in a positive control sample (medulloblastoma) but not in rT1 or 
rT2, regardless of hTau expression. 
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IV. Discussion  
The 30 different tauopathy mouse models harboring MAPT-related modifications 
(https://www.alzforum.org/research-models) have extreme variability in their phenotypes, 
creating confusion in attempts to understand how the tau protein causes 
neurodegenerative diseases. Using novel genetically matched mouse lines, we sought 
to determine how the pathogenic P301L mutation affects tau biology in vivo. 
Surprisingly, we have identified a development-specific toxicity of 4R NM hTau, which 
undergoes abnormal regulation in very young animals and eventually causes cognitive 
impairments. Strikingly, both the molecular and behavioral phenotypes associated with 
4R NM hTau were lost with the P301L mutation. 
We found that clearance of hTau was impaired in rT1 mice, underlying an 
elevation of steady-state levels. The half-life of 4R NM hTau was significantly longer 
than P301L hTau (Figure 22, Table 9), and is comparable to a different tauopathy mouse 
model (401). The hyperphosphorylation of NM hTau (Figure 23) may explain its long 
half-life because phosphorylation of Ser396 and Ser404, elevated in rT1 mice, has been 
associated with impaired proteasome function (410,411). The robust pSer202 
phosphorylation of NM hTau (Figures 23 and 27) may be particularly important for 
regulating tau dynamics because this event primes tau for Ser396/404 phosphorylation 
(253,254), which could ultimately lead to elevated stability due to proteasome inhibition.  
Patterns of tau phosphorylation during normal rodent development suggest that 
NM hTau remains aberrantly hyperphosphorylated. Many sites on tau, including Ser202 
and Ser404, are highly phosphorylated early on and slowly decline thereafter (250). 
P301L hTau in rT2 mice follows this normal developmental pattern, however, by 4-5 
weeks of age 4R NM hTau remains hyperphosphorylated (Figures 23 and 27), strongly 
suggesting developmental dysregulation of hTau in rT1 brains. These findings parallel 
those of other transgenic lines in which developmental mislocalization (383) and 
hyperphosphorylation (385,393,394) of overexpressed NM hTau is observed. In 
particular, a non-progressive developmental phenotype associated with NM but not 
P301L hTau was previously published (173), suggesting a similar pathogenic process 
occurs in rT1 and rTg21221 (rTgWT) lines. We previously found that the level of hTau 
overexpression in P301L 0N4R transgenic lines positively correlates with the degree of 
hTau histopathology (hTau -hemizygous rT2 vs. -homozygous rT2/T2) (396). Similarly, 
our current results show elevated tau phosphorylation in rT1, which overexpress hTau 
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by about two-fold compared to rT2 (Figure 21E). Future studies on tau histopathology in 
young rT1 and rT2 will clarify whether the level of hTau overexpression, regardless of 
any disease-linked mutations, is the determining factor in the severity of histopathology.  
The rise in 4R NM hTau levels in rT1 brains, in addition to the 12.6-fold 
overexpression of human relative to endogenous mouse tau, causes massive 
overrepresentation of 4R tau isoforms. Compounding this, although we detected normal 
levels of mTau mRNA (Figure 25), our collaborator has found severe downregulation of 
3R mTau protein in rT1 and rT2 compared to tTA mice (M. Orr, personal 
communication). Most MAPT mutations that alter splicing in human tauopathies increase 
the 4R:3R ratio (14) (Table 1), leading 4R tau to be labeled as a toxic variant (420). 
Therefore, it is no surprise that 4R NM hTau exhibits an abnormal molecular phenotype, 
especially when considering the importance of splice variant regulation during 
development. In both rodent (33) and human (32) fetal brain, 3R tau is much more 
abundant than 4R tau. With a three-fold lower MT-binding capacity than 4R tau (196), 
3R tau facilitates MT dynamics necessary for developmental processes such as neurite 
outgrowth (198,421). The dramatic imbalance of 3R and 4R tau in postnatal rT1, during 
which newborn neurons require dynamic rather than stable microtubules, likely 
contributes to the abnormal rT1 phenotype. 
Counterintuitively, yet consistent with our other findings, rT1 and not rT2 mice 
were cognitively impaired in the Morris Water Maze at 5 months of age (Figure 28). 
Hyperphosphorylated tau, when mislocalized to dendritic spines, can cause deficits in 
postsynaptic transmission due to internalization of postsynaptic AMPA receptors (173). 
Phosphorylation at the sites we have reported here is required both for tau 
mislocalization to the postsynapse and for tau-induced reduction of AMPARs (422). Our 
observations of hyperphosphorylated 4R NM hTau within PSD-95-enriched fractions 
(Figure 23C, D) suggest that a reduction in postsynaptic signaling underlies rT1 
cognitive deficits. Tau-induced deficits in presynaptic signaling (423,424) could also 
contribute to rT1 cognitive impairments. 
Disruption of mitochondrial dynamics and oxidative stress (Figures 30-31) may 
be related to the subtle deficiencies in brain mass (Figure 32). Tau overexpression in 
other experimental models is associated with MT elongation (415) via increased 
expression of fusion proteins (413). Impaired fission is linked to neurodevelopmental 
abnormalities in humans (414) and rodents (425), as neural stem cell fate requires a 
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switch from elongated to fragmented mitochondria (426). Our findings suggest that 4R 
NM hTau is associated with a failure of mitochondria to switch to a fragmented 
phenotype, disrupting stem cell fate decisions. Although we do not show the relative 
timing of these events, previous studies suggest that oxidative stress associated with 
mitochondrial dysfunction occurs upstream of tau hyperphosphorylation via imbalanced 
activation of kinases and phosphatases (300,427). Taken together, our results are 
consistent with a neurodevelopmental failure, rather than a progressive 
neurodegenerative phenotype. 
Developmental suppression temporarily reduced NM hTau levels and 
phosphorylation (Figure 27) and prevented cognitive deficits in rT1 (Figure 28G-I, M-O, 
S-U). 4 weeks had essentially the same effects as 12 weeks of suppression, suggesting 
that 4R NM hTau overexpression specifically interferes with developmental milestones 
during the first 4 weeks of life such as peaks in brain growth, synaptic density, and 
myelination rate (200). Importantly, DOX treatment did not lower hTau expression after 8 
weeks (Figure 27), establishing that amelioration of the phenotype is not due to 
reduction of hTau per se. Furthermore, despite a moderate rise in NM hTau levels and 
phosphorylation after suppression (Figure 27), rT1 cognition remained intact, indicating 
that those molecular phenotypes are harmful during the first 4 weeks but not afterwards. 
Because hTau expression and tTA toxicity are intrinsically linked in our models, we 
cannot exclude the possibility that tTA-driven toxicity and suppression of tTA contribute 
to the abnormal rT1 phenotype and amelioration of that phenotype, respectively (364). 
Further examination of the tTA mouse phenotype in future studies may provide a 
mechanistic explanation for the specificity of these effects to rT1 mice.  
We found that the MT-bound to -unbound ratio was significantly higher for 4R NM 
hTau than P301L hTau (Figure 29), suggesting that a function of the MT-binding domain 
encoded by exon 10 is part of a pathogenic pathway in developing rT1 brains. Because 
we made this observation in 8-week old mice, it is possible that stronger MT-binding of 
NM than P301L hTau is downstream of other events. However, because of natural 
physiological differences between 4R NM and P301L tau (34,196), we view strong MT-
binding as a pathological trigger rather than a downstream effect. In this context, it 
appears that the P301L mutation is protective. Future studies on aged rT1 and rT2 will 
determine whether pathogenicity of P301L hTau requires the unique milieu of the aging 
brain. 
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The developmental pathogenicity of 4R NM hTau we have uncovered may be 
relevant to a range of neurological conditions. Infantile tauopathies, which include 
neurodevelopmental conditions such as hemimegalencephaly, ganglioglioma, and 
tuberous sclerosis, are characterized by upregulation and hyperphosphorylation of tau 
(428,429). Future experiments will determine if the pathway we have identified may be 
involved in the pathogenesis of these diseases. Although our results strongly suggest a 
development-specific mechanism, the massive overexpression of 4R tau may 
exaggerate and accelerate the phenotype. Therefore, our results may be indicative of an 
event that occurs early in human disease, yet slowly manifests over time, similar to what 
occurs in Huntington’s disease (430).  
In summary, genetic matching between transgenic mouse lines has allowed us to 
explore molecular and cognitive phenotypes associated with different forms of tau in a 
well-controlled manner, and to identify a pathogenic mechanism of 4R NM hTau distinct 
from classical aging-related tauopathy. Future studies using a tTA line without the 
transgene INDEL mutation (396) will clarify whether the phenotypes we observed here 
are due to hTau alone or in concert with other tTA-induced dysfunctions. It will also be 
useful to characterize phenotypes associated with other tau isoforms and expression 
patterns, and to use this system to test hypotheses concerning other disease-linked 
mutations, truncated forms of tau, etc.  
We believe our findings also highlight the importance of assaying the effects of 
transgenic proteins at appropriate stages in life, as the milieu of the infantile brain 
consists of an entirely different proteome than the aged brain (431,432). This study is 
one example among others (364,365,433) demonstrating that the effects of transgenic 
proteins differ in mice at different times during their lifespan. Finally, now that advances 
in techniques allow more precise characterization and manipulation of genomes of 
transgenic mice, models of neurodegenerative diseases can be held to higher 
standards. We hope that this type of work will improve translatability of therapies from 
mice to humans in clinical trials, and bring the field closer to solving the complex puzzle 
of tauopathies like Alzheimer’s disease.  
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Chapter Four: 
Concluding Remarks 
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Mouse modeling is an invaluable research tool for studying human diseases for 
several reasons: 1) genetic variation can be minimized with inbreeding, 2) large numbers 
of mice can be obtained in a relatively short period of time, and 3) many aspects of 
biology are evolutionarily conserved between mice and humans (434,435). Using mice 
to study neurodegenerative diseases poses a unique challenge because mice do not 
naturally develop these diseases, perhaps due to their short lifespans. Therefore, 
transgenesis is frequently used to introduce human genes into the mouse genome in the 
hopes of mimicking human disease in a different species. Historically, technological 
limitations required the use of ‘conventional’ methods to generate transgenic mice by 
injecting artificial human mini-gene constructs into pronuclear mouse embryos, resulting 
in random integration of transgenes (436). Advances in genome engineering technology 
now allow more precise and sophisticated manipulation of transgenes such that longer 
sequences (including whole genes) can be inserted into predetermined genomic loci in a 
‘targeted’ manner (437).  
To date, 30 mouse models with MAPT-related modifications have been 
generated to study tauopathies (https://www.alzforum.org/research-models). Extreme 
variability in the phenotypes of these models, in part attributed to the choice of tau 
isoform, promoter, and expression level, has complicated our understanding of the role 
of tau in disease pathogenesis. In addition, over 300 therapeutics that have succeeded 
in such models have gone on to fail in human clinical trials (361). While this problem of 
translatability could be caused by a number of variables such as treating patients too 
late in disease progression, it is also strongly suggestive of shortcomings with the mouse 
models themselves (438). In what began as a project to determine the role of post-
translational modifications in tau toxicity, we have found that genomic disruption is an 
additional variable contributing to phenotypic variability in mouse models, that the level 
of tau expression directly correlates with phenotype severity, and that developmental 
overexpression of transgenes can cause phenotypes irrelevant to aging-dependent 
neurodegenerative disease. 
Ironically, efforts to accelerate drug discovery for tauopathies like Alzheimer’s 
disease have in some ways slowed the progress of research. Researchers in the 
neurodegeneration field have been encouraged to prioritize phenotypes rather than 
genotypes of mouse models (361), and while following these guidelines has resulted in 
widespread use of models with robust tauopathy-like phenotypes, confounding genetic 
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variables have gone unnoticed or unpursued. As we have shown, unintended genomic 
disruption caused by random transgene insertion (conventional transgenesis) called into 
question the precise role of tau in the rTg4510 phenotype (396). The rTg4510 model 
was selected amongst other founder lines because of the dramatic loss of neurons 
(274,347), which other groups had achieved to a lesser degree with limited success in 
other P301L lines (348,380,382). However, the profound neurodegeneration in rTg4510 
was interpreted as successful phenocopying of human disease rather than an indication 
of confounding variables. Because transgene suppression with doxycycline prevented 
neuron loss and cognitive deficits in rTg4510 (274), phenotypic improvements were 
assumed to be caused by reduction of hTau.  
 It has now come to light that the severity of the neurodegenerative phenotype in 
rTg4510 is due in part to disruption and dysregulation of Fgf14, a gene prominently 
expressed in the developing and adult mouse brain (368,371), with functions related to 
neurogenesis (374), learning and memory (372), and synaptic transmission (369). By 
comparing rTg4510 to a targeted-equivalent lacking the Fgf14 Tg-INDEL mutation, 
rT2/T2, we were able to show that Fgf14 disruption accelerates the progression of 
neurodegeneration and tau histopathology (396). However, the relative contribution of 
hTau and FGF14 to neurodegeneration is complicated by three factors: 1) hTau and 
FGF14 V1 overexpression are intrinsically linked, 2) rTg4510 is also haploinsufficient for 
FGF14 V2, X1, and X2, and 3) more than 100 other Fgf14 transcripts may be involved 
(360). Furthermore, the hTauP301L Tg-INDEL mutation also affects chromatin 
architecture, modulating Fgf14 expression in the absence of the activator transgene 
(396). To understand if this precise disruption of Fgf14 can cause neurodegeneration in 
and of itself, all of these intricate details would need to be replicated in a mouse that 
does not express hTau – a daunting task that may introduce additional confounds. 
Importantly, a recent large-scale analysis revealed genomic disruptions in over 20 other 
conventionally made transgenic mice sold by The Jackson Laboratory (395), 
demonstrating that the rTg4510 story is not an isolated case. 
 An additional confounding variable in the rTg4510 line is the tTA TgINDEL that 
disrupts five annotated genes, four of which also have prominent forebrain expression 
patterns (396) (http://www.ncbi.nlm.nih.gov/gene/). Unfortunately, because tTA is 
intrinsically linked to hTau expression in all lines investigated in these studies, we cannot 
draw firm conclusions about the relative contributions of hTau, Fgf14, and tTA to mouse 
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phenotypes. Because this activator line exhibits a neurodegenerative phenotype (364), 
the tTA TgINDEL likely contributes to neuron loss and reduced brain mass in all mouse 
lines examined. Although the transgene itself is matched between rTg4510 and rT2/T2, 
the number of responder transgene copies may modulate the effect of tTA expression on 
neurons. Off-target DNA binding of tTA has phenotypic consequences (439), and the 
presence of a responder transgene could sequester excess tTA to reduce that binding. 
Therefore, the level of excess tTA is likely different between rT2/T2 and rTg4510 
because of the large difference in responder transgene copies. Furthermore, the driver 
line itself can never serve as a perfect control due to the absence of a responder 
transgene to sequester tTA. Though there are many possible biological mechanisms to 
explain the progression of the rTg4510 phenotype, one model consistent with our 
findings is that a combination of tTA toxicity and Fgf14 disruption makes forebrain 
neurons vulnerable to hTau overexpression, allowing for acceleration of hTau 
histopathology and neurodegeneration.  
 Fortunately, we avoid Fgf14-related confounding variables in our targeted lines, 
allowing us to conclude that the level of hTau expression positively correlates with 
severity of mouse phenotypes. rT2/T2 mice are homozygous for the hTau transgene and 
therefore express roughly twice the amount of hTau as hemizygous rT2 mice. 
Assessments of these lines revealed that in comparison to rT2, the progression of hTau 
histopathology, loss of brain mass, and behavioral deficits were accelerated and/or more 
severe in rT2/T2 (396). Acceleration of phenotypes in the field of neurodegeneration 
research has typically been viewed as a convenience because mice do not have to be 
aged as long, reducing costs and time needed for experiments. However, 
overexpression of transgenes is an artificial way of exaggerating phenotypes and may 
impact biology in ways that are not relevant to the disease of interest, for example, by 
introducing unnatural cellular stress. Extreme overexpression (or ‘hyperexpression’) of 
transgenes like that in rT2/T2 and rTg4510, which is 13-fold higher or more than the 
level of endogenous tau expression, may be even more problematic. Although a certain 
level of transgene overexpression may be needed to drive observable phenotypes, 
effects of overexpression on cell biology must be precisely defined in order to exclude it 
as an additional confounding variable in mouse models.  
 Genetic matching between rT1 and rT2 mice has advantageously provided a 
platform for probing molecular phenotypes of different forms of hTau, essentially using 
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the mammalian brain as an assay system. Importantly, these lines lack Fgf14 disruption 
and have matched tTA-related confounds because both lines have a single copy of the 
responder transgene. The original intention was to use rT1 (NM hTau) as a control line 
to determine effects of the P301L mutation on hTau biology in rT2. Surprisingly, we 
found that rT1 mice had a neurodevelopmental phenotype characterized by slower 
turnover and hyperphosphorylation of NM hTau, underlying eventual cognitive deficits. 
We found that excessive MT-binding of NM hTau may trigger a pathogenic pathway in 
young rT1 mice that involves disruption of mitochondrial dynamics in neurons and 
interferes with normal brain development. Our developmental suppression experiments 
revealed that NM hTau overexpression during the first 4 weeks of life is necessary to 
drive hTau pathogenicity. We hypothesize that overrepresentation of 4R compared to 3R 
tau isoforms in this artificial system is pathogenic (14,420), and that the P301L mutation 
confers a beneficial loss of function in this context. In addition, we found that tTA 
contributes to reduced brain mass in postnatal rT1 and rT2, but NM hTau exacerbates 
this phenomenon. tTA toxicity is known to be development-specific (364), and may be a 
driving factor in NM hTau toxicity. Overall, these studies demonstrate the importance of 
expressing transgenes at relevant stages in life, as the milieu of the developing brain is 
different from the adult and aging brain (431,432). We have shown that the developing 
mouse brain is selectively vulnerable to NM hTau overexpression, and recommend 
delaying the start of hTau expression in these models to test hypotheses related to 
aging-dependent tauopathy.  
 This work represents a first step to understanding contributions of confounding 
variables to mouse model phenotypes, and has yielded three overarching themes: 1) 
random transgene insertion in conventional transgenesis can affect mouse phenotypes 
in surprising and complicated ways, 2) the level and timing of transgene expression 
needs to be taken into careful consideration when designing and using mouse models, 
and 3) genetic matching is an advantageous tool to probe phenotypes associated with 
different forms of a protein of interest. The observations made in this work are indicative 
of a much broader problem affecting the field of neurodegeneration research (395). 
Because mice do not naturally develop tauopathies, researchers have created 
increasingly artificial systems, deviating further away from normal mouse biology to 
generate robust phenotypes. In extreme cases, mice are generated to harbor multiple 
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transgenes and mutations that have never cooccurred in humans with tauopathies, such 
as in the 3xTg and 5xFAD models (440,441).  
The work presented in this thesis advocates for elimination of confounding 
variables where possible, and for the use of proper controls to ensure phenotypes, 
whether molecular or behavioral, are relevant to the disease of interest. While models 
with robust phenotypes have a certain utility, prioritization of genotype over phenotype 
will hopefully be increasingly encouraged in light of these findings and those of similar 
studies. Avoiding genomic disruption will greatly improve the validity of mouse models, 
and the future of mouse modeling is heading in new directions due to continued 
technical advancements and widespread availability of sophisticated tools. For instance, 
inserting human orthologs into corresponding mouse genomic loci places genes in the 
correct regulatory context, an approach termed ‘humanization’ of mice (437). In theory, 
this would allow for expression of splice variants at appropriate times during 
development, in the appropriate cells, and at endogenous levels. A limited but growing 
number of validated humanized mouse models now exist, but investigating more 
complex disease loci may require humanization of multiple genes to fully replicate 
human biology (437).  
Although less artificial models may exhibit mild phenotypes, more sensitive 
methods such as ‘omics’ approaches and detailed cellular and molecular analyses may 
bring the field closer to understanding human diseases (438). Even as genome 
engineering continues to improve, there will always be limitations with mouse models 
such as differences between mouse and human circuitry and biology and lack of genetic 
diversity in single-background strains. Therefore, further validation of findings in 
additional mouse models and other model systems like human-derived induced 
pluripotent stem cells (hIPSCs) (442), organoids (443), or in species more closely 
related to humans such as non-human primates (444) will always be beneficial to solidify 
findings and ultimately improve translatability of therapeutic approaches. 
 A plethora of complicated questions remain about tau biology: 1) which 
posttranslational modifications create toxic species of tau?, 2) is cellular dysfunction 
caused by soluble or insoluble tau?, 3) do glial cells play a role in tau toxicity?, etc. An 
important question raised from the current work is: does tau cause neuron loss? The 
failed attempts to generate MAPT mouse models with strong neurodegenerative 
phenotypes align with the idea that while tau is a pathogenic agent, it primarily functions 
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to reduce synaptic transmission without inducing neuron death (346). The rTg4510 
model was initially lauded for its strong neurodegenerative phenotype, but we have now 
shown that confounding variables play a part. A final broad question is whether or not 
mutation-based models provide information relevant to sporadic diseases. Disease-
linked mutations have traditionally been used as a modeling tool, but pathogenic 
mechanisms may nonetheless differ between familial and sporadic diseases. These 
types of questions can be answered with improvements in mouse modeling like the 
genetic matching approach we have employed, and with humanized models 
complemented by other methods like hIPSCs. Confounding variables in transgenic 
mouse models of tauopathy have complicated our understanding of the role of tau in 
neurodegenerative diseases, but if researchers take advantage of the new genome 
engineering tools available, we will move at a faster pace toward solving the complex tau 
puzzle, identifying new therapeutic avenues, and ultimately developing treatments for 
tauopathies like Alzheimer’s disease. 
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